sentence,label,drug1,drug2
"DRUGOTHER Inhibitors: DRUG1, an inhibitor of the DRUGOTHER metabolizing enzyme DRUGOTHER, significantly increased plasma concentrations of DRUG2 when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and DRUGOTHER-DRUGOTHER Interactions). ",mechanism,Ketoconazole,tolterodine
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,azole antifungals
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG2, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,itraconazole
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG2) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,miconazole
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,macrolide antibiotics
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,erythromycin
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,clarithromycin
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,cyclosporine
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,ketoconazole,vinblastine
"For patients receiving DRUG1 or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,ketoconazole,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG2, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,itraconazole
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG2) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,miconazole
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,macrolide antibiotics
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,erythromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,clarithromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,azole antifungals,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,azole antifungals,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUG2) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,miconazole
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,macrolide antibiotics
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,erythromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,clarithromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,itraconazole,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUG1, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,itraconazole,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,miconazole,macrolide antibiotics
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,miconazole,erythromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,miconazole,clarithromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,miconazole,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,miconazole,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUG1) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,miconazole,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG2, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,macrolide antibiotics,erythromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,macrolide antibiotics,clarithromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,macrolide antibiotics,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,macrolide antibiotics,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,macrolide antibiotics,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG1, DRUG2) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,erythromycin,clarithromycin
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,erythromycin,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,erythromycin,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUG1, DRUGOTHER) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,erythromycin,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUG2 or DRUGOTHER, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,clarithromycin,cyclosporine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,clarithromycin,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUG1) or DRUGOTHER or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,clarithromycin,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 or DRUG2, the recommended dose of DRUGOTHER is 2 mg daily. ",negative,cyclosporine,vinblastine
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUG1 or DRUGOTHER, the recommended dose of DRUG2 is 2 mg daily. ",advise,cyclosporine,DETROL LA
"For patients receiving DRUGOTHER or other potent DRUGOTHER inhibitors such as other azole DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or macrolide DRUGOTHER (eg, DRUGOTHER, DRUGOTHER) or DRUGOTHER or DRUG1, the recommended dose of DRUG2 is 2 mg daily. ",advise,vinblastine,DETROL LA
Potential for DRUG1    to Affect Other DRUGOTHER DRUG2 is not expected to cause clinically important pharmacokinetic interactions with DRUGOTHER that are metabolized by cytochrome P450 isozymes. ,negative,INVEGA,Paliperidone
"Given the primary CNS effects of DRUG1, DRUG2    should be used with caution in combination with other centrally acting DRUGOTHER and DRUGOTHER. ",negative,paliperidone,INVEGA
"Given the primary CNS effects of DRUG1, DRUGOTHER    should be used with caution in combination with other centrally acting DRUGOTHER and DRUGOTHER. ",advise,paliperidone,centrally acting drugs
"Given the primary CNS effects of DRUG1, DRUGOTHER    should be used with caution in combination with other centrally acting DRUGOTHER and DRUG2. ",advise,paliperidone,alcohol
"Given the primary CNS effects of DRUGOTHER, DRUG1    should be used with caution in combination with other centrally acting DRUGOTHER and DRUGOTHER. ",advise,INVEGA,centrally acting drugs
"Given the primary CNS effects of DRUGOTHER, DRUG1    should be used with caution in combination with other centrally acting DRUGOTHER and DRUG2. ",advise,INVEGA,alcohol
"Given the primary CNS effects of DRUGOTHER, DRUGOTHER    should be used with caution in combination with other centrally acting DRUGOTHER and DRUG2. ",negative,centrally acting drugs,alcohol
DRUG1 may antagonize the effect of DRUG2 and other DRUGOTHER. ,effect,Paliperidone,levodopa
DRUG1 may antagonize the effect of DRUGOTHER and other DRUGOTHER agonists. ,effect,Paliperidone,dopamine agonists
DRUGOTHER may antagonize the effect of DRUG1 and other DRUGOTHER agonists. ,negative,levodopa,dopamine agonists
"Potential for Other DRUGOTHER to Affect DRUG1    DRUG2 is not a substrate of DRUGOTHER, CYP2A6, DRUGOTHER, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",negative,INVEGA,Paliperidone
"The concomitant use of DRUG1 with other DRUGOTHER DRUGOTHER or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other DRUGOTHER-like effects may increase the frequency and/or severity of such effects. ",effect,oxybutynin,anticholinergic drugs
"Mean DRUGOTHER chloride plasma concentrations were approximately 2 fold higher when DRUG2 was administered with DRUGOTHER, a potent DRUGOTHER inhibitor. ",negative,oxybutynin chloride,DITROPAN XL
"Mean DRUGOTHER chloride plasma concentrations were approximately 2 fold higher when DRUGOTHER was administered with DRUG2, a potent DRUGOTHER inhibitor. ",negative,oxybutynin chloride,ketoconazole
"Mean DRUGOTHER plasma concentrations were approximately 2 fold higher when DRUG1 was administered with DRUG2, a potent DRUGOTHER inhibitor. ",mechanism,DITROPAN XL,ketoconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUG2 and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,itraconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUGOTHER and DRUG2) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,antimycotic agents,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUG1 (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,antimycotic agents,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUG2) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,itraconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUG1 and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,itraconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or macrolide DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,miconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUG1) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,miconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUG2 and DRUGOTHER), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,macrolide antibiotics,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,macrolide antibiotics,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,macrolide antibiotics,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUG1 and DRUG2), may alter DRUGOTHER mean pharmacokinetic parameters (i.e., Cmax and AUC). ",negative,erythromycin,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUG1 and DRUGOTHER), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,erythromycin,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER) or macrolide DRUGOTHER (e.g., DRUGOTHER and DRUG1), may alter DRUG2 mean pharmacokinetic parameters (i.e., Cmax and AUC). ",mechanism,clarithromycin,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,antacid
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,aluminum hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,magnesium hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG2) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,simethicone
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or DRUGOTHER.    ",negative,antacid,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",negative,antacid,desethyloxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,aluminum hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,magnesium hydroxide
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG2) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,antacid,simethicone
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or DRUGOTHER.    ",negative,antacid,oxybutynin
"Concurrent ingestion of DRUG1 (20 mL of DRUG1 containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",negative,antacid,desethyloxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,aluminum hydroxide,magnesium hydroxide
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG2) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,aluminum hydroxide,simethicone
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or DRUGOTHER.    ",negative,aluminum hydroxide,oxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",negative,aluminum hydroxide,desethyloxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG2) did not significantly affect the exposure of DRUGOTHER or DRUGOTHER.    ",negative,magnesium hydroxide,simethicone
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUG2 or DRUGOTHER.    ",negative,magnesium hydroxide,oxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",negative,magnesium hydroxide,desethyloxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG1) did not significantly affect the exposure of DRUG2 or DRUGOTHER.    ",negative,simethicone,oxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUG1) did not significantly affect the exposure of DRUGOTHER or DRUG2.    ",negative,simethicone,desethyloxybutynin
"Concurrent ingestion of DRUGOTHER (20 mL of DRUGOTHER containing DRUGOTHER hydroxide, DRUGOTHER hydroxide, and DRUGOTHER) did not significantly affect the exposure of DRUG1 or DRUG2.    ",negative,oxybutynin,desethyloxybutynin
"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",mechanism,Mitotane,warfarin
"DRUG1 has been reported to accelerate the metabolism of DRUG2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG2. ",negative,Mitotane,warfarin
"DRUGOTHER has been reported to accelerate the metabolism of DRUG1 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for DRUG1. ",negative,warfarin,warfarin
"Therefore, physicians should closely monitor patients for a change in DRUG1 dosage requirements when administering DRUG2 to patients on DRUGOTHER-type DRUGOTHER. ",negative,anticoagulant,Mitotane
"Therefore, physicians should closely monitor patients for a change in DRUG1 dosage requirements when administering DRUGOTHER to patients on DRUGOTHER-type DRUGOTHER. ",negative,anticoagulant,coumarin-type anticoagulants
"Therefore, physicians should closely monitor patients for a change in DRUGOTHER dosage requirements when administering DRUG1 to patients on DRUGOTHER-type DRUGOTHER. ",advise,Mitotane,coumarin-type anticoagulants
Concomitant administration of DRUG1 and DRUGOTHER agents has been associated with erythema and DRUGOTHER-like flushing and anaphylactoid reactions. ,effect,vancomycin,anesthetic agents
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUG2, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,amphotericin B,aminoglycosides
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUGOTHER, DRUG2, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,amphotericin B,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,amphotericin B,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,amphotericin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",negative,amphotericin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER B, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",negative,amphotericin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,aminoglycosides,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,aminoglycosides,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER B, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,aminoglycosides,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",negative,aminoglycosides,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",negative,aminoglycosides,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,bacitracin,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER B, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,bacitracin,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER B, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",negative,bacitracin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",negative,bacitracin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUG2, DRUGOTHER, or DRUGOTHER, when indicated, requires careful monitoring.",negative,polymyxin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",negative,polymyxin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",negative,polymyxin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUG1, DRUG2, or DRUGOTHER, when indicated, requires careful monitoring.",negative,colistin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUG1, DRUGOTHER, or DRUG2, when indicated, requires careful monitoring.",negative,colistin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER B, DRUGOTHER, DRUG1, or DRUG2, when indicated, requires careful monitoring.",negative,viomycin,cisplatin
"Coadministration of DRUG1 with DRUG2 resulted in increased plasma DRUGOTHER concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased DRUGOTHER plasma concentrations (31%). ",mechanism,TRITEC,clarithromycin
"Coadministration of DRUG1 with DRUGOTHER resulted in increased plasma DRUG2 concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased DRUGOTHER plasma concentrations (31%). ",negative,TRITEC,ranitidine
"Coadministration of DRUG1 with DRUGOTHER resulted in increased plasma DRUGOTHER concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased 14- hydroxy- DRUGOTHER plasma concentrations (31%). ",negative,TRITEC,14- hydroxy- clarithromycin
"Coadministration of DRUGOTHER with DRUG1 resulted in increased plasma DRUG2 concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased DRUGOTHER plasma concentrations (31%). ",negative,clarithromycin,ranitidine
"Coadministration of DRUGOTHER with DRUG1 resulted in increased plasma DRUGOTHER concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased 14- hydroxy- DRUG1 plasma concentrations (31%). ",negative,clarithromycin,14- hydroxy- clarithromycin
"Coadministration of DRUGOTHER with DRUGOTHER resulted in increased plasma DRUG1 concentrations (57%), increased plasma DRUGOTHER trough concentrations (48%), and increased 14- hydroxy- DRUGOTHER plasma concentrations (31%). ",negative,ranitidine,14- hydroxy- clarithromycin
Coadministration with DRUG1 results in a slight decrease in the rate of DRUG2 absorption that is clinically unimportant. ,negative,aspirin,salicylate
Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of DRUG2 and may decrease plasma concentrations of DRUGOTHER from DRUGOTHER. ,mechanism,antacid,ranitidine
Coadministration with a high dose of DRUG1 (170 mEq) results in a 28% decrease in plasma concentrations of DRUGOTHER and may decrease plasma concentrations of DRUGOTHER from DRUG2. ,mechanism,antacid,TRITEC
Coadministration with a high dose of DRUGOTHER (170 mEq) results in a 28% decrease in plasma concentrations of DRUG1 and may decrease plasma concentrations of DRUGOTHER from DRUG2. ,negative,ranitidine,TRITEC
"For information on DRUGOTHER interactions associated with DRUG1, refer to the DRUG2     package insert.",negative,ranitidine,ZANTAC
"These include DRUGOTHER DRUGOTHER, DRUG2, and oral and inhaled DRUGOTHER. ",negative,sympathomimetic bronchodilators,methylxanthines
"These include DRUGOTHER DRUGOTHER, DRUGOTHER, and oral and inhaled DRUG2. ",negative,sympathomimetic bronchodilators,steroids
"These include DRUGOTHER, DRUG1, and oral and inhaled DRUG2. ",negative,methylxanthines,steroids
"However, the DRUGOTHER   administration of DRUG1 with other DRUG2   containing DRUGOTHER (e.g., DRUGOTHER) has not been studied and is therefore not recommended.",advise,SPIRIVA,anticholinergic
"However, the DRUGOTHER   administration of DRUG1 with other DRUGOTHER   containing DRUGOTHER (e.g., DRUG2) has not been studied and is therefore not recommended.",advise,SPIRIVA,ipratropium
"However, the DRUGOTHER   administration of DRUGOTHER with other DRUG1   containing DRUGOTHER (e.g., DRUG2) has not been studied and is therefore not recommended.",negative,anticholinergic,ipratropium
Prothrombin time or other suitable anticoagulation test should be monitored if DRUG1 is administered with DRUG2.   ,advise,tigecycline,warfarin
Concurrent use of DRUGOTHER DRUGOTHER with oral DRUG2 may render oral DRUG2 less effective.  ,effect,antibacterial drugs,contraceptives
Concurrent use of DRUGOTHER DRUGOTHER with oral DRUG2 may render oral DRUG2 less effective.  ,negative,antibacterial drugs,contraceptives
Concurrent use of DRUGOTHER DRUGOTHER with oral DRUG1 may render oral DRUG1 less effective.  ,negative,contraceptives,contraceptives
"DRUG1 may enhance the DRUGOTHER effects of DRUG2 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Triprolidine,central nervous system depressants
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Triprolidine,alcohol
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Triprolidine,barbiturates
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Triprolidine,hypnotics
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Triprolidine,narcotic analgesics
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",effect,Triprolidine,sedatives
"DRUG1 may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",effect,Triprolidine,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,central nervous system depressants,alcohol
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,central nervous system depressants,barbiturates
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,central nervous system depressants,hypnotics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,central nervous system depressants,narcotic analgesics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,central nervous system depressants,sedatives
"DRUGOTHER may enhance the DRUGOTHER effects of DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,central nervous system depressants,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUG1, DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,alcohol,barbiturates
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUG1, DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,alcohol,hypnotics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,alcohol,narcotic analgesics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,alcohol,sedatives
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,alcohol,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUG1, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,barbiturates,hypnotics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,barbiturates,narcotic analgesics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,barbiturates,sedatives
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,barbiturates,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,hypnotics,narcotic analgesics
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,hypnotics,sedatives
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,hypnotics,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,narcotic analgesics,sedatives
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,narcotic analgesics,tranquillisers
"DRUGOTHER may enhance the DRUGOTHER effects of DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG1, and DRUG2. ",negative,sedatives,tranquillisers
"The effects of DRUGOTHER DRUGOTHER, such as DRUG2 and DRUGOTHER may be enhanced by the concomitant administration of DRUGOTHER. ",negative,anticholinergic drugs,atropine
"The effects of DRUGOTHER DRUGOTHER, such as DRUGOTHER and DRUGOTHER DRUGOTHER may be enhanced by the concomitant administration of DRUGOTHER. ",negative,anticholinergic drugs,tricyclic antidepressants
"The effects of DRUGOTHER DRUGOTHER, such as DRUGOTHER and DRUGOTHER may be enhanced by the concomitant administration of DRUG2. ",effect,anticholinergic drugs,triprolidine
"The effects of DRUGOTHER DRUGOTHER, such as DRUG1 and DRUGOTHER DRUGOTHER may be enhanced by the concomitant administration of DRUGOTHER. ",negative,atropine,tricyclic antidepressants
"The effects of DRUGOTHER DRUGOTHER, such as DRUG1 and DRUGOTHER may be enhanced by the concomitant administration of DRUG2. ",effect,atropine,triprolidine
"The effects of DRUGOTHER DRUGOTHER, such as DRUGOTHER and DRUGOTHER DRUGOTHER may be enhanced by the concomitant administration of DRUG2. ",effect,tricyclic antidepressants,triprolidine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUG2) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUGOTHER and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,Protease Inhibitors
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER alkaloid DRUGOTHER (e.g. DRUGOTHER and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUG2 and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUGOTHER and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Macrolide Antibiotics,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER alkaloid DRUGOTHER (e.g. DRUGOTHER and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUG2 and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUG1) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUGOTHER and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,Protease Inhibitors,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER alkaloid DRUGOTHER (e.g. DRUG2 and DRUGOTHER) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,ergot alkaloid drugs,dihydroergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER alkaloid DRUGOTHER (e.g. DRUGOTHER and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,ergot alkaloid drugs,ergotamine
"CYP 3A4 Inhibitors (e.g. Macrolide DRUGOTHER and DRUGOTHER) There have been rare reports of serious adverse events in connection with the coadministration of certain DRUGOTHER (e.g. DRUG1 and DRUG2) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",negative,dihydroergotamine,ergotamine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,erythromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,macrolide antibiotics,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,macrolide antibiotics,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,macrolide antibiotics,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,erythromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,erythromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,erythromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,troleandomycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,troleandomycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,troleandomycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,clarithromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,clarithromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,clarithromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,HIV protease inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,HIV protease inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,HIV protease inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,reverse transcriptase inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,reverse transcriptase inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,reverse transcriptase inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,ritonavir,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,ritonavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,ritonavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,ritonavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,ritonavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,ritonavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,ritonavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,indinavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,indinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,indinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,indinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,indinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,indinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,nelfinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,nelfinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,nelfinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,nelfinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,nelfinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,delavirdine,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,delavirdine,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,delavirdine,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,delavirdine,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER). ",negative,azole antifungals,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER). ",negative,azole antifungals,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2). ",negative,azole antifungals,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER). ",negative,ketoconazole,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2). ",negative,ketoconazole,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include macrolide DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER), HIV protease or DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) or azole DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2). ",negative,itraconazole,voriconazole
"Less potent inhibitors include DRUG1, DRUG2, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,saquinavir,nefazodone
"Less potent inhibitors include DRUG1, DRUGOTHER, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,saquinavir,fluconazole
"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,saquinavir,fluoxetine
"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,saquinavir,fluvoxamine
"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,saquinavir,zileuton
"Less potent inhibitors include DRUG1, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,saquinavir,clotrimazole
"Less potent inhibitors include DRUGOTHER, DRUG1, DRUG2, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,nefazodone,fluconazole
"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,nefazodone,fluoxetine
"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,nefazodone,fluvoxamine
"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,nefazodone,zileuton
"Less potent inhibitors include DRUGOTHER, DRUG1, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,nefazodone,clotrimazole
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,fluconazole,fluoxetine
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,fluconazole,fluvoxamine
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,fluconazole,zileuton
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUG1, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,fluconazole,clotrimazole
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,fluoxetine,fluvoxamine
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,fluoxetine,zileuton
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,fluoxetine,clotrimazole
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,fluvoxamine,zileuton
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,fluvoxamine,clotrimazole
"Less potent inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,zileuton,clotrimazole
Caution should be exercised when DRUG1    (DRUGOTHER maleate) is used concurrently with other DRUGOTHER or DRUGOTHER.,negative,Methergine,methylergonovine maleate
Caution should be exercised when DRUG1    (DRUGOTHER) is used concurrently with other DRUG2 or DRUGOTHER.,advise,Methergine,vasoconstrictors
Caution should be exercised when DRUG1    (DRUGOTHER) is used concurrently with other DRUGOTHER or DRUGOTHER alkaloids.,advise,Methergine,ergot alkaloids
Caution should be exercised when DRUGOTHER    (DRUGOTHER maleate) is used concurrently with other DRUG2 or DRUGOTHER.,advise,methylergonovine maleate,vasoconstrictors
Caution should be exercised when DRUGOTHER    (DRUGOTHER maleate) is used concurrently with other DRUGOTHER or DRUGOTHER alkaloids.,negative,methylergonovine maleate,ergot alkaloids
Caution should be exercised when DRUGOTHER    (DRUGOTHER) is used concurrently with other DRUG1 or DRUGOTHER alkaloids.,negative,vasoconstrictors,ergot alkaloids
"Since DRUG1 is metabolized by a P450 enzyme system, DRUGOTHER that induce or inhibit this DRUGOTHER metabolizing enzyme system may elicit important DRUGOTHER-DRUGOTHER interactions that may alter DRUG1 plasma concentrations. ",negative,trimetrexate,trimetrexate
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,trimetrexate,erythromycin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,trimetrexate,rifampin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",effect,trimetrexate,rifabutin
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",effect,trimetrexate,ketoconazole
"Agents that might be coadministered with DRUG1 in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",effect,trimetrexate,fluconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,erythromycin,rifampin
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,erythromycin,rifabutin
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,erythromycin,ketoconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,erythromycin,fluconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,rifampin,rifabutin
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,rifampin,ketoconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,rifampin,fluconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,rifabutin,ketoconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,rifabutin,fluconazole
"Agents that might be coadministered with DRUGOTHER in AIDS patients for other indications that could elicit this activity include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,ketoconazole,fluconazole
In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in DRUG2 metabolism and that DRUGOTHER altered the relative concentration of DRUG2 metabolites possibly by competing for sulfate metabolites. ,mechanism,cimetidine,trimetrexate
In vitro perfusion of isolated rat liver has shown that DRUG1 caused a significant reduction in DRUGOTHER metabolism and that DRUG2 altered the relative concentration of DRUGOTHER metabolites possibly by competing for sulfate metabolites. ,negative,cimetidine,acetaminophen
In vitro perfusion of isolated rat liver has shown that DRUGOTHER caused a significant reduction in DRUG1 metabolism and that DRUG2 altered the relative concentration of DRUG1 metabolites possibly by competing for sulfate metabolites. ,negative,trimetrexate,acetaminophen
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,imidazole drugs,clotrimazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,imidazole drugs,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,imidazole drugs,miconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,imidazole drugs,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,clotrimazole,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,clotrimazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,clotrimazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) were potent, non-competitive inhibitors of DRUGOTHER metabolism. ",negative,ketoconazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,ketoconazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) were potent, non-competitive inhibitors of DRUG2 metabolism. ",mechanism,miconazole,trimetrexate
DRUG1 has been studied on a background of DRUG2 and DRUGOTHER. ,negative,AGGRASTAT,aspirin
DRUG1 has been studied on a background of DRUGOTHER and DRUG2. ,negative,AGGRASTAT,heparin
DRUGOTHER has been studied on a background of DRUG1 and DRUG2. ,negative,aspirin,heparin
"The use of DRUG1, in combination with DRUG2 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG2 and DRUGOTHER alone (see",effect,AGGRASTAT,heparin
"The use of DRUG1, in combination with DRUGOTHER and DRUG2, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG2 alone (see",effect,AGGRASTAT,aspirin
"The use of DRUG1, in combination with DRUG2 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG2 and DRUGOTHER alone (see",negative,AGGRASTAT,heparin
"The use of DRUG1, in combination with DRUGOTHER and DRUG2, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG2 alone (see",negative,AGGRASTAT,aspirin
"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"The use of DRUGOTHER, in combination with DRUG1 and DRUGOTHER, has been associated with an increase in bleeding compared to DRUG1 and DRUGOTHER alone (see",negative,heparin,heparin
"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"The use of DRUGOTHER, in combination with DRUG2 and DRUG1, has been associated with an increase in bleeding compared to DRUG2 and DRUG1 alone (see",negative,aspirin,heparin
"The use of DRUGOTHER, in combination with DRUGOTHER and DRUG1, has been associated with an increase in bleeding compared to DRUGOTHER and DRUG1 alone (see",negative,aspirin,aspirin
"The use of DRUGOTHER, in combination with DRUG1 and DRUG2, has been associated with an increase in bleeding compared to DRUG1 and DRUG2 alone (see",negative,heparin,aspirin
"however, in patients with Paget's Disease prior DRUG1 use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",effect,diphosphonate,Calcitonin (salmon)
"To minimize CNS depression and possible potentiation, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER should be used with caution. ",negative,barbiturates,antihistamines
"To minimize CNS depression and possible potentiation, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER should be used with caution. ",negative,barbiturates,narcotics
"To minimize CNS depression and possible potentiation, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER should be used with caution. ",negative,barbiturates,hypotensive agents
"To minimize CNS depression and possible potentiation, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2 should be used with caution. ",negative,barbiturates,phenothiazines
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER should be used with caution. ",negative,antihistamines,narcotics
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER should be used with caution. ",negative,antihistamines,hypotensive agents
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2 should be used with caution. ",negative,antihistamines,phenothiazines
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER should be used with caution. ",negative,narcotics,hypotensive agents
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2 should be used with caution. ",negative,narcotics,phenothiazines
"To minimize CNS depression and possible potentiation, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2 should be used with caution. ",negative,hypotensive agents,phenothiazines
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,sympathomimetic drugs
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,tricyclic antidepressant
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,amitriptyline HCl
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,imipramine HCl
"Because DRUG1 exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",advise,Matulane,tyramine
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,tricyclic antidepressant
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,amitriptyline HCl
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,imipramine HCl
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,sympathomimetic drugs,tyramine
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,amitriptyline HCl
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,imipramine HCl
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,tricyclic antidepressant,tyramine
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUGOTHER content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,amitriptyline HCl,imipramine HCl
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,amitriptyline HCl,tyramine
"Because DRUGOTHER exhibits some monoamine oxidase inhibitory activity, DRUGOTHER, DRUGOTHER DRUGOTHER DRUGOTHER (e.g., DRUGOTHER HCl, DRUGOTHER HCl) and other DRUGOTHER and foods with known high DRUG2 content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ",negative,imipramine HCl,tyramine
"No cross-resistance with other DRUG1, radiotherapy or DRUG2 has been demonstrated.",negative,chemotherapeutic agents,steroids
patients receiving DRUG1 and DRUG2 should have more frequent monitoring of neutrophil counts.,advise,lithium,Neulasta
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,mycophenolate mofetil
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,cyclosporine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,tacrolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,prednisolone
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,sirolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,MYCAMINE,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,MYCAMINE,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,MYCAMINE,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,cyclosporine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,tacrolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,prednisolone
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,sirolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,mycophenolate mofetil,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,mycophenolate mofetil,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,mycophenolate mofetil,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cyclosporine,tacrolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cyclosporine,prednisolone
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cyclosporine,sirolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cyclosporine,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,cyclosporine,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,cyclosporine,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,cyclosporine,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tacrolimus,prednisolone
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tacrolimus,sirolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tacrolimus,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,tacrolimus,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,tacrolimus,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,tacrolimus,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,sirolimus
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,prednisolone,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,prednisolone,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,sirolimus,nifedipine
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,sirolimus,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,sirolimus,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,sirolimus,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,nifedipine,fluconazole
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,nifedipine,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,nifedipine,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,fluconazole,ritonavir
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,fluconazole,rifampin
"A total of 11 clinical DRUGOTHER-DRUGOTHER interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,ritonavir,rifampin
"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,MYCAMINE,mycophenolate mofetil
"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,MYCAMINE,cyclosporine
"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,MYCAMINE,tacrolimus
"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",negative,MYCAMINE,prednisolone
"There was no effect of a single dose or multiple doses of DRUG1 on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",negative,MYCAMINE,fluconazole
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER mofetil, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,mycophenolate mofetil,cyclosporine
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER mofetil, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,mycophenolate mofetil,tacrolimus
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",negative,mycophenolate mofetil,prednisolone
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER mofetil, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",negative,mycophenolate mofetil,fluconazole
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER pharmacokinetics. ",negative,cyclosporine,tacrolimus
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER pharmacokinetics. ",negative,cyclosporine,prednisolone
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 pharmacokinetics. ",negative,cyclosporine,fluconazole
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER pharmacokinetics. ",negative,tacrolimus,prednisolone
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2 pharmacokinetics. ",negative,tacrolimus,fluconazole
"There was no effect of a single dose or multiple doses of DRUGOTHER on DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 pharmacokinetics. ",negative,prednisolone,fluconazole
DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG2 compared with DRUG1 alone. ,mechanism,Sirolimus,MYCAMINE
DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUGOTHER compared with DRUG1 alone. ,negative,Sirolimus,sirolimus
DRUG2 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUG1 compared with DRUG2 alone. ,negative,MYCAMINE,sirolimus
"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG2 compared with DRUG1 alone. ",mechanism,Nifedipine,MYCAMINE
"DRUG1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUGOTHER compared with DRUG1 alone. ",negative,Nifedipine,nifedipine
"DRUG2 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state DRUG1 compared with DRUG2 alone. ",negative,MYCAMINE,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or DRUGOTHER in combination with DRUG2 should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,advise,sirolimus,MYCAMINE
Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUGOTHER or DRUG1 in combination with DRUG2 should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,advise,nifedipine,MYCAMINE
Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,negative,MYCAMINE,sirolimus
Patients receiving DRUGOTHER or DRUG2 in combination with DRUG1 should be monitored for DRUGOTHER or DRUG2 toxicity and DRUGOTHER or DRUG2 dosage should be reduced if necessary. ,negative,MYCAMINE,nifedipine
Patients receiving DRUG2 or DRUGOTHER in combination with DRUG1 should be monitored for DRUG2 or DRUGOTHER toxicity and DRUG2 or DRUGOTHER dosage should be reduced if necessary. ,negative,MYCAMINE,sirolimus
Patients receiving DRUGOTHER or DRUG2 in combination with DRUG1 should be monitored for DRUGOTHER or DRUG2 toxicity and DRUGOTHER or DRUG2 dosage should be reduced if necessary. ,negative,MYCAMINE,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,negative,sirolimus,sirolimus
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
Patients receiving DRUG2 or DRUG1 in combination with DRUGOTHER should be monitored for DRUG2 or DRUG1 toxicity and DRUG2 or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,sirolimus
Patients receiving DRUGOTHER or DRUG1 in combination with DRUGOTHER should be monitored for DRUGOTHER or DRUG1 toxicity and DRUGOTHER or DRUG1 dosage should be reduced if necessary. ,negative,nifedipine,nifedipine
Patients receiving DRUG1 or DRUG2 in combination with DRUGOTHER should be monitored for DRUG1 or DRUG2 toxicity and DRUG1 or DRUG2 dosage should be reduced if necessary. ,negative,sirolimus,nifedipine
"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because DRUG2 amplifies the therapeutic actions and side-effects of DRUG1. ",effect,opioids,levomepromazine
"Dosages of concomitantly administered DRUG1 should be reduced by approximately half, because DRUGOTHER amplifies the therapeutic actions and side-effects of DRUG1. ",negative,opioids,opioids
"Dosages of concomitantly administered DRUG2 should be reduced by approximately half, because DRUG1 amplifies the therapeutic actions and side-effects of DRUG2. ",effect,levomepromazine,opioids
Combination with DRUG1 (DRUG2) is associated with increased risk of seizures. ,negative,tramadol,Ultram
Additive DRUGOTHER effects and confusional states may emerge if DRUG1 is given with DRUG2 or DRUGOTHER. ,effect,levomepromazine,benzodiazepines
Additive DRUGOTHER effects and confusional states may emerge if DRUG1 is given with DRUGOTHER or DRUG2. ,effect,levomepromazine,barbiturates
Additive DRUGOTHER effects and confusional states may emerge if DRUGOTHER is given with DRUG1 or DRUG2. ,negative,benzodiazepines,barbiturates
"Exert particular caution in combining DRUG1 with other DRUGOTHER DRUGOTHER (DRUGOTHER and DRUGOTHER): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,anticholinergic drugs
"Exert particular caution in combining DRUG1 with other DRUGOTHER DRUGOTHER (DRUGOTHER DRUGOTHER and DRUGOTHER): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,tricyclic antidepressants
"Exert particular caution in combining DRUG1 with other DRUGOTHER DRUGOTHER (DRUGOTHER and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",advise,levomepromazine,antiparkinsonian-agents
"Exert particular caution in combining DRUGOTHER with other DRUGOTHER DRUGOTHER (DRUGOTHER DRUGOTHER and DRUGOTHER): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,anticholinergic drugs,tricyclic antidepressants
"Exert particular caution in combining DRUGOTHER with other DRUGOTHER DRUGOTHER (DRUGOTHER and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,anticholinergic drugs,antiparkinsonian-agents
"Exert particular caution in combining DRUGOTHER with other DRUGOTHER DRUGOTHER (DRUGOTHER DRUGOTHER and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",negative,tricyclic antidepressants,antiparkinsonian-agents
DRUG1 and/or stimulantes of the DRUG2/DRUGOTHER type may counteract the specific actions of DRUGOTHER. ,negative,Caffeine,ephedrine
DRUG1 and/or stimulantes of the DRUGOTHER/DRUG2 type may counteract the specific actions of DRUGOTHER. ,negative,Caffeine,amphetamine
DRUG1 and/or stimulantes of the DRUGOTHER/DRUGOTHER type may counteract the specific actions of DRUG2. ,effect,Caffeine,levomepromazine
DRUGOTHER and/or stimulantes of the DRUG1/DRUG2 type may counteract the specific actions of DRUGOTHER. ,negative,ephedrine,amphetamine
DRUGOTHER and/or stimulantes of the DRUG1/DRUGOTHER type may counteract the specific actions of DRUG2. ,effect,ephedrine,levomepromazine
DRUGOTHER and/or stimulantes of the DRUGOTHER/DRUG1 type may counteract the specific actions of DRUG2. ,effect,amphetamine,levomepromazine
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUGOTHER-facilitated tracheal intubation, the interaction between DRUG1 and DRUGOTHER has not been systematically studied. ",negative,MIVACRON,MIVACRON
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",negative,MIVACRON,succinylcholine
"Although DRUG1 (a mixture of three stereoisomers) has been administered safely following DRUG2-facilitated tracheal intubation, the interaction between DRUG1 and DRUG2 has not been systematically studied. ",negative,MIVACRON,succinylcholine
Prior administration of DRUG1 can potentiate the neuromuscular blocking effects of DRUG2. ,effect,succinylcholine,nondepolarizing agents
Evidence of spontaneous recovery from DRUG1 should be observed before the administration of DRUG2. ,advise,succinylcholine,MIVACRON
The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,negative,MIVACRON,succinylcholine
The use of DRUG1 before DRUG2 to attenuate some of the side effects of DRUG2 has not been studied. ,negative,MIVACRON,succinylcholine
The use of DRUGOTHER before DRUG1 to attenuate some of the side effects of DRUG1 has not been studied. ,negative,succinylcholine,succinylcholine
There are no clinical data on the use of DRUG1 with other nondepolarizing DRUGOTHER. ,negative,MIVACRON,nondepolarizing neuromuscular blocking agents
DRUG1 and DRUG2 (administered with DRUGOTHER/DRUGOTHER to achieve 1.25 M.C. ,negative,Isoflurane,enflurane
DRUG1 and DRUGOTHER (administered with DRUG2/DRUGOTHER to achieve 1.25 M.C. ,negative,Isoflurane,nitrous oxide
DRUG1 and DRUGOTHER (administered with DRUGOTHER/DRUG2 to achieve 1.25 M.C. ,negative,Isoflurane,oxygen
DRUGOTHER and DRUG1 (administered with DRUG2/DRUGOTHER to achieve 1.25 M.C. ,negative,enflurane,nitrous oxide
DRUGOTHER and DRUG1 (administered with DRUGOTHER/DRUG2 to achieve 1.25 M.C. ,negative,enflurane,oxygen
DRUGOTHER and DRUGOTHER (administered with DRUG1/DRUG2 to achieve 1.25 M.C. ,negative,nitrous oxide,oxygen
A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of DRUG2 or DRUGOTHER. ,negative,MIVACRON,enflurane
A greater potentiation of the neuromuscular blocking effects of DRUG1 may be expected with higher concentrations of DRUGOTHER or DRUG2. ,negative,MIVACRON,isoflurane
A greater potentiation of the neuromuscular blocking effects of DRUGOTHER may be expected with higher concentrations of DRUG1 or DRUG2. ,negative,enflurane,isoflurane
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUG2 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,nondepolarizing agents,MIVACRON
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,antibiotics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,aminoglycosides
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,tetracyclines
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,bacitracin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",int,nondepolarizing agents,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",int,nondepolarizing agents,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUG1 such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",int,nondepolarizing agents,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,antibiotics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,aminoglycosides
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,tetracyclines
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,bacitracin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",int,MIVACRON,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",int,MIVACRON,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUG1 include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",int,MIVACRON,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,aminoglycosides
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,tetracyclines
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,bacitracin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,antibiotics,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,antibiotics,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,antibiotics,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,tetracyclines
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,bacitracin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,aminoglycosides,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,aminoglycosides,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,aminoglycosides,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,bacitracin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,tetracyclines,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,tetracyclines,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,tetracyclines,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,polymyxins
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,bacitracin,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,bacitracin,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,bacitracin,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,lincomycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,polymyxins,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,polymyxins,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,polymyxins,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,clindamycin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,lincomycin,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,lincomycin,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,lincomycin,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clindamycin,colistin
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clindamycin,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clindamycin,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clindamycin,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,clindamycin,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,clindamycin,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,clindamycin,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,colistin,sodium colistimethate
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,colistin,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,colistin,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,colistin,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,colistin,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,colistin,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUG2 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,sodium colistimethate,magnesium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,sodium colistimethate,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,sodium colistimethate,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,sodium colistimethate,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,sodium colistimethate,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG1 salts, DRUG2, local DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,magnesium,lithium
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG1 salts, DRUGOTHER, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,magnesium,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG1 salts, DRUGOTHER, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,magnesium,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUG1 salts, DRUGOTHER, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,magnesium,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG1, local DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,lithium,anesthetics
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG1, local DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,lithium,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUG1, local DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,lithium,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG1, DRUG2, and DRUGOTHER. ",negative,anesthetics,procainamide
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUG1, DRUGOTHER, and DRUG2. ",negative,anesthetics,quinidine
"Other DRUGOTHER which may enhance the neuromuscular blocking action of DRUGOTHER such as DRUGOTHER include certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER), DRUGOTHER salts, DRUGOTHER, local DRUGOTHER, DRUG1, and DRUG2. ",negative,procainamide,quinidine
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG2, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",effect,MIVACRON,contraceptives
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG2, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",effect,MIVACRON,glucocorticoids
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG2) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",effect,MIVACRON,monoamine oxidase inhibitors
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,MIVACRON,neuromuscular blocking agents
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",negative,MIVACRON,phenytoin
"The neuromuscular blocking effect of DRUG1 may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",negative,MIVACRON,carbamazepine
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUG2, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,contraceptives,glucocorticoids
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUG2) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,contraceptives,monoamine oxidase inhibitors
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,contraceptives,neuromuscular blocking agents
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",negative,contraceptives,phenytoin
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUG1, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",negative,contraceptives,carbamazepine
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUG2) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,glucocorticoids,monoamine oxidase inhibitors
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,glucocorticoids,neuromuscular blocking agents
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",negative,glucocorticoids,phenytoin
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUG1, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",negative,glucocorticoids,carbamazepine
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUGOTHER. ",negative,monoamine oxidase inhibitors,neuromuscular blocking agents
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",negative,monoamine oxidase inhibitors,phenytoin
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUG1) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",negative,monoamine oxidase inhibitors,carbamazepine
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUG2 or DRUGOTHER. ",effect,neuromuscular blocking agents,phenytoin
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of DRUGOTHER has been demonstrated in patients chronically administered DRUGOTHER or DRUG2. ",effect,neuromuscular blocking agents,carbamazepine
"The neuromuscular blocking effect of DRUGOTHER may be enhanced by DRUGOTHER that reduce plasma cholinesterase activity (e.g., chronically administered oral DRUGOTHER, DRUGOTHER, or certain DRUGOTHER) or by DRUGOTHER that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing DRUGOTHER has been demonstrated in patients chronically administered DRUG1 or DRUG2. ",negative,phenytoin,carbamazepine
"While the effects of chronic DRUG1 or DRUG2 therapy on the action of DRUGOTHER are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",negative,phenytoin,carbamazepine
"While the effects of chronic DRUG1 or DRUGOTHER therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",effect,phenytoin,MIVACRON
"While the effects of chronic DRUGOTHER or DRUG1 therapy on the action of DRUG2 are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",effect,carbamazepine,MIVACRON
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG2 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,phenytoin
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG2 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,carbamazepine
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,antibiotics
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,cisplatin
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,edrophonium
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,corticosteroids,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,corticosteroids,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUG1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,corticosteroids,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUG2 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,carbamazepine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,antibiotics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,cisplatin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,edrophonium
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,phenytoin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,phenytoin,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,phenytoin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,phenytoin,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUG1 or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,phenytoin,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUG2 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,antibiotics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,cisplatin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,edrophonium
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,carbamazepine,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,carbamazepine,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUG1 - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,carbamazepine,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUG2 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,cisplatin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUG2 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,edrophonium
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,antibiotics,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,antibiotics,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,antibiotics,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,antibiotics,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUG1 given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,antibiotics,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUG2 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,cisplatin,edrophonium
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,cisplatin,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,cisplatin,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,cisplatin,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,cisplatin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,cisplatin,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,cisplatin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,cisplatin,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUG1 - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,cisplatin,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUG2 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,edrophonium,neostigmine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,edrophonium,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,edrophonium,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,edrophonium,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,edrophonium,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,edrophonium,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,edrophonium,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUG1 - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,edrophonium,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,neostigmine,polymyxin B
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,neostigmine,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,neostigmine,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,neostigmine,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,neostigmine,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,neostigmine,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUG1 - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,neostigmine,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG2 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,polymyxin B,bacitracin
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,polymyxin B,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,polymyxin B,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,polymyxin B,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,polymyxin B,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,polymyxin B,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG1 - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,bacitracin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG1 - local DRUGOTHER such as DRUG2 - general DRUGOTHER - DRUGOTHER or other DRUGOTHER,negative,bacitracin,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG1 - local DRUG2 such as DRUGOTHER - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,bacitracin,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG1 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,bacitracin,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUG1 - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,bacitracin,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUG2 - general DRUG1 - DRUGOTHER or other DRUGOTHER,negative,anesthetics,procaine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUGOTHER or other DRUGOTHER,negative,anesthetics,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUG2 or other DRUGOTHER,negative,anesthetics,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUGOTHER or other DRUG2,negative,anesthetics,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG2 such as DRUG1 - general DRUG2 - DRUGOTHER or other DRUGOTHER,negative,procaine,anesthetics
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG1 - general DRUGOTHER - DRUG2 or other DRUGOTHER,negative,procaine,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUG1 - general DRUGOTHER - DRUGOTHER or other DRUG2,negative,procaine,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUG2 or other DRUGOTHER,negative,anesthetics,succinylcholine
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUG1 such as DRUGOTHER - general DRUG1 - DRUGOTHER or other DRUG2,negative,anesthetics,muscle relaxants
Some DRUGOTHER interactions are:  - birth control pills - DRUGOTHER - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as DRUGOTHER or DRUGOTHER - certain DRUGOTHER given by injection - DRUGOTHER - DRUGOTHER - DRUGOTHER - DRUGOTHER B or DRUGOTHER - local DRUGOTHER such as DRUGOTHER - general DRUGOTHER - DRUG1 or other DRUG2,negative,succinylcholine,muscle relaxants
Do not exceed a 5 mg daily dose of DRUG1 when administered with therapeutic doses of DRUG2 or other potent DRUGOTHER inhibitors. ,advise,VESIcare,ketoconazole
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUGOTHER at its therapeutic dose. ",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of DRUG1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with DRUG1 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of DRUG1 30 mg did not appear as large as that of the positive control DRUG2 at its therapeutic dose. ",negative,solifenacin,moxifloxacin
"Interaction with DRUG1: Although DRUG2 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG1 can result in profound orthostatic effects. ",negative,Guanethidine,minoxidil
"Interaction with DRUG1: Although DRUGOTHER does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG1 can result in profound orthostatic effects. ",negative,Guanethidine,guanethidine
"Interaction with DRUG2: Although DRUG1 does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG2 can result in profound orthostatic effects. ",effect,minoxidil,guanethidine
If at all possible DRUG1 should be discontinued well before DRUG2 is begun. ,advise,guanethidine,minoxidil
"While DRUGOTHER-administration of DRUG1    appeared to increase the clearance of DRUG2 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG2. ",mechanism,ZAVESCA,Cerezyme
"While DRUGOTHER-administration of DRUG1    appeared to increase the clearance of DRUG2 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG2. ",negative,ZAVESCA,Cerezyme
"While DRUGOTHER-administration of DRUGOTHER    appeared to increase the clearance of DRUG1 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of DRUG1. ",negative,Cerezyme,Cerezyme
Combination therapy with DRUG1    (DRUG2) and DRUGOTHER    is not indicated.,negative,Cerezyme,imiglucerase
Combination therapy with DRUG1    (DRUGOTHER) and DRUG2    is not indicated.,advise,Cerezyme,ZAVESCA
Combination therapy with DRUGOTHER    (DRUG1) and DRUG2    is not indicated.,advise,imiglucerase,ZAVESCA
DRUG1 administered concomitantly with DRUG2 may significantly decrease the serum concentrations of DRUGOTHER. ,mechanism,Aminoglutethimide,depo-subQ provera 104
DRUG1 administered concomitantly with DRUGOTHER may significantly decrease the serum concentrations of DRUG2. ,negative,Aminoglutethimide,MPA
DRUGOTHER administered concomitantly with DRUG1 may significantly decrease the serum concentrations of DRUG2. ,negative,depo-subQ provera 104,MPA
Hypokalemia may develop during concomitant use of DRUG1 or DRUG2. ,negative,steroids,ACTH
DRUG1 may decrease arterial responsiveness to DRUG2. ,effect,Thiazides,norepinephrine
DRUGOTHER DRUGOTHER may increase the responsiveness of DRUG2. ,effect,Thiazide drugs,tubocurarine
"DRUG1 renal clearance is reduced by DRUG2, increasing the risk of DRUG1 toxicity. ",mechanism,Lithium,thiazides
"DRUG1 renal clearance is reduced by DRUGOTHER, increasing the risk of DRUG1 toxicity. ",negative,Lithium,lithium
"DRUG2 renal clearance is reduced by DRUG1, increasing the risk of DRUG2 toxicity. ",negative,thiazides,lithium
DRUG1 may add to or potentiate the action of other DRUGOTHER DRUGOTHER. ,effect,Thiazides,antihypertensive drugs
Potentiation occurs with ganglionic or peripheral DRUGOTHER blocking DRUGOTHER.,negative,ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUGOTHER    Tablets therapy. ",negative,Diuretics,diuretics
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",negative,Diuretics,ACEON
"DRUG1: Patients on DRUG1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of DRUG2    Tablets therapy. ",effect,diuretics,ACEON
The possibility of hypotensive effects can be minimized by either discontinuing the DRUG1 or increasing the salt intake prior to initiation of treatment with DRUG2. ,effect,diuretic,perindopril
"If DRUG1 cannot be interrupted, close medical supervision should be provided with the first dose of DRUG2    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",advise,diuretics,ACEON
The rate and extent of DRUG1 absorption and elimination are not affected by concomitant DRUG2. ,negative,perindopril,diuretics
"The bioavailability of DRUG1 was reduced by DRUG2, however, and this was associated with a decrease in plasma ACE inhibition. ",negative,perindoprilat,diuretics
DRUG1 Supplements and DRUG1-Sparing DRUGOTHER: DRUGOTHER    Tablets may increase serum DRUG1 because of its potential to decrease aldosterone production. ,negative,Potassium,Potassium-Sparing Diuretics
DRUG1 Supplements and DRUG1-Sparing DRUGOTHER: DRUG2    Tablets may increase serum DRUG1 because of its potential to decrease aldosterone production. ,negative,Potassium,ACEON
DRUGOTHER Supplements and DRUGOTHER-Sparing DRUGOTHER: DRUG2    Tablets may increase serum DRUGOTHER because of its potential to decrease aldosterone production. ,negative,Potassium-Sparing Diuretics,ACEON
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,spironolactone
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,amiloride
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,triamterene
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUG2 supplements or other DRUGOTHER capable of increasing serum DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,indomethacin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,heparin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,cyclosporine
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUG2, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,spironolactone,amiloride
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,spironolactone,triamterene
"Use of DRUG2-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUG2 supplements or other DRUGOTHER capable of increasing serum DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,spironolactone,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,spironolactone,indomethacin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,spironolactone,heparin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,spironolactone,cyclosporine
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUG2 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,amiloride,triamterene
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUG2 supplements or other DRUGOTHER capable of increasing serum DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,amiloride,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,amiloride,indomethacin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,amiloride,heparin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,amiloride,cyclosporine
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUG2 supplements or other DRUGOTHER capable of increasing serum DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,triamterene,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,triamterene,indomethacin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,triamterene,heparin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,triamterene,cyclosporine
"Use of DRUG1-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUG1 supplements or other DRUGOTHER capable of increasing serum DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium,indomethacin
"Use of DRUG1-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUG1 supplements or other DRUGOTHER capable of increasing serum DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,potassium,heparin
"Use of DRUG1-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUG1 supplements or other DRUGOTHER capable of increasing serum DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,potassium,cyclosporine
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG1, DRUG2, DRUGOTHER and others) can increase the risk of hyperkalemia. ",negative,indomethacin,heparin
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,indomethacin,cyclosporine
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER and others), DRUGOTHER supplements or other DRUGOTHER capable of increasing serum DRUGOTHER (DRUGOTHER, DRUG1, DRUG2 and others) can increase the risk of hyperkalemia. ",negative,heparin,cyclosporine
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 and symptoms of DRUG1 toxicity have been reported in patients receiving concomitant DRUG1 and DRUGOTHER therapy. ,negative,lithium,lithium
Use of a DRUG1 may further increase the risk of DRUG2 toxicity. ,negative,diuretic,lithium
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,Digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUG2    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,Digoxin,ACEON
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,Digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/DRUGOTHER has not been excluded. ",negative,Digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",negative,Digoxin,perindoprilat
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUG2    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,digoxin,ACEON
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,digoxin,digoxin
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/DRUGOTHER has not been excluded. ",negative,digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",negative,digoxin,perindoprilat
"DRUG2: A controlled pharmacokinetic study has shown no effect on plasma DRUG2 concentrations when coadministered with DRUG1    Tablets, but an effect of DRUG2 on the plasma concentration of DRUGOTHER/DRUGOTHER has not been excluded. ",negative,ACEON,digoxin
"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUG1    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUG2/DRUGOTHER has not been excluded. ",negative,ACEON,perindopril
"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUG1    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",negative,ACEON,perindoprilat
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUG2/DRUGOTHER has not been excluded. ",mechanism,digoxin,perindopril
"DRUG1: A controlled pharmacokinetic study has shown no effect on plasma DRUG1 concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUG1 on the plasma concentration of DRUGOTHER/DRUG2 has not been excluded. ",mechanism,digoxin,perindoprilat
"DRUGOTHER: A controlled pharmacokinetic study has shown no effect on plasma DRUGOTHER concentrations when coadministered with DRUGOTHER    Tablets, but an effect of DRUGOTHER on the plasma concentration of DRUG1/DRUG2 has not been excluded. ",negative,perindopril,perindoprilat
DRUG1: Animal data have suggested the possibility of interaction between DRUG2 and DRUG1. ,negative,Gentamicin,perindopril
DRUG1: Animal data have suggested the possibility of interaction between DRUGOTHER and DRUG1. ,negative,Gentamicin,gentamicin
DRUG2: Animal data have suggested the possibility of interaction between DRUG1 and DRUG2. ,int,perindopril,gentamicin
Food Interaction: Oral administration of DRUG1    Tablets with food does not significantly lower the rate or extent of DRUG2 absorption relative to the fasted state. ,negative,ACEON,perindopril
"However, the extent of biotransformation of DRUG1 to the active metabolite, DRUG2, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",negative,perindopril,perindoprilat
Concurrent use of DRUG1 and other CNS depression-producing DRUGOTHER may increase the DRUGOTHER effects of DRUGOTHER or these other medications.,negative,alcohol,CNS depression-producing drugs
Concurrent use of DRUG1 and other DRUGOTHER may increase the DRUGOTHER effects of DRUG2 or these other medications.,effect,alcohol,methyprylon
Concurrent use of DRUGOTHER and other CNS depression-producing DRUGOTHER may increase the DRUGOTHER effects of DRUG2 or these other medications.,effect,CNS depression-producing drugs,methyprylon
Administration of DRUG1 decreases oral clearance of DRUG2 by about 5%. ,mechanism,valproic acid,temozolomide
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUG1, sodium DRUGOTHER and DRUGOTHER displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",negative,tolbutamide,sodium salicylate
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUG1, sodium DRUGOTHER and DRUG2 displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",negative,tolbutamide,sulfamethizole
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUG1, sodium DRUGOTHER and DRUGOTHER displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,tolbutamide,teniposide
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUGOTHER, sodium DRUGOTHER and DRUG2 displaced protein-bound DRUGOTHER in fresh human serum to a small but significant extent. ",negative,sodium salicylate,sulfamethizole
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUGOTHER, sodium DRUGOTHER and DRUGOTHER displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,sodium salicylate,teniposide
"In a study in which 34 different DRUGOTHER were tested, therapeutically relevant concentrations of DRUGOTHER, sodium DRUGOTHER and DRUG1 displaced protein-bound DRUG2 in fresh human serum to a small but significant extent. ",mechanism,sulfamethizole,teniposide
"Therefore, caution should be used in administering DRUG1 (DRUG2 injection) to patients receiving these other agents. ",negative,VUMON,teniposide
There was no change in the plasma kinetics of DRUG1 when coadministered with DRUG2. ,negative,teniposide,methotrexate
An increase in intracellular levels of DRUG1 was observed in vitro in the presence of DRUG2.,mechanism,methotrexate,teniposide
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to DRUGOTHER.    ,negative,Anticoagulants,anticoagulants
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to DRUG2.    ,negative,Anticoagulants,methimazole
DRUG1 (oral): The activity of oral DRUG1 may be potentiated by anti-vitamin-K activity attributed to DRUG2.    ,effect,anticoagulants,methimazole
DRUGOTHER DRUGOTHER: Serum DRUGOTHER levels may be increased when hyperthyroid patients on a stable DRUGOTHER glycoside regimen become euthyroid; ,negative,Digitalis glycosides,digitalis glycoside
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,Theophylline
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,theophylline
DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG1 regimen become euthyroid; ,negative,Theophylline,theophylline
The interaction of DRUG1 (DRUG2) with other DRUGOTHER has not been studied in humans. ,negative,CYLERT,pemoline
Decreased seizure threshold has been reported in patients receiving DRUG1 concomitantly with DRUG2.,effect,CYLERT,antiepileptic medications
DRUG1: DRUG2 and probably other DRUGOTHER given concomitantly with DRUGOTHER can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,Furosemide
DRUG1: DRUGOTHER and probably other loop DRUG1 given concomitantly with DRUGOTHER can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,loop diuretics
DRUG1: DRUGOTHER and probably other DRUGOTHER given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Diuretics,metolazone
DRUGOTHER: DRUG1 and probably other loop DRUGOTHER given concomitantly with DRUGOTHER can cause unusually large or prolonged losses of fluid and electrolytes. ,negative,Furosemide,loop diuretics
DRUGOTHER: DRUG1 and probably other loop DRUGOTHER given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,effect,Furosemide,metolazone
DRUGOTHER: DRUGOTHER and probably other loop DRUGOTHER given concomitantly with DRUG2 can cause unusually large or prolonged losses of fluid and electrolytes. ,effect,loop diuretics,metolazone
"Other DRUG1: When DRUG2 Tablets are used with other DRUGOTHER DRUGOTHER, care must be taken, especially during initial therapy. ",negative,Antihypertensives,MYKROX
"Other DRUG1: When DRUGOTHER Tablets are used with other DRUGOTHER DRUGOTHER, care must be taken, especially during initial therapy. ",negative,Antihypertensives,antihypertensive drugs
"Other DRUGOTHER: When DRUG1 Tablets are used with other DRUGOTHER DRUGOTHER, care must be taken, especially during initial therapy. ",advise,MYKROX,antihypertensive drugs
"DRUG1, DRUG2, and DRUGOTHER: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUGOTHER therapy. ",negative,Alcohol,Barbiturates
"DRUG1, DRUGOTHER, and DRUG2: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUGOTHER therapy. ",negative,Alcohol,Narcotics
"DRUG1, DRUGOTHER, and DRUGOTHER: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Alcohol,metolazone
"DRUGOTHER, DRUG1, and DRUG2: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUGOTHER therapy. ",negative,Barbiturates,Narcotics
"DRUGOTHER, DRUG1, and DRUGOTHER: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Barbiturates,metolazone
"DRUGOTHER, DRUGOTHER, and DRUG1: The hypotensive effects of these DRUGOTHER may be potentiated by the volume contraction that may be associated with DRUG2 therapy. ",negative,Narcotics,metolazone
DRUGOTHER DRUGOTHER: DRUG2-induced hypokalemia can increase the sensitivity of the myocardium to DRUGOTHER. ,negative,Digitalis Glycosides,Diuretic
DRUG2 DRUGOTHER: DRUGOTHER-induced hypokalemia can increase the sensitivity of the myocardium to DRUG2. ,negative,Digitalis Glycosides,digitalis
DRUGOTHER: DRUG1-induced hypokalemia can increase the sensitivity of the myocardium to DRUG2. ,effect,Diuretic,digitalis
DRUG1 or DRUG2: May increase the risk of hypokalemia and increase salt and water retention. ,negative,Corticosteroids,ACTH
DRUG1: Serum DRUG1 levels may increase. ,negative,Lithium,lithium
Curariform DRUGOTHER: DRUG2-induced hypokalemia may enhance neuromuscular blocking effects of curariform DRUGOTHER (such as DRUGOTHER) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,Diuretic
Curariform DRUGOTHER: DRUGOTHER-induced hypokalemia may enhance neuromuscular blocking effects of curariform DRUGOTHER (such as DRUGOTHER) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,curariform drugs
Curariform DRUGOTHER: DRUGOTHER-induced hypokalemia may enhance neuromuscular blocking effects of curariform DRUGOTHER (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,Curariform Drugs,tubocurarine
Curariform DRUGOTHER: DRUG1-induced hypokalemia may enhance neuromuscular blocking effects of curariform DRUGOTHER (such as DRUGOTHER) the most serious effect would be respiratory depression which could proceed to apnea. ,effect,Diuretic,curariform drugs
DRUGOTHER: DRUG1-induced hypokalemia may enhance neuromuscular blocking effects of DRUGOTHER (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,effect,Diuretic,tubocurarine
Curariform DRUGOTHER: DRUGOTHER-induced hypokalemia may enhance neuromuscular blocking effects of curariform DRUGOTHER (such as DRUG2) the most serious effect would be respiratory depression which could proceed to apnea. ,negative,curariform drugs,tubocurarine
DRUG1 and Other Non-Steroidal DRUGOTHER DRUGOTHER: May decrease the DRUGOTHER effects of DRUGOTHER Tablets. ,negative,Salicylates,Non-Steroidal Anti-Inflammatory Drugs
DRUG1 and Other Non-Steroidal DRUGOTHER DRUGOTHER: May decrease the DRUGOTHER effects of DRUG2 Tablets. ,effect,Salicylates,MYKROX
DRUGOTHER and Other Non-Steroidal DRUGOTHER DRUGOTHER: May decrease the DRUGOTHER effects of DRUG2 Tablets. ,effect,Non-Steroidal Anti-Inflammatory Drugs,MYKROX
"DRUG1: DRUG2 may decrease arterial responsiveness to DRUGOTHER, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",negative,Sympathomimetics,Metolazone
"DRUG1: DRUGOTHER may decrease arterial responsiveness to DRUG2, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",negative,Sympathomimetics,norepinephrine
"DRUGOTHER: DRUG1 may decrease arterial responsiveness to DRUG2, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ",effect,Metolazone,norepinephrine
DRUG1: Efficacy may be decreased due to urinary alkalizing effect of DRUG2. ,effect,Methenamine,metolazone
"DRUG1: DRUG2, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,Metolazone
"DRUG1: DRUGOTHER, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,thiazide-like diuretics
"DRUG1: DRUGOTHER, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUG1; ",negative,Anticoagulants,anticoagulants
"DRUGOTHER: DRUG1, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUGOTHER; ",negative,Metolazone,thiazide-like diuretics
"DRUG2: DRUG1, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUG2; ",effect,Metolazone,anticoagulants
"DRUG2: DRUGOTHER, as well as other DRUGOTHER-like DRUGOTHER, may affect the hypoprothrombinemic response to DRUG2; ",negative,thiazide-like diuretics,anticoagulants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,amantadine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,quinidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,antihistamines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",effect,anticholinergic drugs,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,quinidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,antihistamines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,amantadine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUG2), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,quinidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,antihistamines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER agents of class I (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antiarrhythmic agents of class I,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,antihistamines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUG2 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,quinidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUG2 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,antipsychotic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antihistamines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,phenothiazines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1 (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,antipsychotic agents,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,benzodiazepines
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,phenothiazines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUG2, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,MAO inhibitors
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,benzodiazepines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,narcotic analgesics
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,MAO inhibitors,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG2), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,narcotic analgesics,meperidine
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,narcotic analgesics,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,narcotic analgesics,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,narcotic analgesics,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,narcotic analgesics,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG1), DRUG2 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,meperidine,nitrates
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,meperidine,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,meperidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUG1), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,meperidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUG2, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,nitrates,nitrites
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,nitrates,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUG1 and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,nitrates,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG1, DRUGOTHER agents, DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,nitrites,sympathomimetic agents
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUG1, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,nitrites,tricyclic antidepressants
"The following agents may increase certain actions or side effects of DRUGOTHER DRUGOTHER: DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER and DRUGOTHER, DRUGOTHER agents, DRUGOTHER DRUGOTHER, and other DRUGOTHER having DRUGOTHER activity. ",negative,sympathomimetic agents,tricyclic antidepressants
DRUG1 antagonize the effects of DRUG2. ,effect,Anticholinergics,antiglaucoma agents
DRUGOTHER DRUGOTHER in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as DRUG2. ,effect,Anticholinergic drugs,corticosteroids
"DRUGOTHER agents may affect gastrointestinal absorption of various DRUGOTHER, such as slowly dissolving dosage forms of DRUG2; ",mechanism,Anticholinergic agents,digoxin
"DRUGOTHER DRUGOTHER may antagonize the effects of DRUGOTHER that alter gastrointestinal motility, such as DRUG2. ",effect,Anticholinergic drugs,metoclopramide
"Because DRUG1 may interfere with the absorption of DRUGOTHER agents, simultaneous use of these DRUGOTHER should be avoided. ",mechanism,antacids,anticholinergic agents
"DRUG1 should be used with caution in patients receiving other local DRUG2 or agents structurally related to DRUGOTHER, since the toxic effects of these DRUGOTHER are additive. ",advise,Ropivacaine,anesthetics
"DRUG1 should be used with caution in patients receiving other local DRUGOTHER or agents structurally related to amide-type local DRUGOTHER, since the toxic effects of these DRUGOTHER are additive. ",negative,Ropivacaine,amide-type local anesthetics
"DRUGOTHER should be used with caution in patients receiving other local DRUG1 or agents structurally related to amide-type local DRUG1, since the toxic effects of these DRUGOTHER are additive. ",negative,anesthetics,amide-type local anesthetics
"In vivo, the plasma clearance of DRUG1 was reduced by 70% during coadministration of DRUG2 (25 mg bid for 2 days), a selective and potent DRUGOTHER inhibitor. ",mechanism,ropivacaine,fluvoxamine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",int,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",negative,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUG1, given concomitantly during administration of DRUG2, can interact with DRUG2 leading to increased DRUG2 plasma levels. ",negative,fluvoxamine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as DRUGOTHER, given concomitantly during administration of DRUG1, can interact with DRUG1 leading to increased DRUG1 plasma levels. ",negative,Ropivacaine,ropivacaine
Possible interactions with DRUGOTHER known to be metabolized by DRUGOTHER via competitive inhibition such as DRUG1 and DRUG2 may also occur. ,negative,theophylline,imipramine
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",negative,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUG1 (100 mg bid for 2 days with DRUGOTHER infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUGOTHER.",negative,ketoconazole,ketoconazole
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",mechanism,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUG2 (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after DRUG2) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",negative,ropivacaine,ketoconazole
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUGOTHER (100 mg bid for 2 days with DRUG1 infusion administered 1 hour after DRUGOTHER) caused a 15% reduction in in-vivo plasma clearance of DRUG1.",negative,ropivacaine,ropivacaine
"Coadministration of a selective and potent inhibitor of DRUGOTHER, DRUG1 (100 mg bid for 2 days with DRUG2 infusion administered 1 hour after DRUG1) caused a 15% reduction in in-vivo plasma clearance of DRUG2.",negative,ketoconazole,ropivacaine
"In elderly patients concurrently receiving certain DRUG1, primarily DRUG2, an increased incidence of thrombopenia with purpura has been reported. ",negative,diuretics,thiazides
It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the DRUG2 DRUGOTHER. ,negative,sulfamethoxazole,anticoagulant
It has been reported that DRUG1 may prolong the prothrombin time in patients who are receiving the DRUGOTHER DRUG2. ,effect,sulfamethoxazole,warfarin
It has been reported that DRUGOTHER may prolong the prothrombin time in patients who are receiving the DRUG1 DRUG2. ,negative,anticoagulant,warfarin
DRUG1 may inhibit the hepatic metabolism of DRUG2. ,mechanism,Sulfamethoxazole,phenytoin
"At a 1.6-g dose, DRUG1 produced a slight but significant increase in the half-life of DRUG2 but did not produce a corresponding decrease in the metabolic clearance rate. ",mechanism,sulfamethoxazole,phenytoin
"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",mechanism,Sulfonamides,methotrexate
"DRUG1 can also displace DRUG2 from plasma protein-binding sites, thus increasing free DRUG2 concentrations. ",negative,Sulfonamides,methotrexate
"DRUGOTHER can also displace DRUG1 from plasma protein-binding sites, thus increasing free DRUG1 concentrations. ",negative,methotrexate,methotrexate
There is usually complete cross-resistance between DRUG1 (DRUG2) and DRUGOTHER brand DRUGOTHER. ,negative,PURINETHOL,mercaptopurine
There is usually complete cross-resistance between DRUG1 (DRUGOTHER) and DRUG2 brand DRUGOTHER. ,effect,PURINETHOL,TABLOID
There is usually complete cross-resistance between DRUG1 (DRUGOTHER) and DRUGOTHER brand DRUG2. ,effect,PURINETHOL,Thioguanine
There is usually complete cross-resistance between DRUGOTHER (DRUG1) and DRUG2 brand DRUGOTHER. ,effect,mercaptopurine,TABLOID
There is usually complete cross-resistance between DRUGOTHER (DRUG1) and DRUGOTHER brand DRUG2. ,effect,mercaptopurine,Thioguanine
There is usually complete cross-resistance between DRUGOTHER (DRUGOTHER) and DRUG1 brand DRUG2. ,negative,TABLOID,Thioguanine
"As there is in vitro evidence that DRUG1 (e.g., DRUG2, DRUGOTHER, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,aminosalicylate derivatives,olsalazine
"As there is in vitro evidence that DRUG1 (e.g., DRUGOTHER, DRUG2, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,aminosalicylate derivatives,mesalazine
"As there is in vitro evidence that DRUG1 (e.g., DRUGOTHER, DRUGOTHER, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,aminosalicylate derivatives,sulphasalazine
"As there is in vitro evidence that DRUG1 (e.g., DRUGOTHER, DRUGOTHER, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,aminosalicylate derivatives,thioguanine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUG2, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,olsalazine,mesalazine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,olsalazine,sulphasalazine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUG1, DRUGOTHER, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,olsalazine,thioguanine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUG1, or DRUG2) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUGOTHER therapy.    ",negative,mesalazine,sulphasalazine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUG1, or DRUGOTHER) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,mesalazine,thioguanine
"As there is in vitro evidence that DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, or DRUG1) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent DRUG2 therapy.    ",mechanism,sulphasalazine,thioguanine
"DRUG1 has been reported to enhance the DRUGOTHER activity of DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Thalidomide,barbiturates
"DRUG1 has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,Thalidomide,alcohol
"DRUG1 has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,Thalidomide,chlorpromazine
"DRUG1 has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,Thalidomide,reserpine
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,barbiturates,alcohol
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,barbiturates,chlorpromazine
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,barbiturates,reserpine
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,alcohol,chlorpromazine
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,alcohol,reserpine
"DRUGOTHER has been reported to enhance the DRUGOTHER activity of DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,chlorpromazine,reserpine
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of DRUG2 and DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER and 75    g of DRUGOTHER were studied. ",negative,Contraceptives,norethindrone
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of ethinyl DRUGOTHER were studied. ",negative,Contraceptives,ethinyl estradiol
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of DRUGOTHER were studied. ",negative,Contraceptives,norethindrone acetate
"Oral DRUG1: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of ethinyl DRUGOTHER were studied. ",negative,Contraceptives,ethinyl estradiol
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER and 75    g of ethinyl DRUGOTHER were studied. ",negative,norethindrone,ethinyl estradiol
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and DRUGOTHER following administration of a single dose containing 1.0 mg of DRUG1 acetate and 75    g of DRUGOTHER were studied. ",negative,norethindrone,norethindrone acetate
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUG1 and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER and 75    g of ethinyl DRUGOTHER were studied. ",negative,norethindrone,ethinyl estradiol
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of ethinyl DRUGOTHER were studied. ",negative,ethinyl estradiol,norethindrone acetate
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of ethinyl DRUGOTHER were studied. ",negative,ethinyl estradiol,ethinyl estradiol
"Oral DRUGOTHER: In 10 healthy women, the pharmacokinetic profiles of DRUGOTHER and ethinyl DRUGOTHER following administration of a single dose containing 1.0 mg of DRUGOTHER acetate and 75    g of ethinyl DRUGOTHER were studied. ",negative,norethindrone acetate,ethinyl estradiol
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,Hormonal Contraceptives
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,HIV-protease inhibitors
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,griseofulvin
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,modafinil
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,penicillins
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,rifampin
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,rifabutin
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,Thalidomide,phenytoin
"Important Non-DRUG1 DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,Thalidomide,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,HIV-protease inhibitors
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,griseofulvin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,modafinil
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,penicillins
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,rifampin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,Hormonal Contraceptives,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,griseofulvin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,modafinil
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,penicillins
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,rifampin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,HIV-protease inhibitors,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,griseofulvin,modafinil
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,griseofulvin,penicillins
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,griseofulvin,rifampin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,griseofulvin,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,griseofulvin,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,griseofulvin,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,modafinil,penicillins
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,modafinil,rifampin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,modafinil,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,modafinil,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,modafinil,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,penicillins,rifampin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,penicillins,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,penicillins,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,penicillins,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or certain herbal supplements such as St. ",negative,rifampin,rifabutin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,rifampin,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,rifampin,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or certain herbal supplements such as St. ",negative,rifabutin,phenytoin
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or certain herbal supplements such as St. ",negative,rifabutin,carbamazepine
"Important Non-DRUGOTHER DRUGOTHER Interactions DRUGOTHER That Interfere with Hormonal DRUGOTHER: Concomitant use of HIV-DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or certain herbal supplements such as St. ",negative,phenytoin,carbamazepine
DRUG1 with hormonal DRUGOTHER agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,effect,John's Wort,hormonal contraceptive agents
"Catecholamine-depleting DRUGOTHER (e.g., DRUG1) may have an additive effect when given with DRUGOTHER agents. ",effect,reserpine,beta-blocking agents
"The CNS-depressant effect of DRUG1 is additive with that of other DRUG2, including DRUGOTHER. ",effect,propoxyphene,CNS depressants
"The CNS-depressant effect of DRUG1 is additive with that of other DRUGOTHER, including DRUG2. ",effect,propoxyphene,alcohol
"The CNS-depressant effect of DRUGOTHER is additive with that of other DRUG1, including DRUG2. ",negative,CNS depressants,alcohol
"Such occurrences have been reported when DRUG1 was administered to patients on DRUG2, DRUGOTHER, or DRUGOTHER-like DRUGOTHER. ",negative,propoxyphene,antidepressants
"Such occurrences have been reported when DRUG1 was administered to patients on DRUGOTHER, DRUG2, or DRUGOTHER-like DRUGOTHER. ",negative,propoxyphene,anticonvulsants
"Such occurrences have been reported when DRUG1 was administered to patients on DRUGOTHER, DRUGOTHER, or DRUG2-like DRUGOTHER. ",negative,propoxyphene,warfarin
"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUG1, DRUG2, or DRUGOTHER-like DRUGOTHER. ",negative,antidepressants,anticonvulsants
"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUG1, DRUGOTHER, or DRUG2-like DRUGOTHER. ",negative,antidepressants,warfarin
"Such occurrences have been reported when DRUGOTHER was administered to patients on DRUGOTHER, DRUG1, or DRUG2-like DRUGOTHER. ",negative,anticonvulsants,warfarin
DRUG1 at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of DRUG2 (predominantly a cytochrome P450 1A2 substrate). ,negative,Montelukast,theophylline
- did not change the pharmacokinetic profile of DRUG1 (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of DRUG1 on prothrombin time or the INR (International Normalized Ratio). ,negative,warfarin,warfarin
"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or DRUG2, its carboxylated metabolite, and did not prolong the QTc interval following DRUGOTHER-administration with DRUG1 60 mg twice daily. ",negative,terfenadine,fexofenadine
"- did not change the plasma concentration profile of DRUG1 (a substrate of cytochrome P450 3A4) or DRUGOTHER, its carboxylated metabolite, and did not prolong the QTc interval following DRUGOTHER-administration with DRUG1 60 mg twice daily. ",negative,terfenadine,terfenadine
"- did not change the plasma concentration profile of DRUG2 (a substrate of cytochrome P450 3A4) or DRUG1, its carboxylated metabolite, and did not prolong the QTc interval following DRUGOTHER-administration with DRUG2 60 mg twice daily. ",negative,fexofenadine,terfenadine
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG2 containing DRUGOTHER 1 mg/DRUGOTHER 35 mcg. ,negative,Montelukast,contraceptive
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUG2 1 mg/DRUGOTHER 35 mcg. ,negative,Montelukast,norethindrone
DRUG1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUGOTHER 1 mg/DRUGOTHER 35 mcg. ,negative,Montelukast,estradiol
DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing DRUG2 1 mg/DRUGOTHER 35 mcg. ,negative,contraceptive,norethindrone
DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUG1 containing DRUGOTHER 1 mg/DRUGOTHER 35 mcg. ,negative,contraceptive,estradiol
DRUGOTHER at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral DRUGOTHER containing DRUG1 1 mg/DRUGOTHER 35 mcg. ,negative,norethindrone,estradiol
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUGOTHER following administration of either oral DRUG1 or intravenous DRUGOTHER.  ,negative,prednisone,prednisone
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG2 or DRUG1 following administration of either oral DRUG2 or intravenous DRUG1.  ,negative,prednisolone,prednisone
- did not cause any clinically significant change in plasma profiles of DRUGOTHER or DRUG1 following administration of either oral DRUGOTHER or intravenous DRUG1.  ,negative,prednisolone,prednisolone
- did not cause any clinically significant change in plasma profiles of DRUG1 or DRUG2 following administration of either oral DRUG1 or intravenous DRUG2.  ,negative,prednisone,prednisolone
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUGOTHER, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are DRUGOTHER-administered with DRUGOTHER. ",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUGOTHER, are DRUGOTHER-administered with DRUG2. ",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUGOTHER or DRUG1, are DRUGOTHER-administered with DRUG2. ",advise,rifampin,montelukast
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,theophylline
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,prednisone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,prednisolone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,contraceptives
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,norethindrone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,montelukast,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,montelukast,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUG1 did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,montelukast,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUG2, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,prednisone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,prednisolone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,contraceptives
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,norethindrone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,theophylline,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,theophylline,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,theophylline,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUG2, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisone,prednisolone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisone,contraceptives
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisone,norethindrone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisone,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,prednisone,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,prednisone,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,prednisone,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUG2 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,contraceptives
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,norethindrone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,prednisolone,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,prednisolone,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,prednisolone,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUG2 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,contraceptives,norethindrone
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,contraceptives,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,contraceptives,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,contraceptives,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUG1 (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,contraceptives,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,norethindrone,ethinyl estradiol
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,norethindrone,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,norethindrone,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUG1 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,norethindrone,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,ethinyl estradiol,terfenadine
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,ethinyl estradiol,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/ethinyl DRUGOTHER 35 mcg), DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,ethinyl estradiol,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG1, DRUG2, and DRUGOTHER. ",negative,terfenadine,digoxin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUG1, DRUGOTHER, and DRUG2. ",negative,terfenadine,warfarin
"In DRUGOTHER-interaction studies, the recommended clinical dose of DRUGOTHER did not have clinically important effects on the pharmacokinetics of the following DRUGOTHER: DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER (DRUGOTHER 1 mg/DRUGOTHER 35 mcg), DRUGOTHER, DRUG1, and DRUG2. ",negative,digoxin,warfarin
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,thyroid hormones,sedative hypnotics
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, non-steroidal DRUGOTHER agents, DRUGOTHER, and DRUGOTHER. ",negative,thyroid hormones,non-steroidal anti-inflammatory agents
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,thyroid hormones,benzodiazepines
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,thyroid hormones,decongestants
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, non-steroidal DRUGOTHER agents, DRUGOTHER, and DRUGOTHER. ",negative,sedative hypnotics,non-steroidal anti-inflammatory agents
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,sedative hypnotics,benzodiazepines
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,sedative hypnotics,decongestants
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, non-steroidal DRUGOTHER agents, DRUG2, and DRUGOTHER. ",negative,non-steroidal anti-inflammatory agents,benzodiazepines
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, non-steroidal DRUGOTHER agents, DRUGOTHER, and DRUG2. ",negative,non-steroidal anti-inflammatory agents,decongestants
"These medications included DRUGOTHER hormones, DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,benzodiazepines,decongestants
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUG1, which induces hepatic metabolism, decreased the AUC of DRUG2 approximately 40% following a single 10-mg dose of DRUG2. ",negative,Phenobarbital,montelukast
"DRUGOTHER, which induces hepatic metabolism, decreased the AUC of DRUG1 approximately 40% following a single 10-mg dose of DRUG1. ",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUG2, are DRUGOTHER-administered with DRUGOTHER.",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUG1 or DRUGOTHER, are DRUGOTHER-administered with DRUG2.",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as DRUGOTHER or DRUG1, are DRUGOTHER-administered with DRUG2.",advise,rifampin,montelukast
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Carbidopa,Carbidopa
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Carbidopa,pramipexole
DRUG2/DRUG1: DRUG2/DRUG1 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Levodopa,Carbidopa
DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Levodopa,Levodopa
DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Levodopa,pramipexole
DRUG1/DRUG2: DRUG1/DRUG2 does not influence the pharmacokinetics of DRUGOTHER in healthy volunteers (N= 10). ,negative,Carbidopa,Levodopa
DRUG1/DRUGOTHER: DRUG1/DRUGOTHER does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Carbidopa,pramipexole
DRUGOTHER/DRUG1: DRUGOTHER/DRUG1 does not influence the pharmacokinetics of DRUG2 in healthy volunteers (N= 10). ,negative,Levodopa,pramipexole
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUGOTHER. ",negative,Selegiline,selegiline
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUG2. ",negative,Selegiline,pramipexole
"DRUG1: In healthy volunteers (N= 11), DRUG1 did not influence the pharmacokinetics of DRUG2. ",negative,selegiline,pramipexole
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUGOTHER (N= 54). ,negative,Amantadine,amantadine
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUG2 (N= 54). ,negative,Amantadine,pramipexole
DRUG1: Population pharmacokinetic analysis suggests that DRUG1 is unlikely to alter the oral clearance of DRUG2 (N= 54). ,negative,amantadine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUGOTHER AUC and a 40% increase in half-life (N= 12). ",negative,Cimetidine,Cimetidine
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",negative,Cimetidine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in DRUG2 AUC and a 40% increase in half-life (N= 12). ",mechanism,Cimetidine,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUGOTHER pharmacokinetics (N= 12). ",negative,Probenecid,Probenecid
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",negative,Probenecid,pramipexole
"DRUG1: DRUG1, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence DRUG2 pharmacokinetics (N= 12). ",negative,Probenecid,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,ranitidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,diltiazem
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,triamterene
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,verapamil
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,quinidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,cimetidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cimetidine,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,cimetidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,diltiazem
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,triamterene
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,verapamil
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,quinidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,ranitidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,ranitidine,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,ranitidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,triamterene
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,verapamil
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,quinidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,diltiazem,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,diltiazem,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,diltiazem,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,verapamil
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,quinidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,triamterene,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,triamterene,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,triamterene,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,quinidine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,verapamil,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,verapamil,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,verapamil,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,quinine
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,quinidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinidine,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,quinidine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,quinine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinine,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinine,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinine,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinine,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,quinine,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",negative,quinine,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,cephalosporins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG1 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG1. ",negative,pramipexole,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cephalosporins,penicillins
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cephalosporins,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cephalosporins,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,cephalosporins,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,cephalosporins,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,penicillins,indomethacin
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,penicillins,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,penicillins,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,penicillins,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,indomethacin,hydrochlorothiazide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,indomethacin,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,indomethacin,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUGOTHER by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2) are likely to have little effect on the oral clearance of DRUGOTHER. ",negative,hydrochlorothiazide,chlorpropamide
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,hydrochlorothiazide,pramipexole
"Other DRUGOTHER eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of DRUGOTHER that are secreted by the cationic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER) decreases the oral clearance of DRUG2 by about 20%, while those secreted by the anionic transport system (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1) are likely to have little effect on the oral clearance of DRUG2. ",mechanism,chlorpropamide,pramipexole
CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect DRUG1 elimination because DRUG1 is not appreciably metabolized by these enzymes in vivo or in vitro. ,negative,pramipexole,pramipexole
"DRUGOTHER antagonists: Since DRUG2 is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,pramipexole
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,dopamine agonist
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,dopamine antagonists
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,neuroleptics
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,phenothiazines
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,butyrophenones
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,thioxanthenes
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,Dopamine antagonists,metoclopramide
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",negative,Dopamine antagonists,MIRAPEX
"DRUGOTHER: Since DRUG1 is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,dopamine agonist
"DRUGOTHER antagonists: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,dopamine antagonists
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,neuroleptics
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,phenothiazines
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,butyrophenones
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,thioxanthenes
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,pramipexole,metoclopramide
"DRUGOTHER: Since DRUG1 is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",negative,pramipexole,MIRAPEX
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,dopamine antagonists
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,neuroleptics
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,phenothiazines
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,butyrophenones
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,thioxanthenes
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine agonist,metoclopramide
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER agonist, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",negative,dopamine agonist,MIRAPEX
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine antagonists,neuroleptics
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine antagonists,phenothiazines
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine antagonists,butyrophenones
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine antagonists,thioxanthenes
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,dopamine antagonists,metoclopramide
"DRUGOTHER antagonists: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",effect,dopamine antagonists,MIRAPEX
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,neuroleptics,phenothiazines
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,neuroleptics,butyrophenones
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,neuroleptics,thioxanthenes
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,neuroleptics,metoclopramide
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",effect,neuroleptics,MIRAPEX
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,phenothiazines,butyrophenones
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,phenothiazines,thioxanthenes
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,phenothiazines,metoclopramide
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",effect,phenothiazines,MIRAPEX
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) or DRUGOTHER, may diminish the effectiveness of DRUGOTHER. ",negative,butyrophenones,thioxanthenes
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,butyrophenones,metoclopramide
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",effect,butyrophenones,MIRAPEX
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) or DRUG2, may diminish the effectiveness of DRUGOTHER. ",negative,thioxanthenes,metoclopramide
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) or DRUGOTHER, may diminish the effectiveness of DRUG2. ",effect,thioxanthenes,MIRAPEX
"DRUGOTHER: Since DRUGOTHER is a DRUGOTHER, it is possible that DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1, may diminish the effectiveness of DRUG2. ",effect,metoclopramide,MIRAPEX
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,theophylline
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,cisapride
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,antipyrine
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,caffeine
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,carbamazepine
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,diazepam
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,diclofenac
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,naproxen
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,piroxicam
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,digoxin
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,ethanol
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,glyburide
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,contraceptive
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,levonorgestrel
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,metoprolol
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,nifedipine
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,phenytoin
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,warfarin
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,midazolam
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,pantoprazole,clarithromycin
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,pantoprazole,metronidazole
"Based on studies evaluating possible interactions of DRUG1 with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,pantoprazole,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,cisapride
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,antipyrine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,caffeine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,carbamazepine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,diazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,theophylline,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,theophylline,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,theophylline,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,antipyrine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,caffeine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,carbamazepine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,diazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,cisapride,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,cisapride,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,cisapride,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,caffeine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,carbamazepine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,diazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,antipyrine,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,antipyrine,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,antipyrine,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,carbamazepine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,diazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,caffeine,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,caffeine,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,caffeine,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,diazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,carbamazepine,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,carbamazepine,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,carbamazepine,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,desmethyldiazepam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,diazepam,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,diazepam,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,diazepam,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,diclofenac
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,desmethyldiazepam,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,desmethyldiazepam,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,desmethyldiazepam,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,naproxen
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,diclofenac,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,diclofenac,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,diclofenac,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,piroxicam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,naproxen,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,naproxen,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,naproxen,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,digoxin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,piroxicam,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,piroxicam,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,piroxicam,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,ethanol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,digoxin,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,digoxin,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,glyburide
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,ethanol,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,ethanol,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,ethanol,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUG2 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,contraceptive
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,glyburide,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,glyburide,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,glyburide,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUG2/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,levonorgestrel
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,contraceptive,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,contraceptive,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUG1 (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,contraceptive,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,ethinyl estradiol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,levonorgestrel,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,levonorgestrel,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUG1/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,levonorgestrel,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,metoprolol
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,ethinyl estradiol,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,ethinyl estradiol,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/ethinyl DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,ethinyl estradiol,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,metoprolol,nifedipine
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,metoprolol,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,metoprolol,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,metoprolol,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,metoprolol,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,metoprolol,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,metoprolol,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,nifedipine,phenytoin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,nifedipine,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,nifedipine,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,nifedipine,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,nifedipine,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,nifedipine,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,phenytoin,warfarin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,phenytoin,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,phenytoin,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,phenytoin,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,phenytoin,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,warfarin,midazolam
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,warfarin,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,warfarin,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,warfarin,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,midazolam,clarithromycin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,midazolam,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,midazolam,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,clarithromycin,metronidazole
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",negative,clarithromycin,amoxicillin
"Based on studies evaluating possible interactions of DRUGOTHER with other DRUGOTHER, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",negative,metronidazole,amoxicillin
"Therefore, when coadministered with DRUG1, adjustment of the dosage of DRUG1 or of such DRUGOTHER may not be necessary. ",negative,pantoprazole,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUG1, including DRUG2, and DRUGOTHER concomitantly. ",negative,proton pump inhibitors,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUG1, including DRUGOTHER, and DRUG2 concomitantly. ",effect,proton pump inhibitors,warfarin
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving DRUGOTHER, including DRUG1, and DRUG2 concomitantly. ",effect,pantoprazole,warfarin
Patients treated with DRUG1 and DRUG2 concomitantly should be monitored for increases in INR and prothrombin time. ,advise,proton pump inhibitors,warfarin
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUG2, DRUGOTHER esters, and DRUGOTHER salts). ",mechanism,pantoprazole,ketoconazole
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUGOTHER, DRUG2 esters, and DRUGOTHER salts). ",mechanism,pantoprazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion, DRUG1 may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUGOTHER, DRUGOTHER esters, and DRUG2 salts). ",mechanism,pantoprazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion, DRUGOTHER may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUG1, DRUG2 esters, and DRUGOTHER salts). ",negative,ketoconazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion, DRUGOTHER may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUG1, DRUGOTHER esters, and DRUG2 salts). ",negative,ketoconazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion, DRUGOTHER may interfere with absorption of DRUGOTHER where gastric pH is an important determinant of their bioavailability (eg, DRUGOTHER, DRUG1 esters, and DRUG2 salts). ",negative,ampicillin,iron
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUG2) in patients receiving most DRUGOTHER, including DRUGOTHER. ",negative,tetrahydrocannabinol,THC
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUGOTHER) in patients receiving most DRUG2, including DRUGOTHER. ",negative,tetrahydrocannabinol,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUG1 (DRUGOTHER) in patients receiving most DRUGOTHER, including DRUG2. ",negative,tetrahydrocannabinol,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUGOTHER (DRUG1) in patients receiving most DRUG2, including DRUGOTHER. ",negative,THC,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUGOTHER (DRUG1) in patients receiving most DRUGOTHER, including DRUG2. ",negative,THC,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for DRUGOTHER (DRUGOTHER) in patients receiving most DRUG1, including DRUG2. ",negative,proton pump inhibitors,pantoprazole
"Other eye drops or medications such as DRUG1 (DRUG2) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,acetylcholine chloride,Miochol
"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUG2 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,acetylcholine chloride,carbachol
"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUG2, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,acetylcholine chloride,Carboptic
"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,acetylcholine chloride,Isopto Carbachol
"Other eye drops or medications such as DRUG1 (DRUGOTHER) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",effect,acetylcholine chloride,suprofen
"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUG2 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,Miochol,carbachol
"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUG2, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,Miochol,Carboptic
"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,Miochol,Isopto Carbachol
"Other eye drops or medications such as DRUGOTHER (DRUG1) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",effect,Miochol,suprofen
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUG2, DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,carbachol,Carboptic
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUGOTHER, Isopto DRUG1) may decrease the effects of DRUGOTHER ophthalmic.",negative,carbachol,Isopto Carbachol
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUG1 (DRUGOTHER, DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",effect,carbachol,suprofen
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUG1, Isopto DRUGOTHER) may decrease the effects of DRUGOTHER ophthalmic.",negative,Carboptic,Isopto Carbachol
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUG1, Isopto DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",effect,Carboptic,suprofen
"Other eye drops or medications such as DRUGOTHER (DRUGOTHER) and DRUGOTHER (DRUGOTHER, Isopto DRUGOTHER) may decrease the effects of DRUG2 ophthalmic.",effect,Isopto Carbachol,suprofen
"You cannot take DRUG1 if you have taken a DRUG2 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,monoamine oxidase inhibitor
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUG2) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,MAOI
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,isocarboxazid
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,Marplan
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,tranylcypromine
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",advise,mazindol,Parnate
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",advise,mazindol,phenelzine
"You cannot take DRUG1 if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",advise,mazindol,Nardil
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUG2) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,MAOI
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,isocarboxazid
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,Marplan
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,tranylcypromine
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,Parnate
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,monoamine oxidase inhibitor,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUG1 (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,monoamine oxidase inhibitor,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,MAOI,isocarboxazid
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,MAOI,Marplan
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,MAOI,tranylcypromine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,MAOI,Parnate
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,MAOI,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUG1) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,MAOI,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,isocarboxazid,Marplan
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,isocarboxazid,tranylcypromine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,isocarboxazid,Parnate
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,isocarboxazid,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,isocarboxazid,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,Marplan,tranylcypromine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,Marplan,Parnate
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,Marplan,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,Marplan,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), or DRUGOTHER (DRUGOTHER) in the last 14 days. ",negative,tranylcypromine,Parnate
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,tranylcypromine,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,tranylcypromine,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUG2 (DRUGOTHER) in the last 14 days. ",negative,Parnate,phenelzine
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUGOTHER (DRUG2) in the last 14 days. ",negative,Parnate,Nardil
"You cannot take DRUGOTHER if you have taken a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG1 (DRUG2) in the last 14 days. ",negative,phenelzine,Nardil
Changes in DRUG1 and other diabetes DRUGOTHER therapies may be necessary during treatment with DRUG2.,advise,insulin,mazindol
DRUG1 may reduce the effects of DRUG2 (DRUGOTHER). ,effect,Mazindol,guanethidine
DRUG1 may reduce the effects of DRUGOTHER (DRUG2). ,effect,Mazindol,Ismelin
DRUGOTHER may reduce the effects of DRUG1 (DRUG2). ,negative,guanethidine,Ismelin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,amitriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Elavil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,amoxapine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Asendin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,tricyclic antidepressant,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,tricyclic antidepressant,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,tricyclic antidepressant,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Elavil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,amoxapine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Asendin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,amitriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,amitriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,amitriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,amoxapine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Asendin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Elavil,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Elavil,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Elavil,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Asendin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,amoxapine,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,amoxapine,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,amoxapine,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,doxepin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Asendin,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Asendin,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Asendin,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,Sinequan
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,doxepin,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,doxepin,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,doxepin,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,nortriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Sinequan,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Sinequan,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Sinequan,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,nortriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,nortriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,nortriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,imipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Pamelor,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Pamelor,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Pamelor,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,imipramine,Tofranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,imipramine,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,imipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,imipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,imipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,imipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,imipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Tofranil,clomipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Tofranil,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Tofranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Tofranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Tofranil,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Tofranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,clomipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,clomipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,clomipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,clomipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,clomipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUG2 (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",negative,Anafranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,Anafranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,Anafranil,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,Anafranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), or DRUGOTHER (DRUGOTHER). ",negative,protriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUG2 (DRUGOTHER). ",negative,protriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), or DRUGOTHER (DRUG2). ",negative,protriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUG2 (DRUGOTHER). ",negative,Vivactil,desipramine
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), or DRUGOTHER (DRUG2). ",negative,Vivactil,Norpramin
"Before taking this medication, tell your doctor if you are taking a DRUGOTHER DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUG1 (DRUG2). ",negative,desipramine,Norpramin
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or DRUGOTHER or the combination of DRUG2 and DRUGOTHER. ,negative,abacavir,lamivudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUGOTHER or DRUG2 or the combination of DRUGOTHER and DRUG2. ,negative,abacavir,zidovudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUG2 or DRUGOTHER or the combination of DRUG2 and DRUGOTHER. ,negative,abacavir,lamivudine
Pharmacokinetic properties of DRUG1 were not altered by the addition of either DRUGOTHER or DRUG2 or the combination of DRUGOTHER and DRUG2. ,negative,abacavir,zidovudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUGOTHER or the combination of DRUG1 and DRUGOTHER. ,negative,lamivudine,lamivudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG2 or DRUG1 or the combination of DRUG2 and DRUG1. ,negative,zidovudine,lamivudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUGOTHER or DRUG1 or the combination of DRUGOTHER and DRUG1. ,negative,zidovudine,zidovudine
Pharmacokinetic properties of DRUGOTHER were not altered by the addition of either DRUG1 or DRUG2 or the combination of DRUG1 and DRUG2. ,negative,lamivudine,zidovudine
No clinically significant changes to DRUG1 or DRUG2 pharmacokinetics were observed following concomitant administration of DRUGOTHER. ,negative,lamivudine,zidovudine
No clinically significant changes to DRUG1 or DRUGOTHER pharmacokinetics were observed following concomitant administration of DRUG2. ,negative,lamivudine,abacavir
No clinically significant changes to DRUGOTHER or DRUG1 pharmacokinetics were observed following concomitant administration of DRUG2. ,negative,zidovudine,abacavir
DRUG1 has no effect on the pharmacokinetic properties of DRUG2. ,negative,Abacavir,ethanol
DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,mechanism,Ethanol,abacavir
DRUG1 decreases the elimination of DRUGOTHER causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of DRUGOTHER. ,negative,Ethanol,methadone
DRUG1 decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,negative,Ethanol,abacavir
DRUGOTHER decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of DRUG2 has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,negative,abacavir,methadone
DRUGOTHER decreases the elimination of DRUG1 causing an increase in overall exposure . The addition of DRUGOTHER has no clinically significant effect on the pharmacokinetic properties of DRUG1. ,negative,abacavir,abacavir
DRUGOTHER decreases the elimination of DRUG2 causing an increase in overall exposure . The addition of DRUG1 has no clinically significant effect on the pharmacokinetic properties of DRUG2. ,negative,methadone,abacavir
"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG2 twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",mechanism,methadone,ZIAGEN
"In a study of 11 HIV-infected patients receiving DRUG1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUGOTHER twice daily (twice the currently recommended dose), oral DRUG1 clearance increased 22% (90% CI 6% to 42%). ",negative,methadone,methadone
"In a study of 11 HIV-infected patients receiving DRUG2-maintenance therapy (40 mg and 90 mg daily) with 600 mg of DRUG1 twice daily (twice the currently recommended dose), oral DRUG2 clearance increased 22% (90% CI 6% to 42%). ",negative,ZIAGEN,methadone
"DRUG1 may increase the effects of DRUG2, DRUGOTHER, and DRUGOTHER. ",effect,Sulfoxone,barbiturates
"DRUG1 may increase the effects of DRUGOTHER, DRUG2, and DRUGOTHER. ",effect,Sulfoxone,tolbutamide
"DRUG1 may increase the effects of DRUGOTHER, DRUGOTHER, and DRUG2. ",effect,Sulfoxone,uricosurics
"DRUGOTHER may increase the effects of DRUG1, DRUG2, and DRUGOTHER. ",negative,barbiturates,tolbutamide
"DRUGOTHER may increase the effects of DRUG1, DRUGOTHER, and DRUG2. ",negative,barbiturates,uricosurics
"DRUGOTHER may increase the effects of DRUGOTHER, DRUG1, and DRUG2. ",negative,tolbutamide,uricosurics
"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,cyclosporine
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,sulfonylurea agents
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,warfarin
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,sulfonylurea agents
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,warfarin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,warfarin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,warfarin,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,warfarin,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,methotrexate,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",negative,phenytoin,phenytoin
"DRUG1 are capable of potentiating DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) ",effect,Phenothiazines,CNS depressants
"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) ",effect,Phenothiazines,barbiturates
"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",effect,Phenothiazines,anesthetics
"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.) ",effect,Phenothiazines,opiates
"DRUG1 are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",effect,Phenothiazines,alcohol
"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.) ",negative,CNS depressants,barbiturates
"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",negative,CNS depressants,anesthetics
"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.) ",negative,CNS depressants,opiates
"DRUGOTHER are capable of potentiating DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",negative,CNS depressants,alcohol
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, etc.) ",negative,barbiturates,anesthetics
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, etc.) ",negative,barbiturates,opiates
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, etc.) ",negative,barbiturates,alcohol
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, etc.) ",negative,anesthetics,opiates
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, etc.) ",negative,anesthetics,alcohol
"DRUGOTHER are capable of potentiating DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, etc.) ",negative,opiates,alcohol
as well as DRUG1 and DRUG2.,negative,atropine,phosphorous insecticides
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or DRUG2 to warrant dosage adjustment when DRUGOTHER is administered with these DRUGOTHER. ,negative,zidovudine,rifabutin
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUG1 or DRUGOTHER to warrant dosage adjustment when DRUG2 is administered with these DRUGOTHER. ,negative,zidovudine,megestrol acetate
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of DRUGOTHER or DRUG1 to warrant dosage adjustment when DRUG2 is administered with these DRUGOTHER. ,negative,rifabutin,megestrol acetate
A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,mechanism,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of DRUG1 and DRUG2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG2. ,negative,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of DRUGOTHER and DRUG1 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of DRUG1. ,negative,indinavir,indinavir
Administration of a higher dose of DRUG1 should be considered when coadministering with DRUG2. ,advise,indinavir,megestrol acetate
"The effects of DRUG1, DRUG2 or DRUGOTHER on the pharmacokinetics of DRUGOTHER were not studied.",negative,indinavir,zidovudine
"The effects of DRUG1, DRUGOTHER or DRUG2 on the pharmacokinetics of DRUGOTHER were not studied.",negative,indinavir,rifabutin
"The effects of DRUG1, DRUGOTHER or DRUGOTHER on the pharmacokinetics of DRUG2 were not studied.",negative,indinavir,megestrol acetate
"The effects of DRUGOTHER, DRUG1 or DRUG2 on the pharmacokinetics of DRUGOTHER were not studied.",negative,zidovudine,rifabutin
"The effects of DRUGOTHER, DRUG1 or DRUGOTHER on the pharmacokinetics of DRUG2 were not studied.",negative,zidovudine,megestrol acetate
"The effects of DRUGOTHER, DRUGOTHER or DRUG1 on the pharmacokinetics of DRUG2 were not studied.",negative,rifabutin,megestrol acetate
DRUG1 has been reported to prolong the elimination half-life of DRUG2 and may DRUGOTHER to severe bone marrow suppression; ,mechanism,Streptozocin,doxorubicin
a reduction of the DRUG1 dosage should be considered in patients receiving DRUG2 concurrently. ,advise,doxorubicin,ZANOSAR
The concurrent use of DRUG1 and DRUG2 has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,effect,streptozocin,phenytoin
The concurrent use of DRUG1 and DRUGOTHER has been reported in one case to result in reduced DRUG1 cytotoxicity.    ,negative,streptozocin,streptozocin
The concurrent use of DRUG2 and DRUG1 has been reported in one case to result in reduced DRUG2 cytotoxicity.    ,negative,phenytoin,streptozocin
"DRUG1 should be used with caution in digitalized patients, since the combination of DRUG2 and DRUGOTHER may cause ectopic arrhythmias. ",negative,ARAMINE,digitalis
"DRUG1 should be used with caution in digitalized patients, since the combination of DRUGOTHER and DRUGOTHER amines may cause ectopic arrhythmias. ",negative,ARAMINE,sympathomimetic amines
"DRUGOTHER should be used with caution in digitalized patients, since the combination of DRUG1 and DRUGOTHER amines may cause ectopic arrhythmias. ",effect,digitalis,sympathomimetic amines
DRUG1 or DRUGOTHER DRUGOTHER may potentiate the action of DRUGOTHER. ,negative,Monoamine oxidase inhibitors,tricyclic antidepressants
DRUG1 or DRUGOTHER may potentiate the action of DRUGOTHER amines. ,effect,Monoamine oxidase inhibitors,sympathomimetic amines
DRUGOTHER or DRUGOTHER DRUGOTHER may potentiate the action of DRUGOTHER amines. ,effect,tricyclic antidepressants,sympathomimetic amines
"DRUG1 can interact with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Mequitazine,CNS depressant
"DRUG1 can interact with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Mequitazine,antichlolinergic
"DRUG1 can interact with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",int,Mequitazine,TCA
"DRUG1 can interact with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",int,Mequitazine,MAOIs
"DRUG1 can interact with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",int,Mequitazine,alcohol
"DRUGOTHER can interact with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,CNS depressant,antichlolinergic
"DRUGOTHER can interact with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,CNS depressant,TCA
"DRUGOTHER can interact with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,CNS depressant,MAOIs
"DRUGOTHER can interact with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,CNS depressant,alcohol
"DRUGOTHER can interact with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,antichlolinergic,TCA
"DRUGOTHER can interact with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,antichlolinergic,MAOIs
"DRUGOTHER can interact with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,antichlolinergic,alcohol
"DRUGOTHER can interact with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",negative,TCA,MAOIs
"DRUGOTHER can interact with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",negative,TCA,alcohol
"DRUGOTHER can interact with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",negative,MAOIs,alcohol
"DRUG1 may decrease the effectiveness of oral DRUG2, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Barbiturates,contraceptives
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Barbiturates,antibiotics
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Barbiturates,quinidine
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",int,Barbiturates,theophylline
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",int,Barbiturates,corticosteroids
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",int,Barbiturates,anticoagulants
"DRUG1 may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",int,Barbiturates,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,contraceptives,antibiotics
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,contraceptives,quinidine
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,contraceptives,theophylline
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,contraceptives,corticosteroids
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,contraceptives,anticoagulants
"DRUGOTHER may decrease the effectiveness of oral DRUG1, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,contraceptives,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,antibiotics,quinidine
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,antibiotics,theophylline
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,antibiotics,corticosteroids
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,antibiotics,anticoagulants
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,antibiotics,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,quinidine,theophylline
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,quinidine,corticosteroids
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,quinidine,anticoagulants
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,quinidine,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,theophylline,corticosteroids
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,theophylline,anticoagulants
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,theophylline,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",negative,corticosteroids,anticoagulants
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",negative,corticosteroids,beta blockers
"DRUGOTHER may decrease the effectiveness of oral DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",negative,anticoagulants,beta blockers
"DRUG1 may increase the effects of DRUG2, DRUGOTHER, and DRUGOTHER. ",effect,Sulfamethizole,barbiturates
"DRUG1 may increase the effects of DRUGOTHER, DRUG2, and DRUGOTHER. ",effect,Sulfamethizole,tolbutamide
"DRUG1 may increase the effects of DRUGOTHER, DRUGOTHER, and DRUG2. ",effect,Sulfamethizole,uricosurics
"DRUGOTHER may increase the effects of DRUG1, DRUG2, and DRUGOTHER. ",negative,barbiturates,tolbutamide
"DRUGOTHER may increase the effects of DRUG1, DRUGOTHER, and DRUG2. ",negative,barbiturates,uricosurics
"DRUGOTHER may increase the effects of DRUGOTHER, DRUG1, and DRUG2. ",negative,tolbutamide,uricosurics
"It may also interact with DRUG1 (increased thrombocytopenia), DRUG2 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,cyclosporine
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,sulfonylurea agents
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,warfarin
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,thiazides,methotrexate
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,thiazides,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,sulfonylurea agents
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,warfarin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,cyclosporine,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUG1 (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,cyclosporine,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUG2 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,warfarin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,sulfonylurea agents,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER agents (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,sulfonylurea agents,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,warfarin,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUG2 (decreased renal excretion of DRUG2), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,warfarin,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUG1 (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",negative,warfarin,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUGOTHER (decreased hepatic clearance of DRUGOTHER).",negative,methotrexate,methotrexate
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUG1 (decreased renal excretion of DRUG1), DRUG2 (decreased hepatic clearance of DRUG2).",negative,methotrexate,phenytoin
"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased DRUGOTHER response), DRUGOTHER (increased DRUGOTHER effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",negative,phenytoin,phenytoin
Patients studied in clinical trials of DRUG1 were routinely treated with DRUG2 and DRUGOTHER. ,negative,TNKase,heparin
Patients studied in clinical trials of DRUG1 were routinely treated with DRUGOTHER and DRUG2. ,negative,TNKase,aspirin
Patients studied in clinical trials of DRUGOTHER were routinely treated with DRUG1 and DRUG2. ,negative,heparin,aspirin
"DRUG1 (such as DRUG2 and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,Anticoagulants,heparin
"DRUG1 (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,Anticoagulants,vitamin K antagonists
"DRUG1 (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUG2, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,Anticoagulants,acetylsalicylic acid
"DRUG1 (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,Anticoagulants,dipyridamole
"DRUG1 (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,Anticoagulants,TNKase
"DRUGOTHER (such as DRUG1 and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,heparin,vitamin K antagonists
"DRUGOTHER (such as DRUG1 and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUG2, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,heparin,acetylsalicylic acid
"DRUGOTHER (such as DRUG1 and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,heparin,dipyridamole
"DRUGOTHER (such as DRUG1 and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,heparin,TNKase
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUG2, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,vitamin K antagonists,acetylsalicylic acid
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,vitamin K antagonists,dipyridamole
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,vitamin K antagonists,TNKase
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUG1, DRUG2, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUGOTHER therapy. ",negative,acetylsalicylic acid,dipyridamole
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUG1, DRUGOTHER, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,acetylsalicylic acid,TNKase
"DRUGOTHER (such as DRUGOTHER and DRUGOTHER antagonists) and DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG1, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy. ",effect,dipyridamole,TNKase
DRUG1: The effects of chronic DRUG1 use on the metabolism of DRUGOTHER are not known. ,negative,Cimetidine,cimetidine
DRUG1: The effects of chronic DRUG1 use on the metabolism of DRUG2 are not known. ,negative,Cimetidine,rimantadine
DRUG1: The effects of chronic DRUG1 use on the metabolism of DRUG2 are not known. ,negative,cimetidine,rimantadine
"When a single 100 mg dose of DRUGOTHER HCl was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUG2). ",mechanism,rimantadine HCl,Cimetidine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of DRUG1 was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUGOTHER). ",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of DRUGOTHER HCl was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine HCl,cimetidine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,rimantadine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUG2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG2 clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,rimantadine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG1 (300 mg four times a day), the apparent total DRUGOTHER clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUGOTHER clearance in the same subjects in the absence of DRUG1). ",negative,Cimetidine,cimetidine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUGOTHER (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUGOTHER). ",negative,rimantadine,rimantadine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine,cimetidine
"When a single 100 mg dose of DRUGOTHER was administered one hour after the initiation of DRUG2 (300 mg four times a day), the apparent total DRUG1 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total DRUG1 clearance in the same subjects in the absence of DRUG2). ",negative,rimantadine,cimetidine
"DRUG1: DRUGOTHER HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",negative,Acetaminophen,Rimantadine HCl
Coadministration with DRUG1 reduced the peak concentration and AUC values for DRUG2 by approximately 11%. ,mechanism,acetaminophen,rimantadine
"DRUG1: DRUGOTHER HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",negative,Aspirin,Rimantadine HCl
Peak plasma concentrations and AUC of DRUG1 were reduced approximately 10% in the presence of DRUG2.,mechanism,rimantadine,aspirin
DRUG1 may inhibit the hepatic metabolism of DRUG2. ,mechanism,Trimethoprim,phenytoin
"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",mechanism,Trimethoprim,phenytoin
"DRUG1, given at a common clinical dosage, increased the DRUG2 half-life by 51% and decreased the DRUG2 metabolic clearance rate by 30%. ",mechanism,Trimethoprim,phenytoin
"DRUGOTHER, given at a common clinical dosage, increased the DRUG1 half-life by 51% and decreased the DRUG1 metabolic clearance rate by 30%. ",negative,phenytoin,phenytoin
DRUG1 should be administered with caution to patients taking beta DRUGOTHER antagonists because of the possibility of conduction disturbances. ,advise,Pilocarpine,beta adrenergic antagonists
"These effects should be considered when DRUGOTHER properties may be contributing to the therapeutic effect of concomitant medication (e.g., DRUG1, inhaled DRUG2). ",negative,atropine,ipratropium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUG2, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,calcium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,conjugated estrogens
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,hydroxychloroquine sulfate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG2, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,ibuprofen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,levothyroxine sodium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,acetylsalicylic acid,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,acetylsalicylic acid,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUG1, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,acetylsalicylic acid,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,conjugated estrogens
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,hydroxychloroquine sulfate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG2, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,ibuprofen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,levothyroxine sodium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,calcium,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,calcium,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,calcium,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUG1, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,calcium,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,hydroxychloroquine sulfate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG2, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,ibuprofen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,levothyroxine sodium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,conjugated estrogens,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,conjugated estrogens,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,conjugated estrogens,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG2, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,ibuprofen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,levothyroxine sodium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,hydroxychloroquine sulfate,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,hydroxychloroquine sulfate,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,hydroxychloroquine sulfate,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,levothyroxine sodium
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,ibuprofen,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,ibuprofen,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUG1, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,ibuprofen,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,levothyroxine sodium,medroxyprogesterone acetate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,levothyroxine sodium,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,levothyroxine sodium,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,levothyroxine sodium,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,levothyroxine sodium,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,levothyroxine sodium,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,levothyroxine sodium,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,medroxyprogesterone acetate,methotrexate
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,medroxyprogesterone acetate,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,medroxyprogesterone acetate,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,medroxyprogesterone acetate,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,medroxyprogesterone acetate,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,medroxyprogesterone acetate,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,methotrexate,multivitamins
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,methotrexate,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,methotrexate,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,methotrexate,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,methotrexate,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",negative,multivitamins,naproxen
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,multivitamins,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,multivitamins,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,multivitamins,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER.",negative,naproxen,omeprazole
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER.",negative,naproxen,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2.",negative,naproxen,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER.",negative,omeprazole,paracetamol
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2.",negative,omeprazole,prednisone
"While no formal DRUGOTHER interaction studies have been performed, the following concomitant DRUGOTHER were used in at least 10% of patients in either or both Sj   grens efficacy studies: DRUGOTHER, artificial tears, DRUGOTHER, conjugated DRUGOTHER, DRUGOTHER sulfate, DRUGOTHER, DRUGOTHER sodium, DRUGOTHER acetate, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2.",negative,paracetamol,prednisone
Mutual inhibition of metabolism occurs with concurrent use of DRUG1 and DRUG2; ,mechanism,cyclosporin,methylprednisolone
convulsions have been reported with concurrent use of DRUG1 and DRUG2. ,effect,methylprednisolone,cyclosporin
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUG2, and DRUGOTHER may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",negative,phenobarbital,phenytoin
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUG2 may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",negative,phenobarbital,rifampin
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,phenobarbital,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,phenobarbital,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUG2 may increase the clearance of DRUGOTHER and may require increased in DRUGOTHER dose to achieve the desired response. ",negative,phenytoin,rifampin
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,phenytoin,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1, and DRUGOTHER may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,phenytoin,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",mechanism,rifampin,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUG1 may increase the clearance of DRUG2 and may require increased in DRUG2 dose to achieve the desired response. ",advise,rifampin,methylprednisolone
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER, and DRUGOTHER may increase the clearance of DRUG1 and may require increased in DRUG1 dose to achieve the desired response. ",negative,methylprednisolone,methylprednisolone
DRUGOTHER such as DRUG1 and DRUG2 may inhibit the metabolism of DRUGOTHER and thus decrease its clearance. ,negative,troleandomycin,ketoconazole
DRUGOTHER such as DRUG1 and DRUGOTHER may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,mechanism,troleandomycin,methylprednisolone
DRUGOTHER such as DRUGOTHER and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease its clearance. ,mechanism,ketoconazole,methylprednisolone
DRUG1 may increase the clearance of chronic high dose DRUG2. ,mechanism,Methylprednisolone,aspirin
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUGOTHER is withdrawn. ,negative,salicylate,salicylate
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,negative,salicylate,methylprednisolone
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,effect,salicylate,methylprednisolone
DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,advise,Aspirin,corticosteroids
The effect of DRUG1 on oral DRUG2 is variable. ,negative,methylprednisolone,anticoagulants
There are reports of enhanced as well as diminished effects of DRUG1 when given concurrently with DRUG2. ,effect,anticoagulant,corticosteroids
The effects of DRUG1 on gastrointestinal motility are antagonized by DRUGOTHER DRUGOTHER and DRUGOTHER DRUGOTHER. ,effect,metoclopramide,anticholinergic drugs
The effects of DRUG1 on gastrointestinal motility are antagonized by DRUGOTHER DRUGOTHER and DRUGOTHER DRUGOTHER. ,effect,metoclopramide,narcotic analgesics
The effects of DRUGOTHER on gastrointestinal motility are antagonized by DRUGOTHER DRUGOTHER and DRUGOTHER DRUGOTHER. ,negative,anticholinergic drugs,narcotic analgesics
"Additive DRUGOTHER effects can occur when DRUG1 is given with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",effect,metoclopramide,alcohol
"Additive DRUGOTHER effects can occur when DRUG1 is given with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",effect,metoclopramide,sedatives
"Additive DRUGOTHER effects can occur when DRUG1 is given with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",effect,metoclopramide,hypnotics
"Additive DRUGOTHER effects can occur when DRUG1 is given with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",effect,metoclopramide,narcotics
"Additive DRUGOTHER effects can occur when DRUG1 is given with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",effect,metoclopramide,tranquilizers
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,alcohol,sedatives
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,alcohol,hypnotics
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,alcohol,narcotics
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,alcohol,tranquilizers
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,sedatives,hypnotics
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,sedatives,narcotics
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,sedatives,tranquilizers
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,hypnotics,narcotics
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",negative,hypnotics,tranquilizers
"Additive DRUGOTHER effects can occur when DRUGOTHER is given with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",negative,narcotics,tranquilizers
"The finding that DRUG1 releases DRUGOTHER in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving DRUG2. ",advise,metoclopramide,monoamine oxi-dase inhibitors
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUG2, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,digoxin,metoclopramide
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,digoxin,acetaminophen
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,digoxin,tetracycline
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",negative,digoxin,levodopa
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",negative,digoxin,ethanol
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUG1) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",negative,digoxin,cyclosporine
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,metoclopramide,acetaminophen
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,metoclopramide,tetracycline
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",negative,metoclopramide,levodopa
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",negative,metoclopramide,ethanol
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUG1, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",negative,metoclopramide,cyclosporine
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,acetaminophen,tetracycline
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER). ",negative,acetaminophen,levodopa
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",negative,acetaminophen,ethanol
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",negative,acetaminophen,cyclosporine
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER). ",negative,tetracycline,levodopa
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER). ",negative,tetracycline,ethanol
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2). ",negative,tetracycline,cyclosporine
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER). ",negative,levodopa,ethanol
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2). ",negative,levodopa,cyclosporine
"Absorption of DRUGOTHER from the stomach may be diminished (e.g., DRUGOTHER) by DRUGOTHER, whereas the rate and/or extent of absorption of DRUGOTHER from the small bowel may be increased (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2). ",negative,ethanol,cyclosporine
"Because the action of DRUG1 will influence the delivery of food to the intestines and thus the rate of absorption, DRUG2 dosage or timing of dosage may require adjustment.",advise,metoclopramide,insulin
"DRUG1, particularly DRUG2, may cause serious cardiac arrhythmias during DRUGOTHER DRUGOTHER and therefore should be used only with great caution or not at all. ",negative,Vasopressors,metaraminol
"DRUG1, particularly DRUGOTHER, may cause serious cardiac arrhythmias during DRUG2 DRUGOTHER and therefore should be used only with great caution or not at all. ",effect,Vasopressors,halothane
"DRUGOTHER, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 DRUGOTHER and therefore should be used only with great caution or not at all. ",effect,metaraminol,halothane
DRUG1: The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUGOTHER (DRUGOTHER). ,negative,MAO Inhibitors,sympathomimetic pressor amines
DRUG1: The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,negative,MAO Inhibitors,monoamine oxidase inhibitors
DRUG1: The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUGOTHER (DRUG2). ,negative,MAO Inhibitors,MAOI
DRUGOTHER: The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
DRUGOTHER: The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUGOTHER (DRUG2). ,effect,sympathomimetic pressor amines,MAOI
DRUGOTHER: The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG1 (DRUG2). ,negative,monoamine oxidase inhibitors,MAOI
The pressor response of DRUGOTHER agents may also be potentiated by DRUGOTHER DRUGOTHER.,effect,adrenergic agents,tricyclic antidepressants
"DRUG1 may interact with DRUG2 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,Methscopolamine,antidepressants
"DRUG1 may interact with DRUGOTHER (DRUG2 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,tricyclic
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,MAO inhibitors
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,phenelzine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,linezolid
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,tranylcypromine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,isocarboxazid
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,selegiline
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,furazolidone
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,quinidine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,amantadine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,antihistamines
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,diphenhydramine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,anticholinergics
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,potassium chloride
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,antacids
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,absorbent-type anti-diarrhea medicines
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,kaolin
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,pectin
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",int,Methscopolamine,phenothiazines
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",int,Methscopolamine,chlorpromazine
"DRUG1 may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",int,Methscopolamine,promethazine
"DRUGOTHER may interact with DRUG1 (DRUG2 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,tricyclic
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,MAO inhibitors
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,phenelzine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,linezolid
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,tranylcypromine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,isocarboxazid
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,selegiline
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,furazolidone
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,quinidine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,amantadine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,antihistamines
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,diphenhydramine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,anticholinergics
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,potassium chloride
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,antacids
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,kaolin
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,pectin
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,antidepressants,phenothiazines
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,antidepressants,chlorpromazine
"DRUGOTHER may interact with DRUG1 (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,antidepressants,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUG2 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,MAO inhibitors
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,phenelzine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,linezolid
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,tranylcypromine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,isocarboxazid
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,tricyclic,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,tricyclic,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUG1 type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,tricyclic,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,phenelzine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,linezolid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,tranylcypromine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,isocarboxazid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,MAO inhibitors,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,MAO inhibitors,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,MAO inhibitors,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,linezolid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,tranylcypromine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,isocarboxazid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,phenelzine,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,phenelzine,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,phenelzine,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,tranylcypromine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,isocarboxazid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,linezolid,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,linezolid,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,linezolid,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,isocarboxazid
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,tranylcypromine,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,tranylcypromine,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,tranylcypromine,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,selegiline
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,isocarboxazid,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,isocarboxazid,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,isocarboxazid,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,furazolidone
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,selegiline,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,selegiline,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,selegiline,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUG2, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,quinidine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,furazolidone,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,furazolidone,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,furazolidone,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUG2, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,amantadine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,quinidine,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,quinidine,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,quinidine,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUG2 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,antihistamines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,amantadine,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,amantadine,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,amantadine,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUG2), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,diphenhydramine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,antihistamines,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,antihistamines,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1 (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,antihistamines,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUG2, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,anticholinergics
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,diphenhydramine,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,diphenhydramine,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUG1), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,diphenhydramine,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,potassium chloride
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,anticholinergics,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,anticholinergics,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUG1, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,anticholinergics,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUG2, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,potassium chloride,antacids
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,potassium chloride,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,potassium chloride,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,potassium chloride,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,potassium chloride,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,potassium chloride,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER chloride supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,potassium chloride,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUG2 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antacids,absorbent-type anti-diarrhea medicines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUGOTHER (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antacids,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUGOTHER (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,antacids,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,antacids,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,antacids,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUG1, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,antacids,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG1 (e.g., DRUG2-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,absorbent-type anti-diarrhea medicines,kaolin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG1 (e.g., DRUGOTHER-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,absorbent-type anti-diarrhea medicines,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG1 (e.g., DRUGOTHER-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,absorbent-type anti-diarrhea medicines,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG1 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,absorbent-type anti-diarrhea medicines,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUG1 (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,absorbent-type anti-diarrhea medicines,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUG2), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER).",negative,kaolin,pectin
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,kaolin,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,kaolin,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUG1-DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,kaolin,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUG2 (e.g., DRUGOTHER, DRUGOTHER).",negative,pectin,phenothiazines
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUGOTHER (e.g., DRUG2, DRUGOTHER).",negative,pectin,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUG1), DRUGOTHER (e.g., DRUGOTHER, DRUG2).",negative,pectin,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG1 (e.g., DRUG2, DRUGOTHER).",negative,phenothiazines,chlorpromazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUG1 (e.g., DRUGOTHER, DRUG2).",negative,phenothiazines,promethazine
"DRUGOTHER may interact with DRUGOTHER (DRUGOTHER type), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), other DRUGOTHER, DRUGOTHER supplements, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER-DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUG2).",negative,chlorpromazine,promethazine
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER agents such as DRUGOTHER) and agents that slow the intestinal absorption of nutrients (e.g., DRUGOTHER). ",advise,SYMLIN,anticholinergic agents
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER such as DRUG2) and agents that slow the intestinal absorption of nutrients (e.g., DRUGOTHER). ",advise,SYMLIN,atropine
"Due to its effects on gastric emptying, DRUG1 therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER such as DRUGOTHER) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",advise,SYMLIN,alpha glucosidase inhibitors
"Due to its effects on gastric emptying, DRUGOTHER therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER agents such as DRUG2) and agents that slow the intestinal absorption of nutrients (e.g., DRUGOTHER). ",negative,anticholinergic agents,atropine
"Due to its effects on gastric emptying, DRUGOTHER therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER agents such as DRUGOTHER) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",negative,anticholinergic agents,alpha glucosidase inhibitors
"Due to its effects on gastric emptying, DRUGOTHER therapy should not be considered for patients taking DRUGOTHER that alter gastrointestinal motility (e.g., DRUGOTHER such as DRUG1) and agents that slow the intestinal absorption of nutrients (e.g., DRUG2). ",negative,atropine,alpha glucosidase inhibitors
"When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as DRUG1), the agent should be administered at least 1 hour prior to or 2 hours after DRUG2 injection. ",advise,analgesics,SYMLIN
"In clinical trials, the concomitant use of DRUG1 or DRUG2 did not alter the adverse event profile of DRUGOTHER. ",negative,sulfonylureas,biguanides
"In clinical trials, the concomitant use of DRUG1 or DRUGOTHER did not alter the adverse event profile of DRUG2. ",negative,sulfonylureas,SYMLIN
"In clinical trials, the concomitant use of DRUGOTHER or DRUG1 did not alter the adverse event profile of DRUG2. ",negative,biguanides,SYMLIN
No formal interaction studies have been performed to assess the effect of DRUG1 on the kinetics of oral DRUG2. ,negative,SYMLIN,antidiabetic agents
"Mixing DRUG1 and DRUG2 The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUGOTHER immediately prior to injection. ",negative,SYMLIN,Insulin
"Mixing DRUG1 and DRUGOTHER The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUGOTHER immediately prior to injection. ",negative,SYMLIN,SYMLIN
"Mixing DRUG1 and DRUGOTHER The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUGOTHER immediately prior to injection. ",negative,SYMLIN,human insulin
"Mixing DRUG2 and DRUG1 The pharmacokinetic parameters of DRUG2 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant DRUGOTHER immediately prior to injection. ",negative,Insulin,SYMLIN
"Mixing DRUGOTHER and DRUG1 The pharmacokinetic parameters of DRUGOTHER were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUG1 immediately prior to injection. ",negative,Insulin,human insulin
"Mixing DRUG1 and DRUGOTHER The pharmacokinetic parameters of DRUG1 were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human DRUGOTHER immediately prior to injection. ",mechanism,SYMLIN,human insulin
"Thus, DRUG1 and DRUG2 should not be mixed and must be administered separately.",negative,SYMLIN,insulin
Patients receiving DRUG1 and DRUG2 generally should not be treated with DRUGOTHER.  ,negative,antibiotics,sulfonamides
Patients receiving DRUG1 and DRUGOTHER generally should not be treated with DRUG2.  ,advise,antibiotics,ganglion blockers
Patients receiving DRUGOTHER and DRUG1 generally should not be treated with DRUG2.  ,advise,sulfonamides,ganglion blockers
"The action of DRUG1 may be potentiated by DRUGOTHER, other DRUGOTHER DRUGOTHER and DRUGOTHER.",effect,Mecamylamine,antihypertensive drugs
"The action of DRUG1 may be potentiated by DRUGOTHER, other DRUGOTHER DRUGOTHER and DRUG2.",effect,Mecamylamine,alcohol
"The action of DRUGOTHER may be potentiated by DRUGOTHER, other DRUGOTHER DRUGOTHER and DRUG2.",negative,antihypertensive drugs,alcohol
"Oral DRUG1 has been reported to potentiate the DRUGOTHER effect of DRUG2 and DRUGOTHER, resulting in a prolongation of prothrombin time. ",effect,metronidazole,coumarin
"Oral DRUG1 has been reported to potentiate the DRUGOTHER effect of DRUGOTHER and DRUG2, resulting in a prolongation of prothrombin time. ",effect,metronidazole,warfarin
"Oral DRUGOTHER has been reported to potentiate the DRUGOTHER effect of DRUG1 and DRUG2, resulting in a prolongation of prothrombin time. ",negative,coumarin,warfarin
"DRUGOTHER interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving DRUGOTHER treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",negative,METROGEL,metronidazole
"DRUGOTHER interactions should be kept in mind when DRUG1 (DRUG2 gel), 1% is prescribed for patients who are receiving DRUGOTHER treatment, although they are less likely to occur with topical DRUG2 administration because of low absorption.    ",negative,METROGEL,metronidazole
"DRUGOTHER interactions should be kept in mind when DRUGOTHER (DRUG1 gel), 1% is prescribed for patients who are receiving DRUGOTHER treatment, although they are less likely to occur with topical DRUG1 administration because of low absorption.    ",negative,metronidazole,metronidazole
Concomitant use of DRUG1 with DRUG2 may result in an adverse DRUGOTHER interaction.,int,alcohol,phentermine hydrochloride
Other short-acting DRUGOTHER should not be used concomitantly with DRUG2 because they may have additive effects.,advise,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER
A study published in 2002 found that DRUG1 causes a statistically significant increase in plasma clearance of DRUG2. ,mechanism,vigabatrin,carbamazepine
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",mechanism,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUG1 with DRUG2 lowered the serum DRUG2 concentration in patients with treatment-resistant epilepsy. ",negative,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUGOTHER with DRUG1 lowered the serum DRUG1 concentration in patients with treatment-resistant epilepsy. ",negative,phenytoin,phenytoin
DRUG1: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUGOTHER hydrochloride. ,negative,Anticholinesterases,procaine hydrochloride
DRUG1: Concurrent use of DRUGOTHER and DRUGOTHER agents may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUGOTHER. ,negative,Anticholinesterases,anticholinesterase agents
DRUG1: Concurrent use of DRUGOTHER and DRUGOTHER may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUGOTHER. ,negative,Anticholinesterases,anticholinesterases
DRUG1: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUGOTHER hydrochloride. ,negative,Anticholinesterases,procaine hydrochloride
DRUGOTHER: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER agents may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUGOTHER hydrochloride. ,effect,procaine hydrochloride,anticholinesterase agents
DRUG2: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in increased systemic toxicity since DRUG2 inhibit the breakdown of DRUGOTHER hydrochloride. ,negative,procaine hydrochloride,anticholinesterases
DRUGOTHER: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUGOTHER hydrochloride. ,negative,procaine hydrochloride,procaine hydrochloride
DRUG2: Concurrent use of DRUGOTHER and DRUGOTHER agents may result in increased systemic toxicity since DRUG2 inhibit the breakdown of DRUGOTHER. ,negative,anticholinesterase agents,anticholinesterases
DRUGOTHER: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER agents may result in increased systemic toxicity since DRUGOTHER inhibit the breakdown of DRUGOTHER hydrochloride. ,negative,anticholinesterase agents,procaine hydrochloride
DRUG1: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in increased systemic toxicity since DRUG1 inhibit the breakdown of DRUGOTHER hydrochloride. ,mechanism,anticholinesterases,procaine hydrochloride
DRUGOTHER: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in additive depressant effects. ,negative,CNS depressant,procaine hydrochloride
DRUG1 medications: Concurrent use of DRUGOTHER and DRUG1 medications may result in additive depressant effects. ,negative,CNS depressant,CNS depressant medications
DRUGOTHER medications: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER medications may result in additive depressant effects. ,effect,procaine hydrochloride,CNS depressant medications
"DRUG1: DRUG1 may increase the diffusion rate of DRUGOTHER, resulting in a decreased time of onset, but an increase in systemic toxicity. ",negative,Hyaluronidase,Hyaluronidase
"DRUG1: DRUG1 may increase the diffusion rate of DRUGOTHER hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",negative,Hyaluronidase,procaine hydrochloride
"DRUG1: DRUG1 may increase the diffusion rate of DRUGOTHER hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ",mechanism,Hyaluronidase,procaine hydrochloride
DRUG1 (such as DRUG2): Concurrent use of DRUGOTHER and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,suxamethonium chloride
DRUG1 (such as DRUGOTHER): Concurrent use of DRUGOTHER hydrochloride and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,procaine hydrochloride
DRUG1 (such as DRUGOTHER): Concurrent use of DRUGOTHER and DRUG1 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,Neuromuscular blocking agents,neuromuscular blocking agents
DRUGOTHER (such as DRUG1): Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in prolongation or enhancement of the neuromuscular blockade. ,negative,suxamethonium chloride,procaine hydrochloride
DRUG2 (such as DRUG1): Concurrent use of DRUGOTHER and DRUG2 may result in prolongation or enhancement of the neuromuscular blockade. ,negative,suxamethonium chloride,neuromuscular blocking agents
DRUG2 (such as DRUGOTHER): Concurrent use of DRUGOTHER hydrochloride and DRUG2 may result in prolongation or enhancement of the neuromuscular blockade. ,effect,procaine hydrochloride,neuromuscular blocking agents
DRUG1: Concurrent use of DRUGOTHER hydrochloride and DRUG1 may result in a reduction of the DRUGOTHER action of the DRUGOTHER. ,negative,Sulfonamides,procaine hydrochloride
DRUG1: Concurrent use of DRUGOTHER and DRUG1 may result in a reduction of the DRUGOTHER action of the DRUGOTHER. ,negative,Sulfonamides,sulfonamides
DRUG1: Concurrent use of DRUGOTHER and DRUG1 may result in a reduction of the DRUGOTHER action of the DRUG2. ,negative,Sulfonamides,sulfonamide
DRUG2: Concurrent use of DRUGOTHER hydrochloride and DRUG2 may result in a reduction of the DRUGOTHER action of the DRUGOTHER. ,effect,procaine hydrochloride,sulfonamides
DRUGOTHER: Concurrent use of DRUGOTHER hydrochloride and DRUGOTHER may result in a reduction of the DRUGOTHER action of the DRUG2. ,negative,procaine hydrochloride,sulfonamide
DRUG1: Concurrent use of DRUGOTHER and DRUG1 may result in a reduction of the DRUGOTHER action of the DRUG2. ,negative,sulfonamides,sulfonamide
DRUG1: Concurrent use of DRUG1 and DRUGOTHER may extend the plasma half-life of DRUGOTHER.,negative,Acetazolamide,acetazolamide
DRUG1: Concurrent use of DRUG1 and DRUGOTHER hydrochloride may extend the plasma half-life of DRUGOTHER.,negative,Acetazolamide,procaine hydrochloride
DRUG1: Concurrent use of DRUG1 and DRUGOTHER may extend the plasma half-life of DRUG2.,negative,Acetazolamide,procaine
DRUG1: Concurrent use of DRUG1 and DRUGOTHER hydrochloride may extend the plasma half-life of DRUGOTHER.,mechanism,acetazolamide,procaine hydrochloride
DRUG1: Concurrent use of DRUG1 and DRUGOTHER may extend the plasma half-life of DRUG2.,negative,acetazolamide,procaine
DRUGOTHER: Concurrent use of DRUGOTHER and DRUG1 may extend the plasma half-life of DRUG2.,negative,procaine hydrochloride,procaine
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,ketoconazole
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,itraconazole
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,clarithromycin
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,atazanavir
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,indinavir
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,nefazodone
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,nelfinavir
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,ritonavir
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,saquinavir
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,telithromycin
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",mechanism,SUTENT,voriconizole
"DRUGOTHER-administration of DRUG1 with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,SUTENT,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,itraconazole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,clarithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,atazanavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,indinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,nefazodone
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ketoconazole,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,ketoconazole,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,ketoconazole,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,clarithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,atazanavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,indinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,nefazodone
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,itraconazole,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,itraconazole,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,itraconazole,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,atazanavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,indinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,nefazodone
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,clarithromycin,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,clarithromycin,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,clarithromycin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,indinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,nefazodone
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,atazanavir,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,atazanavir,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,atazanavir,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,indinavir,nefazodone
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,indinavir,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,indinavir,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,indinavir,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,indinavir,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,indinavir,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,indinavir,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nefazodone,nelfinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nefazodone,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nefazodone,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nefazodone,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,nefazodone,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,nefazodone,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nelfinavir,ritonavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nelfinavir,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,nelfinavir,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,nelfinavir,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,nelfinavir,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ritonavir,saquinavir
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,ritonavir,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,ritonavir,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,ritonavir,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",negative,saquinavir,telithromycin
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) may increases DRUGOTHER concentrations. ",negative,saquinavir,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may increases DRUG2 concentrations. ",negative,saquinavir,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) may increases DRUGOTHER concentrations. ",negative,telithromycin,voriconizole
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) may increases DRUG2 concentrations. ",negative,telithromycin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with strong inhibitors of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) may increases DRUG2 concentrations. ",negative,voriconizole,sunitinib
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,dexamethasone
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,phenytoin
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,carbamazepine
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,rifampin
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,rifabutin
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,rifapentin
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",mechanism,SUTENT,phenobarbital
"DRUGOTHER-administration of DRUG1 with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,SUTENT,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,phenytoin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,carbamazepine
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,rifampin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,rifabutin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,rifapentin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,dexamethasone,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,dexamethasone,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,phenytoin,carbamazepine
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,phenytoin,rifampin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,phenytoin,rifabutin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,phenytoin,rifapentin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,phenytoin,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,phenytoin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,carbamazepine,rifampin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,carbamazepine,rifabutin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,carbamazepine,rifapentin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,carbamazepine,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,carbamazepine,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifampin,rifabutin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifampin,rifapentin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifampin,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifampin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifabutin,rifapentin
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifabutin,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifabutin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, St. Johns Wort) may decrease DRUGOTHER concentrations. ",negative,rifapentin,phenobarbital
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,rifapentin,sunitinib
"DRUGOTHER-administration of DRUGOTHER with inducers of the DRUGOTHER family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, St. Johns Wort) may decrease DRUG2 concentrations. ",negative,phenobarbital,sunitinib
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUG2 and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",negative,phenobarbital,phenytoin
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",negative,phenobarbital,rifampin
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",mechanism,phenobarbital,corticosteroids
"DRUGOTHER that induce hepatic enzymes such as DRUG1, DRUGOTHER and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,phenobarbital,corticosteroid
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUG2 may increase the clearance of DRUGOTHER and may require increases in DRUGOTHER dose to achieve the desired response. ",negative,phenytoin,rifampin
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",mechanism,phenytoin,corticosteroids
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUG1 and DRUGOTHER may increase the clearance of DRUGOTHER and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,phenytoin,corticosteroid
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUG1 may increase the clearance of DRUG2 and may require increases in DRUGOTHER dose to achieve the desired response. ",mechanism,rifampin,corticosteroids
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUG1 may increase the clearance of DRUGOTHER and may require increases in DRUG2 dose to achieve the desired response. ",mechanism,rifampin,corticosteroid
"DRUGOTHER that induce hepatic enzymes such as DRUGOTHER, DRUGOTHER and DRUGOTHER may increase the clearance of DRUG1 and may require increases in DRUG2 dose to achieve the desired response. ",negative,corticosteroids,corticosteroid
DRUGOTHER such as DRUG1 and DRUG2 may inhibit the metabolism of DRUGOTHER and thus decrease their clearance. ,negative,troleandomycin,ketoconazole
DRUGOTHER such as DRUG1 and DRUGOTHER may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,mechanism,troleandomycin,corticosteroids
DRUGOTHER such as DRUGOTHER and DRUG1 may inhibit the metabolism of DRUG2 and thus decrease their clearance. ,mechanism,ketoconazole,corticosteroids
DRUG1 may increase the clearance of chronic high dose DRUG2. ,mechanism,Corticosteroids,aspirin
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUGOTHER is withdrawn. ,negative,salicylate,salicylate
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,negative,salicylate,corticosteroid
This could DRUGOTHER to decreased DRUG1 serum levels or increase the risk of DRUG1 toxicity when DRUG2 is withdrawn. ,effect,salicylate,corticosteroid
DRUG1 should be used cautiously in conjunction with DRUG2 in patients suffering from hypoprothrombinemia. ,advise,Aspirin,corticosteroids
The effect of DRUG1 on oral DRUG2 is variable. ,effect,corticosteroids,anticoagulants
There are reports of enhanced as well as diminished effects of DRUG1 when given concurrently with DRUG2. ,effect,anticoagulants,corticosteroids
"Interactions for DRUG1 (DRUG2):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER",negative,Vitamin B1,Thiamine
"Interactions for DRUG1 (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER",int,Vitamin B1,Loop Diuretics
"Interactions for DRUG1 (DRUGOTHER):  Loop DRUGOTHER, Oral DRUG2, DRUGOTHER, DRUGOTHER",int,Vitamin B1,Contraceptives
"Interactions for DRUG1 (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER",int,Vitamin B1,Stavudine
"Interactions for DRUG1 (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER",int,Vitamin B1,Tricyclic Antidepressants
"Interactions for DRUGOTHER (DRUG1):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER",int,Thiamine,Loop Diuretics
"Interactions for DRUGOTHER (DRUG1):  Loop DRUGOTHER, Oral DRUG2, DRUGOTHER, DRUGOTHER",int,Thiamine,Contraceptives
"Interactions for DRUGOTHER (DRUG1):  Loop DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER",int,Thiamine,Stavudine
"Interactions for DRUGOTHER (DRUG1):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER",int,Thiamine,Tricyclic Antidepressants
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUG2, DRUGOTHER, DRUGOTHER",negative,Loop Diuretics,Contraceptives
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUG2, DRUGOTHER",negative,Loop Diuretics,Stavudine
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER",negative,Loop Diuretics,Tricyclic Antidepressants
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUG1, DRUG2, DRUGOTHER",negative,Contraceptives,Stavudine
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER",negative,Contraceptives,Tricyclic Antidepressants
"Interactions for DRUGOTHER (DRUGOTHER):  Loop DRUGOTHER, Oral DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER",negative,Stavudine,Tricyclic Antidepressants
DRUGOTHER-DRUGOTHER Interactions Effect of DRUG1    (DRUGOTHER tartrate) on the Metabolism of Other DRUGOTHER: DRUGOTHER is primarily metabolized through hydrolysis by esterases. ,negative,Exelon,rivastigmine tartrate
DRUGOTHER-DRUGOTHER Interactions Effect of DRUG1    (DRUGOTHER) on the Metabolism of Other DRUGOTHER: DRUG2 is primarily metabolized through hydrolysis by esterases. ,negative,Exelon,Rivastigmine
DRUGOTHER-DRUGOTHER Interactions Effect of DRUGOTHER    (DRUG1) on the Metabolism of Other DRUGOTHER: DRUG2 is primarily metabolized through hydrolysis by esterases. ,negative,rivastigmine tartrate,Rivastigmine
"No pharmacokinetic interaction was observed between DRUG1 and DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",negative,rivastigmine,digoxin
"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",negative,rivastigmine,warfarin
"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",negative,rivastigmine,diazepam
"No pharmacokinetic interaction was observed between DRUG1 and DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",negative,rivastigmine,fluoxetine
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER in studies in healthy volunteers. ",negative,digoxin,warfarin
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",negative,digoxin,diazepam
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",negative,digoxin,fluoxetine
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER in studies in healthy volunteers. ",negative,warfarin,diazepam
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2 in studies in healthy volunteers. ",negative,warfarin,fluoxetine
"No pharmacokinetic interaction was observed between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 in studies in healthy volunteers. ",negative,diazepam,fluoxetine
The elevation of prothrombin time induced by DRUG1 is not affected by administration of DRUG2. ,negative,warfarin,Exelon
Effect of Other DRUGOTHER on the Metabolism of DRUG1: DRUGOTHER that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of DRUG2. ,negative,Exelon,rivastigmine
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,rivastigmine,digoxin
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,rivastigmine,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,rivastigmine,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUG1 is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,rivastigmine,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,digoxin,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,digoxin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,digoxin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,warfarin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",negative,warfarin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of DRUGOTHER is not significantly affected by concurrent administration of DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",negative,diazepam,fluoxetine
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUG2 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,antacids
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG2 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG2 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,rivastigmine,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUG1 were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,rivastigmine,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUG2 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG2 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antacids,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,antacids,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUG1 (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,antacids,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUG2 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,antihypertensives,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUG1 (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,antihypertensives,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG2 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,calcium channel blockers,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,calcium channel blockers,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,calcium channel blockers,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,calcium channel blockers,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,calcium channel blockers,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,calcium channel blockers,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG1 (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antidiabetics,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG1 (n=21), DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antidiabetics,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG1 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,antidiabetics,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG1 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,antidiabetics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUG1 (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,antidiabetics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUG2 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,nonsteroidal anti-inflammatory drugs,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,nonsteroidal anti-inflammatory drugs,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,nonsteroidal anti-inflammatory drugs,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), nonsteroidal DRUGOTHER DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,nonsteroidal anti-inflammatory drugs,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG1 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUGOTHER (n=15). ",negative,estrogens,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG1 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,estrogens,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUG1 (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,estrogens,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG2 (n=35), and DRUGOTHER (n=15). ",negative,salicylate analgesics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUGOTHER (n=35), and DRUG2 (n=15). ",negative,salicylate analgesics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of DRUGOTHER were not influenced by commonly prescribed medications such as DRUGOTHER (n=77), DRUGOTHER (n=72), DRUGOTHER channel blockers (n=75), DRUGOTHER (n=21), DRUGOTHER (n=79), DRUGOTHER (n=70), DRUGOTHER DRUGOTHER (n=177), DRUG1 (n=35), and DRUG2 (n=15). ",negative,antianginals,antihistamines
"Use with DRUG1: Because of their mechanism of action, DRUG2 have the potential to interfere with the activity of DRUGOTHER medications. ",negative,Anticholinergics,cholinesterase inhibitors
"Use with DRUG1: Because of their mechanism of action, DRUGOTHER have the potential to interfere with the activity of DRUGOTHER medications. ",negative,Anticholinergics,anticholinergic medications
"Use with DRUGOTHER: Because of their mechanism of action, DRUG1 have the potential to interfere with the activity of DRUGOTHER medications. ",int,cholinesterase inhibitors,anticholinergic medications
"Use with DRUG1 and Other DRUG2: A synergistic effect may be expected when DRUG2 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",negative,Cholinomimetics,Cholinesterase Inhibitors
"Use with DRUG1 and Other DRUG2: A synergistic effect may be expected when DRUG2 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",negative,Cholinomimetics,cholinesterase inhibitors
"Use with DRUG1 and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUG2, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",negative,Cholinomimetics,succinylcholine
"Use with DRUG1 and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUG2 or DRUGOTHER such as DRUGOTHER.",negative,Cholinomimetics,neuromuscular blocking agents
"Use with DRUG1 and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUG2 such as DRUGOTHER.",negative,Cholinomimetics,cholinergic agonists
"Use with DRUG1 and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUG2.",negative,Cholinomimetics,bethanechol
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",negative,Cholinesterase Inhibitors,cholinesterase inhibitors
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUG2, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",negative,Cholinesterase Inhibitors,succinylcholine
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUG2 or DRUGOTHER such as DRUGOTHER.",negative,Cholinesterase Inhibitors,neuromuscular blocking agents
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUG2 such as DRUGOTHER.",negative,Cholinesterase Inhibitors,cholinergic agonists
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUG2.",negative,Cholinesterase Inhibitors,bethanechol
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUG2, similar DRUGOTHER or DRUGOTHER such as DRUGOTHER.",effect,cholinesterase inhibitors,succinylcholine
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUG2 or DRUGOTHER such as DRUGOTHER.",effect,cholinesterase inhibitors,neuromuscular blocking agents
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUG2 such as DRUGOTHER.",effect,cholinesterase inhibitors,cholinergic agonists
"Use with DRUGOTHER and Other DRUG1: A synergistic effect may be expected when DRUG1 are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUGOTHER such as DRUG2.",effect,cholinesterase inhibitors,bethanechol
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUG1, similar DRUG2 or DRUGOTHER such as DRUGOTHER.",negative,succinylcholine,neuromuscular blocking agents
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUG1, similar DRUGOTHER or DRUG2 such as DRUGOTHER.",negative,succinylcholine,cholinergic agonists
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUG1, similar DRUGOTHER or DRUGOTHER such as DRUG2.",negative,succinylcholine,bethanechol
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUG1 or DRUG2 such as DRUGOTHER.",negative,neuromuscular blocking agents,cholinergic agonists
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUG1 or DRUGOTHER such as DRUG2.",negative,neuromuscular blocking agents,bethanechol
"Use with DRUGOTHER and Other DRUGOTHER: A synergistic effect may be expected when DRUGOTHER are given concurrently with DRUGOTHER, similar DRUGOTHER or DRUG1 such as DRUG2.",negative,cholinergic agonists,bethanechol
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUGOTHER demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",negative,Ketoconazole,ketoconazole
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",negative,Ketoconazole,terfenadine
"DRUG1: Spontaneous adverse reaction reports of patients taking concomitant DRUG1 with recommended doses of DRUG2 demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",effect,ketoconazole,terfenadine
"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",mechanism,ketoconazole,terfenadine
"Pharmacokinetic data indicate that DRUG1 markedly inhibits the metabolism of DRUG2, resulting in elevated plasma DRUG2 levels. ",negative,ketoconazole,terfenadine
"Pharmacokinetic data indicate that DRUGOTHER markedly inhibits the metabolism of DRUG1, resulting in elevated plasma DRUG1 levels. ",negative,terfenadine,terfenadine
Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,advise,ketoconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent DRUG2 levels have been reported during concomitant use of DRUG2 and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,terfenadine
DRUG1: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,itraconazole
DRUG1: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,Itraconazole,itraconazole
DRUGOTHER: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUGOTHER in clinical trials of DRUGOTHER and from foreign post-marketing sources. ,negative,terfenadine,terfenadine
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,mechanism,terfenadine,itraconazole
DRUG2: Torsades de pointes and elevated parent DRUG1 levels have been reported during concomitant use of DRUG1 and DRUG2 in clinical trials of DRUG2 and from foreign post-marketing sources. ,negative,terfenadine,itraconazole
DRUG1: Torsades de pointes and elevated parent DRUGOTHER levels have been reported during concomitant use of DRUGOTHER and DRUG1 in clinical trials of DRUG1 and from foreign post-marketing sources. ,negative,itraconazole,itraconazole
Concomitant administration of DRUG1 and DRUG2 is contraindicated. ,advise,itraconazole,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG2, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,fluconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUG2, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,metronidazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG2) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,miconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,ketoconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,azole-type antifungal agents,itraconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,azole-type antifungal agents,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG1, DRUG2, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,fluconazole,metronidazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG1, DRUGOTHER, and DRUG2) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,fluconazole,miconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,fluconazole,ketoconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,fluconazole,itraconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUG1, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,fluconazole,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUG1, and DRUG2) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,metronidazole,miconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,metronidazole,ketoconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,metronidazole,itraconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUG1, and DRUGOTHER) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,metronidazole,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUG2, and DRUGOTHER, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,miconazole,ketoconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUGOTHER, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,miconazole,itraconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUG1) to DRUGOTHER, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",advise,miconazole,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUG1, and DRUG2, concomitant use of these products with DRUGOTHER is not recommended pending full examination of potential interactions. ",negative,ketoconazole,itraconazole
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUG1, and DRUGOTHER, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",negative,ketoconazole,terfenadine
"Due to the chemical similarity of other azole-type DRUGOTHER (including DRUGOTHER, DRUGOTHER, and DRUGOTHER) to DRUGOTHER, and DRUG1, concomitant use of these products with DRUG2 is not recommended pending full examination of potential interactions. ",negative,itraconazole,terfenadine
"DRUG1: Clinical DRUGOTHER interaction studies indicate that DRUG2 and DRUGOTHER can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",negative,Macrolides,erythromycin
"DRUG1: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUG2 can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",negative,Macrolides,clarithromycin
"DRUG1: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUGOTHER can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",negative,Macrolides,terfenadine
"DRUG1: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUGOTHER can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,Macrolides,ketoconazole
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUG1 and DRUG2 can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",negative,erythromycin,clarithromycin
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUG1 and DRUGOTHER can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",mechanism,erythromycin,terfenadine
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUG1 and DRUGOTHER can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,erythromycin,ketoconazole
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUG1 can exert an effect on DRUG2 metabolism by a mechanism which may be similar to that of DRUGOTHER, but to a lesser extent. ",mechanism,clarithromycin,terfenadine
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUG1 can exert an effect on DRUGOTHER metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,clarithromycin,ketoconazole
"DRUGOTHER: Clinical DRUGOTHER interaction studies indicate that DRUGOTHER and DRUGOTHER can exert an effect on DRUG1 metabolism by a mechanism which may be similar to that of DRUG2, but to a lesser extent. ",negative,terfenadine,ketoconazole
"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving DRUG1 or DRUG2. ",negative,erythromycin,troleandomycin
"Concomitant administration of DRUG1 with DRUG2, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",advise,terfenadine,clarithromycin
"Concomitant administration of DRUG1 with DRUGOTHER, DRUG2, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",advise,terfenadine,erythromycin
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",advise,terfenadine,troleandomycin
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,terfenadine,terfenadine
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,terfenadine,macrolide antibiotics
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",negative,terfenadine,azithromycin
"Concomitant administration of DRUGOTHER with DRUG1, DRUG2, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,clarithromycin,erythromycin
"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,clarithromycin,troleandomycin
"Concomitant administration of DRUG2 with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,clarithromycin,terfenadine
"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,clarithromycin,macrolide antibiotics
"Concomitant administration of DRUGOTHER with DRUG1, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",negative,clarithromycin,azithromycin
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUG2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,erythromycin,troleandomycin
"Concomitant administration of DRUG2 with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,erythromycin,terfenadine
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,erythromycin,macrolide antibiotics
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUG1, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",negative,erythromycin,azithromycin
"Concomitant administration of DRUG2 with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG2 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,troleandomycin,terfenadine
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",negative,troleandomycin,macrolide antibiotics
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUG1 is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",negative,troleandomycin,azithromycin
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUGOTHER, is not recommended. ",advise,terfenadine,macrolide antibiotics
"Concomitant administration of DRUG1 with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUG1 with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",advise,terfenadine,azithromycin
"Concomitant administration of DRUGOTHER with DRUGOTHER, DRUGOTHER, or DRUGOTHER is contraindicated: Pending full characterization of potential interactions, concomitant administration of DRUGOTHER with other macrolide DRUGOTHER, including DRUG2, is not recommended. ",negative,macrolide antibiotics,azithromycin
Studies to evaluate potential interactions of DRUG1 with DRUG2 are in progress.,negative,terfenadine,azithromycin
Caution is recommended when administering DRUG1 with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. DRUG2). ,advise,NEXAVAR,irinotecan
Concomitant treatment with DRUG1 resulted in a 21% increase in the AUC of DRUG2. ,mechanism,NEXAVAR,doxorubicin
Caution is recommended when administering DRUG1 with DRUG2. ,advise,doxorubicin,NEXAVAR
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG1, treatment with DRUG2 once weekly for 4 weeks was associated with a mean increase of 16% in DRUG1 AUC; ",mechanism,methadone,PEG-Intron
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG1, treatment with DRUGOTHER once weekly for 4 weeks was associated with a mean increase of 16% in DRUG1 AUC; ",negative,methadone,methadone
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving DRUG2, treatment with DRUG1 once weekly for 4 weeks was associated with a mean increase of 16% in DRUG2 AUC; ",negative,PEG-Intron,methadone
"Since DRUG1 is a substrate for the metabolic pathways involving DRUGOTHER and DRUGOTHER enzymes, inhibition or induction of either of these enzymes would be expected to alter DRUG2 plasma concentrations. ",negative,MEXITIL,mexiletine
"In a formal, single-dose interaction study (n = 6 males) the clearance of DRUG1 was decreased by 38% following the coadministration of DRUG2, an inhibitor of DRUGOTHER. ",mechanism,mexiletine,fluvoxamine
"In another formal study (n = 8 extensive and n = 7 poor metabolizers of DRUGOTHER), coadministration of DRUG1 did not alter the kinetics of DRUG2 in the poor DRUGOTHER metabolizer group. ",negative,propafenone,mexiletine
"In this crossover steady state study, the pharmacokinetics of DRUG1 were unaffected in either phenotype by the coadministration of DRUG2. ",negative,propafenone,mexiletine
"Addition of DRUG1 to DRUG2 did not DRUGOTHER to further electrocardiographic parameters changes of QRS, QTc, DRUGOTHER, and PR intervals than DRUG2 alone. ",negative,mexiletine,propafenone
"Addition of DRUG1 to DRUG2 did not DRUGOTHER to further electrocardiographic parameters changes of QRS, QTc, DRUGOTHER, and PR intervals than DRUG2 alone. ",negative,mexiletine,propafenone
"Addition of DRUGOTHER to DRUG1 did not DRUGOTHER to further electrocardiographic parameters changes of QRS, QTc, DRUGOTHER, and PR intervals than DRUG1 alone. ",negative,propafenone,propafenone
"When concomitant administration of either of these two DRUGOTHER with DRUG1 is initiated, the dose of DRUG1 should be slowly titrated to desired effect. ",negative,mexiletine,mexiletine
"In a large compassionate use program DRUG1    has been used concurrently with commonly employed antianginal, DRUG2, and DRUGOTHER DRUGOTHER without observed interactions. ",negative,Mexitil,antihypertensive
"In a large compassionate use program DRUG1    has been used concurrently with commonly employed antianginal, DRUGOTHER, and DRUGOTHER DRUGOTHER without observed interactions. ",negative,Mexitil,anticoagulant drugs
"In a large compassionate use program DRUGOTHER    has been used concurrently with commonly employed antianginal, DRUG1, and DRUGOTHER DRUGOTHER without observed interactions. ",negative,antihypertensive,anticoagulant drugs
"A variety of DRUG1 such as DRUG2 or DRUGOTHER were also added, sometimes with improved control of ventricular ectopy. ",negative,antiarrhythmics,quinidine
"A variety of DRUG1 such as DRUGOTHER or DRUG2 were also added, sometimes with improved control of ventricular ectopy. ",negative,antiarrhythmics,propranolol
"A variety of DRUGOTHER such as DRUG1 or DRUG2 were also added, sometimes with improved control of ventricular ectopy. ",negative,quinidine,propranolol
"When DRUG1 or other hepatic enzyme inducers such as DRUG2 and DRUGOTHER have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",negative,phenytoin,rifampin
"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUG2 have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",negative,phenytoin,phenobarbital
"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,phenytoin,Mexitil
"When DRUG1 or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,phenytoin,Mexitil
"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUG2 have been taken concurrently with DRUGOTHER   , lowered DRUGOTHER    plasma levels have been reported. ",negative,rifampin,phenobarbital
"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,rifampin,Mexitil
"When DRUGOTHER or other hepatic enzyme inducers such as DRUG1 and DRUGOTHER have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,rifampin,Mexitil
"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",mechanism,phenobarbital,Mexitil
"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUG1 have been taken concurrently with DRUG2   , lowered DRUG2    plasma levels have been reported. ",negative,phenobarbital,Mexitil
"When DRUGOTHER or other hepatic enzyme inducers such as DRUGOTHER and DRUGOTHER have been taken concurrently with DRUG1   , lowered DRUG1    plasma levels have been reported. ",negative,Mexitil,Mexitil
"In a formal study, DRUG1 were shown not to affect DRUG2    plasma concentrations. ",negative,benzodiazepines,Mexitil
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,Mexitil,digoxin
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,Mexitil,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUG1    and DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,Mexitil,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUG1, DRUG2, or DRUGOTHER. ",negative,digoxin,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUG1, DRUGOTHER, or DRUG2. ",negative,digoxin,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent DRUGOTHER    and DRUGOTHER, DRUG1, or DRUG2. ",negative,diuretics,propranolol
"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",mechanism,cimetidine,Mexitil
"Concurrent administration of DRUG1 and DRUG2    has been reported to increase, decrease, or leave unchanged DRUG2    plasma levels; ",negative,cimetidine,Mexitil
"Concurrent administration of DRUGOTHER and DRUG1    has been reported to increase, decrease, or leave unchanged DRUG1    plasma levels; ",negative,Mexitil,Mexitil
"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
"DRUG1    does not alter serum DRUGOTHER levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUGOTHER levels. ",negative,Mexitil,magnesium-aluminum hydroxide
"DRUG1    does not alter serum DRUGOTHER levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUGOTHER levels. ",negative,Mexitil,Mexitil
"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
"DRUGOTHER    does not alter serum DRUG1 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUGOTHER   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,magnesium-aluminum hydroxide
"DRUG2    does not alter serum DRUG1 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG2   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,Mexitil
"DRUGOTHER    does not alter serum DRUG1 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUGOTHER   , has been reported to lower serum DRUG1 levels. ",negative,digoxin,digoxin
"DRUG2    does not alter serum DRUGOTHER levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG2   , has been reported to lower serum DRUGOTHER levels. ",negative,magnesium-aluminum hydroxide,Mexitil
"DRUGOTHER    does not alter serum DRUG2 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUGOTHER   , has been reported to lower serum DRUG2 levels. ",mechanism,magnesium-aluminum hydroxide,digoxin
"DRUG1    does not alter serum DRUG2 levels but DRUGOTHER-DRUGOTHER hydroxide, when used to treat gastrointestinal symptoms due to DRUG1   , has been reported to lower serum DRUG2 levels. ",negative,Mexitil,digoxin
Concurrent use of DRUG1    and DRUG2 may DRUGOTHER to increased plasma DRUG2 levels. ,mechanism,Mexitil,theophylline
Concurrent use of DRUG1    and DRUG2 may DRUGOTHER to increased plasma DRUG2 levels. ,negative,Mexitil,theophylline
Concurrent use of DRUGOTHER    and DRUG1 may DRUGOTHER to increased plasma DRUG1 levels. ,negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",mechanism,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",advise,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUG2 plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG1   . DRUGOTHER plasma levels returned to pre-DRUG1    values within 48 hours after discontinuing DRUG1   . If DRUG1 and DRUGOTHER are to be used concurrently, DRUGOTHER blood levels should be monitored, particularly when the DRUG1    dose is changed. ",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting DRUG2   . DRUG1 plasma levels returned to pre-DRUG2    values within 48 hours after discontinuing DRUG2   . If DRUG2 and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUG2    dose is changed. ",negative,theophylline,Mexitil
"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of DRUG1 was decreased 50% following the administration of DRUG2   .",mechanism,caffeine,Mexitil
"Usage with DRUG1: Due to the potential for increased DRUGOTHER effects, DRUG1 should be used with caution in patients who are currently receiving DRUGOTHER.",negative,Alcohol,alcohol
"Usage with DRUG1: Due to the potential for increased DRUGOTHER effects, DRUG1 should be used with caution in patients who are currently receiving DRUG2.",negative,Alcohol,pentazocine
"Usage with DRUG1: Due to the potential for increased DRUGOTHER effects, DRUG1 should be used with caution in patients who are currently receiving DRUG2.",advise,alcohol,pentazocine
"DRUG1 may compete with other DRUGOTHER, such as DRUG2, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",mechanism,Thiabendazole,theophylline
"Therefore, when concomitant use of DRUG1 and DRUG2 is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",advise,thiabendazole,xanthine derivatives
"DRUG1 may be used with DRUG2, DRUGOTHER and other DRUGOTHER, and with other DRUGOTHER. ",negative,Pyrimethamine,sulfonamides
"DRUG1 may be used with DRUGOTHER, DRUG2 and other DRUGOTHER, and with other DRUGOTHER. ",negative,Pyrimethamine,quinine
"DRUG1 may be used with DRUGOTHER, DRUGOTHER and other DRUG2, and with other DRUGOTHER. ",negative,Pyrimethamine,antimalarials
"DRUG1 may be used with DRUGOTHER, DRUGOTHER and other DRUGOTHER, and with other DRUG2. ",negative,Pyrimethamine,antibiotics
"DRUGOTHER may be used with DRUG1, DRUG2 and other DRUGOTHER, and with other DRUGOTHER. ",negative,sulfonamides,quinine
"DRUGOTHER may be used with DRUG1, DRUGOTHER and other DRUG2, and with other DRUGOTHER. ",negative,sulfonamides,antimalarials
"DRUGOTHER may be used with DRUG1, DRUGOTHER and other DRUGOTHER, and with other DRUG2. ",negative,sulfonamides,antibiotics
"DRUGOTHER may be used with DRUGOTHER, DRUG1 and other DRUG2, and with other DRUGOTHER. ",negative,quinine,antimalarials
"DRUGOTHER may be used with DRUGOTHER, DRUG1 and other DRUGOTHER, and with other DRUG2. ",negative,quinine,antibiotics
"DRUGOTHER may be used with DRUGOTHER, DRUGOTHER and other DRUG1, and with other DRUG2. ",negative,antimalarials,antibiotics
DRUG1 (DRUG2) should be administered until normal hematopoiesis is restored. ,negative,Folinic acid,leucovorin
Mild hepatotoxicity has been reported in some patients when DRUG1 and DRUG2 were administered concomitantly.,effect,lorazepam,pyrimethamine
"DRUG1 inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,Posicor,terfenadine
"DRUG1 inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,Posicor,astemizole
"DRUG1 inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",mechanism,Posicor,cisapride
"DRUG1 inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",mechanism,Posicor,cyclosporine
"DRUG1 inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER DRUGOTHER. ",mechanism,Posicor,tricyclic antidepressants
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terfenadine,astemizole
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,terfenadine,cisapride
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,terfenadine,cyclosporine
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER DRUGOTHER. ",negative,terfenadine,tricyclic antidepressants
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,astemizole,cisapride
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,astemizole,cyclosporine
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER DRUGOTHER. ",negative,astemizole,tricyclic antidepressants
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,cisapride,cyclosporine
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER DRUGOTHER. ",negative,cisapride,tricyclic antidepressants
"DRUGOTHER inhibits some of the liver's ability to metabolize some other DRUGOTHER - DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER DRUGOTHER. ",negative,cyclosporine,tricyclic antidepressants
DRUG1 may interact with DRUG2 or DRUGOTHER (causing too great a decrease in adrenal function).,int,Trilostane,aminoglutethimide
DRUG1 may interact with DRUGOTHER or DRUG2 (causing too great a decrease in adrenal function).,int,Trilostane,mitotane
DRUGOTHER may interact with DRUG1 or DRUG2 (causing too great a decrease in adrenal function).,negative,aminoglutethimide,mitotane
"Concomitant administration of substances that are also tubularly secreted (e.g., DRUG1) could potentially result in delayed clearance of DRUG2. ",mechanism,probenecid,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with DRUGOTHER in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUGOTHER to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ibuprofen
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ibuprofen,ALIMTA
"Although DRUG2 (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG2 concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ALIMTA,ibuprofen
"Although DRUGOTHER (400 mg qid) can be administered with DRUG1 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUGOTHER concurrently with DRUG1 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",negative,ALIMTA,ALIMTA
"Although DRUG1 (400 mg qid) can be administered with DRUG2 in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering DRUG1 concurrently with DRUG2 to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ",advise,ibuprofen,ALIMTA
"Patients with mild to moderate renal insufficiency should avoid taking DRUG1 with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of DRUG2. ",advise,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between DRUG1 and DRUG2 with longer half-lives, all patients taking these DRUG2 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between DRUG1 and DRUG2 with longer half-lives, all patients taking these DRUG2 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between DRUG1 and DRUGOTHER with longer half-lives, all patients taking these DRUGOTHER should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG1 administration. ",negative,ALIMTA,ALIMTA
"In the absence of data regarding potential interaction between DRUGOTHER and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUGOTHER administration. ",negative,NSAIDs,NSAIDs
"In the absence of data regarding potential interaction between DRUG2 and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG2 administration. ",negative,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between DRUG2 and DRUG1 with longer half-lives, all patients taking these DRUG1 should interrupt dosing for at least 5 days before, the day of, and 2 days following DRUG2 administration. ",advise,NSAIDs,ALIMTA
DRUG1 may decrease the hypotensive effect of DRUG2. ,effect,Ritalin,guanethidine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,coumarin anticoagulants
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,anticonvulsants
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,phenobarbital
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,diphenylhydantoin
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,primidone
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,phenylbutazone
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,tricyclic drugs
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",mechanism,Ritalin,imipramine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",mechanism,Ritalin,clomipramine
"Human pharmacologic studies have shown that DRUG1 may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",mechanism,Ritalin,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,anticonvulsants
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,phenobarbital
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,diphenylhydantoin
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,primidone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,phenylbutazone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,coumarin anticoagulants,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,coumarin anticoagulants,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,coumarin anticoagulants,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,phenobarbital
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,diphenylhydantoin
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,primidone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,phenylbutazone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,anticonvulsants,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,anticonvulsants,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,anticonvulsants,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUG2, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,phenobarbital,diphenylhydantoin
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,phenobarbital,primidone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,phenobarbital,phenylbutazone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,phenobarbital,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,phenobarbital,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,phenobarbital,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,phenobarbital,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUG2), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,diphenylhydantoin,primidone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,diphenylhydantoin,phenylbutazone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,diphenylhydantoin,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,diphenylhydantoin,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,diphenylhydantoin,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,diphenylhydantoin,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUG2, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,primidone,phenylbutazone
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,primidone,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,primidone,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,primidone,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,primidone,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,phenylbutazone,tricyclic drugs
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,phenylbutazone,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,phenylbutazone,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUG1, and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,phenylbutazone,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER). ",negative,tricyclic drugs,imipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER). ",negative,tricyclic drugs,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2). ",negative,tricyclic drugs,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG1, DRUG2, DRUGOTHER). ",negative,imipramine,clomipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUG1, DRUGOTHER, DRUG2). ",negative,imipramine,desipramine
"Human pharmacologic studies have shown that DRUGOTHER may inhibit the metabolism of DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, and DRUGOTHER (DRUGOTHER, DRUG1, DRUG2). ",negative,clomipramine,desipramine
The safety of using DRUG1 in combination with DRUG2 or other centrally acting DRUGOTHER has not been systemically evaluated.    ,negative,methylphenidate,clonidine
The safety of using DRUG1 in combination with DRUGOTHER or other centrally acting DRUG2 has not been systemically evaluated.    ,negative,methylphenidate,alpha-2 agonists
The safety of using DRUGOTHER in combination with DRUG1 or other centrally acting DRUG2 has not been systemically evaluated.    ,negative,clonidine,alpha-2 agonists
DRUGOTHER-Derivative DRUGOTHER: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving DRUG2 concomitantly with DRUGOTHER-derivative DRUGOTHER. ,negative,Coumarin-Derivative Anticoagulants,ZOLINZA
DRUGOTHER-Derivative DRUGOTHER: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving DRUGOTHER concomitantly with DRUGOTHER-derivative DRUGOTHER. ,negative,Coumarin-Derivative Anticoagulants,coumarin-derivative anticoagulants
DRUGOTHER-Derivative DRUGOTHER: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving DRUG1 concomitantly with DRUGOTHER-derivative DRUGOTHER. ,effect,ZOLINZA,coumarin-derivative anticoagulants
Physicians should carefully monitor PT and INR in patients concurrently administered DRUG1 and DRUGOTHER derivatives. ,advise,ZOLINZA,coumarin derivatives
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG2 and other DRUG1 (e.g., DRUGOTHER). ",negative,HDAC Inhibitors,ZOLINZA
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUGOTHER and other DRUG1 (e.g., DRUGOTHER). ",negative,HDAC Inhibitors,HDAC inhibitors
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUGOTHER and other DRUG1 (e.g., DRUG2). ",negative,HDAC Inhibitors,valproic acid
"Other DRUG2 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG1 and other DRUG2 (e.g., DRUGOTHER). ",effect,ZOLINZA,HDAC inhibitors
"Other DRUGOTHER Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUG1 and other DRUGOTHER (e.g., DRUG2). ",effect,ZOLINZA,valproic acid
"Other DRUG1 Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of DRUGOTHER and other DRUG1 (e.g., DRUG2). ",negative,HDAC inhibitors,valproic acid
No pharmacokinetic interaction between 85 mg/m2 DRUG1 and infusional DRUG2 has been observed in patients treated every 2 weeks. ,negative,ELOXATIN,5-FU
Increases of DRUG1 plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 DRUG2 dosed every 3 weeks. ,mechanism,5-FU,ELOXATIN
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG2 and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,Alcohol,XENICAL
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,Alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,Alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,Alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,Alcohol,orlistat
"DRUG2: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,XENICAL,alcohol
"DRUG2: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUG2 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG2 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,XENICAL,alcohol
"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,XENICAL,orlistat
"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,XENICAL,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUGOTHER pharmacodynamics (fecal fat excretion), or systemic exposure to DRUGOTHER. ",negative,alcohol,alcohol
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUG1: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUG1 (e.g., approximately 3 glasses of wine) did not result in alteration of DRUG1 pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",negative,alcohol,orlistat
"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG1 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG1. ",negative,orlistat,orlistat
DRUG1: Preliminary data from a DRUG2 and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,Cyclosporine,XENICAL
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,Cyclosporine,XENICAL
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,Cyclosporine,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 DRUGOTHER interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 DRUGOTHER interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
DRUGOTHER: Preliminary data from a DRUG1 and DRUGOTHER DRUGOTHER interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG1 was coadministered with DRUGOTHER. ,negative,XENICAL,XENICAL
DRUG2: Preliminary data from a DRUG1 and DRUG2 DRUGOTHER interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,negative,XENICAL,cyclosporine
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,cyclosporine,XENICAL
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG1: Preliminary data from a DRUG2 and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUG2 was coadministered with DRUG1. ,negative,cyclosporine,XENICAL
DRUG1: Preliminary data from a DRUGOTHER and DRUG1 DRUGOTHER interaction study indicate a reduction in DRUG1 plasma levels when DRUGOTHER was coadministered with DRUG1. ,negative,cyclosporine,cyclosporine
DRUG2: Preliminary data from a DRUG1 and DRUG2 DRUGOTHER interaction study indicate a reduction in DRUG2 plasma levels when DRUG1 was coadministered with DRUG2. ,mechanism,XENICAL,cyclosporine
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not alter the pharmacokinetics of a single dose of DRUG1. ",negative,Digoxin,digoxin
"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",negative,XENICAL,XENICAL
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",negative,XENICAL,digoxin
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUG2. ",negative,XENICAL,digoxin
Fat-soluble DRUGOTHER and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUG2 supplement absorption when concomitantly administered with DRUGOTHER. ,negative,Fat-soluble Vitamin Supplements,beta-carotene
Fat-soluble DRUGOTHER and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUGOTHER supplement absorption when concomitantly administered with DRUG2. ,negative,Fat-soluble Vitamin Supplements,XENICAL
Fat-soluble DRUGOTHER and Analogues: A pharmacokinetic interaction study showed a 30% reduction in DRUG1 supplement absorption when concomitantly administered with DRUG2. ,mechanism,beta-carotene,XENICAL
DRUG1 inhibited absorption of a DRUGOTHER acetate supplement by approximately 60%. ,mechanism,XENICAL,vitamin E acetate
"The effect of DRUG1 on the absorption of supplemental DRUG2, DRUGOTHER, and nutritionally-derived DRUGOTHER is not known at this time. ",negative,orlistat,vitamin D
"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUG2, and nutritionally-derived DRUGOTHER is not known at this time. ",negative,orlistat,vitamin A
"The effect of DRUG1 on the absorption of supplemental DRUGOTHER, DRUGOTHER, and nutritionally-derived DRUG2 is not known at this time. ",negative,orlistat,vitamin K
"The effect of DRUGOTHER on the absorption of supplemental DRUG1, DRUG2, and nutritionally-derived DRUGOTHER is not known at this time. ",negative,vitamin D,vitamin A
"The effect of DRUGOTHER on the absorption of supplemental DRUG1, DRUGOTHER, and nutritionally-derived DRUG2 is not known at this time. ",negative,vitamin D,vitamin K
"The effect of DRUGOTHER on the absorption of supplemental DRUGOTHER, DRUG1, and nutritionally-derived DRUG2 is not known at this time. ",negative,vitamin A,vitamin K
"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUG1. ",negative,Glyburide,orlistat
"DRUG1: In 12 normal-weight subjects receiving DRUG2 80 mg three times a day for 5 days, DRUG2 did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUG1. ",negative,Glyburide,orlistat
"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 80 mg three times a day for 5 days, DRUGOTHER did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUG1. ",negative,Glyburide,glyburide
"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUGOTHER. ",negative,orlistat,orlistat
"DRUG2: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUG2. ",negative,orlistat,glyburide
"DRUG2: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood DRUGOTHER-lowering) of DRUG2. ",negative,orlistat,glyburide
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,XENICAL
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,XENICAL
"DRUG1 (extended-release tablets): In 17 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not alter the bioavailability of DRUG1 (extended-release tablets). ",negative,Nifedipine,nifedipine
"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",negative,XENICAL,XENICAL
"DRUG2 (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",negative,XENICAL,nifedipine
"DRUG2 (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUG2 (extended-release tablets). ",negative,XENICAL,nifedipine
"Oral DRUG1: In 20 normal-weight female subjects, the treatment of DRUG2 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG1. ",negative,Contraceptives,XENICAL
"Oral DRUG1: In 20 normal-weight female subjects, the treatment of DRUGOTHER 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG1. ",negative,Contraceptives,contraceptives
"Oral DRUG2: In 20 normal-weight female subjects, the treatment of DRUG1 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral DRUG2. ",negative,XENICAL,contraceptives
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,XENICAL
"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 7 days, DRUGOTHER did not alter the pharmacokinetics of a single 300-mg dose of DRUG1. ",negative,Phenytoin,phenytoin
"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",negative,XENICAL,XENICAL
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",negative,XENICAL,phenytoin
"DRUG2: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",negative,XENICAL,phenytoin
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,XENICAL
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,XENICAL
"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not affect the pharmacokinetics of DRUG1. ",negative,Pravastatin,pravastatin
"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUGOTHER. ",negative,XENICAL,XENICAL
"DRUG2: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",negative,XENICAL,pravastatin
"DRUG2: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",negative,XENICAL,pravastatin
"DRUG1: In 12 normal-weight subjects, administration of DRUG2 120 mg three times a day for 16 days did not result in any change in either DRUG1 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,Warfarin,XENICAL
"DRUG1: In 12 normal-weight subjects, administration of DRUGOTHER 120 mg three times a day for 16 days did not result in any change in either DRUG1 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,Warfarin,warfarin
"DRUG2: In 12 normal-weight subjects, administration of DRUG1 120 mg three times a day for 16 days did not result in any change in either DRUG2 pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",negative,XENICAL,warfarin
"Although undercarboxylated osteocalcin, a marker of DRUGOTHER nutritional status, was unaltered with DRUG1 administration, DRUGOTHER levels tended to decline in subjects taking DRUG1. ",negative,XENICAL,XENICAL
"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",mechanism,vitamin K,XENICAL
"Therefore, as DRUG1 absorption may be decreased with DRUGOTHER, patients on chronic stable doses of DRUG2 who are prescribed DRUGOTHER should be monitored closely for changes in coagulation parameters.",negative,vitamin K,warfarin
"Therefore, as DRUG1 absorption may be decreased with DRUG2, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",negative,vitamin K,XENICAL
"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUG2 who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",negative,XENICAL,warfarin
"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",negative,XENICAL,XENICAL
"Therefore, as DRUGOTHER absorption may be decreased with DRUG2, patients on chronic stable doses of DRUG1 who are prescribed DRUG2 should be monitored closely for changes in coagulation parameters.",advise,warfarin,XENICAL
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terbinafine,tolbutamide
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,terbinafine,ethinylestradiol
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,terbinafine,ethoxycoumarin
"In vitro studies with human liver microsomes showed that DRUG1 does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,terbinafine,cyclosporine
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,tolbutamide,ethinylestradiol
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,tolbutamide,ethoxycoumarin
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,tolbutamide,cyclosporine
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,ethinylestradiol,ethoxycoumarin
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,ethinylestradiol,cyclosporine
"In vitro studies with human liver microsomes showed that DRUGOTHER does not inhibit the metabolism of DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,ethoxycoumarin,cyclosporine
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER DRUGOTHER,    -blockers, selective DRUGOTHER (DRUGOTHER), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER DRUGOTHER,    -blockers, DRUGOTHER (DRUG2), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER DRUGOTHER,    -blockers, DRUGOTHER (DRUGOTHER), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER,    -blockers, selective DRUGOTHER (DRUG2), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,selective serotonin reuptake inhibitors,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER,    -blockers, selective DRUGOTHER (DRUGOTHER), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as DRUGOTHER,    -blockers, DRUGOTHER (DRUG1), and DRUGOTHER (MAO-Is) Type B, if they have a narrow therapeutic window. ",negative,SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B
In vivo DRUGOTHER-DRUGOTHER interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of DRUG2 or DRUGOTHER. ,negative,terbinafine,antipyrine
In vivo DRUGOTHER-DRUGOTHER interaction studies conducted in normal volunteer subjects showed that DRUG1 does not affect the clearance of DRUGOTHER or DRUG2. ,negative,terbinafine,digoxin
In vivo DRUGOTHER-DRUGOTHER interaction studies conducted in normal volunteer subjects showed that DRUGOTHER does not affect the clearance of DRUG1 or DRUG2. ,negative,antipyrine,digoxin
DRUG1 decreases the clearance of DRUG2 by 19%. ,mechanism,Terbinafine,caffeine
DRUG1 increases the clearance of DRUG2 by 15%. ,mechanism,Terbinafine,cyclosporine
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and DRUG2, however, a causal relationship between DRUGOTHER    Tablets and these changes has not been established. ",effect,terbinafine,warfarin
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUG1 and DRUGOTHER, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",negative,terbinafine,LAMISIL
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral DRUGOTHER and DRUG1, however, a causal relationship between DRUG2    Tablets and these changes has not been established. ",negative,warfarin,LAMISIL
"DRUG1 clearance is increased 100% by DRUG2, a CyP450 enzyme inducer, and decreased 33% by DRUGOTHER, a CyP450 enzyme inhibitor. ",mechanism,Terbinafine,rifampin
"DRUG1 clearance is increased 100% by DRUGOTHER, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",mechanism,Terbinafine,cimetidine
"DRUGOTHER clearance is increased 100% by DRUG1, a CyP450 enzyme inducer, and decreased 33% by DRUG2, a CyP450 enzyme inhibitor. ",negative,rifampin,cimetidine
DRUG1 clearance is unaffected by DRUG2. ,negative,Terbinafine,cyclosporine
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,contraceptives,hypoglycemics
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,contraceptives,theophyllines
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,contraceptives,phenytoins
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,contraceptives,thiazide diuretics
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER channel blockers.",negative,contraceptives,beta blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUG1, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,contraceptives,calcium channel blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,hypoglycemics,theophyllines
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,hypoglycemics,phenytoins
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,hypoglycemics,thiazide diuretics
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER channel blockers.",negative,hypoglycemics,beta blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,hypoglycemics,calcium channel blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,theophyllines,phenytoins
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,theophyllines,thiazide diuretics
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER channel blockers.",negative,theophyllines,beta blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,theophyllines,calcium channel blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,phenytoins,thiazide diuretics
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER channel blockers.",negative,phenytoins,beta blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,phenytoins,calcium channel blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER channel blockers.",negative,thiazide diuretics,beta blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER channel blockers.",negative,thiazide diuretics,calcium channel blockers
"There is no information available from adequate DRUGOTHER-DRUGOTHER interaction studies with the following classes of DRUGOTHER: oral DRUGOTHER, hormone replacement therapies, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG1, and DRUGOTHER channel blockers.",negative,beta blockers,calcium channel blockers
DRUG1 AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUGOTHER AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUGOTHER TO TOXIC LEVELS. ,negative,ASPIRIN,SALICYLATE DRUGS
DRUG1 AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUG2 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUGOTHER TO TOXIC LEVELS. ,effect,ASPIRIN,DISALCID
DRUG1 AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUGOTHER AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,ASPIRIN,SALICYLIC ACID
DRUGOTHER AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUG2 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUGOTHER TO TOXIC LEVELS. ,effect,SALICYLATE DRUGS,DISALCID
DRUGOTHER AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUGOTHER AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,SALICYLATE DRUGS,SALICYLIC ACID
DRUGOTHER AND OTHER DRUGOTHER DRUGOTHER WILL BE ADDITIVE TO DRUG1 AND MAY INCREASE PLASMA CONCENTRATIONS OF DRUG2 TO TOXIC LEVELS. ,negative,DISALCID,SALICYLIC ACID
DRUG1 given concomitantly with DRUGOTHER DRUGOTHER may predispose to systemic bleeding. ,effect,Salicylates,anticoagulant drugs
DRUG1 may enhance the DRUGOTHER effect of oral antidiabetic DRUGOTHER of the DRUGOTHER class. ,effect,Salicylates,antidiabetic drugs
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,penicillin
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,thiopental
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,thyroxine
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,triiodothyronine
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,phenytoin
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,sulfinpyrazone
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,naproxen
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",mechanism,Salicylate,warfarin
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",mechanism,Salicylate,methotrexate
"DRUG1 competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",mechanism,Salicylate,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,thiopental
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,thyroxine
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,triiodothyronine
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,phenytoin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,sulfinpyrazone
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,penicillin,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,penicillin,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,penicillin,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,thyroxine
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,triiodothyronine
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,phenytoin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,sulfinpyrazone
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,thiopental,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,thiopental,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,thiopental,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thyroxine,triiodothyronine
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thyroxine,phenytoin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thyroxine,sulfinpyrazone
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,thyroxine,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,thyroxine,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,thyroxine,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,thyroxine,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,triiodothyronine,phenytoin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,triiodothyronine,sulfinpyrazone
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,triiodothyronine,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,triiodothyronine,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,triiodothyronine,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,triiodothyronine,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,phenytoin,sulfinpyrazone
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,phenytoin,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,phenytoin,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,phenytoin,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,phenytoin,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and possibly DRUGOTHER. ",negative,sulfinpyrazone,naproxen
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,sulfinpyrazone,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,sulfinpyrazone,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,sulfinpyrazone,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and possibly DRUGOTHER. ",negative,naproxen,warfarin
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and possibly DRUGOTHER. ",negative,naproxen,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and possibly DRUG2. ",negative,naproxen,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and possibly DRUGOTHER. ",negative,warfarin,methotrexate
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and possibly DRUG2. ",negative,warfarin,corticosteroids
"DRUGOTHER competes with a number of DRUGOTHER for protein binding sites, notably DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and possibly DRUG2. ",negative,methotrexate,corticosteroids
"Catecholamine-depleting DRUGOTHER (e.g., DRUG1) may have an additive effect when given with DRUGOTHER agents. ",effect,reserpine,beta-blocking agents
"DRUG1 has been used with a variety of DRUGOTHER agents, including DRUGOTHER, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",negative,Pindolol,antihypertensive agents
"DRUG1 has been used with a variety of DRUGOTHER, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",negative,Pindolol,hydrochlorothiazide
"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",negative,Pindolol,hydralazine
"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",negative,Pindolol,guanethidine
"DRUGOTHER has been used with a variety of DRUGOTHER agents, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",negative,antihypertensive agents,hydrochlorothiazide
"DRUGOTHER has been used with a variety of DRUGOTHER agents, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",negative,antihypertensive agents,hydralazine
"DRUGOTHER has been used with a variety of DRUGOTHER agents, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",negative,antihypertensive agents,guanethidine
"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",negative,hydrochlorothiazide,hydralazine
"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",negative,hydrochlorothiazide,guanethidine
"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG1, and DRUG2 without unexpected adverse interactions. ",negative,hydralazine,guanethidine
DRUG1 has been shown to increase serum DRUG2 levels when both DRUGOTHER are DRUGOTHER-administered. ,mechanism,Pindolol,thioridazine
"Although specific DRUGOTHER or food interactions with DRUG1 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUG2, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,ketoconazole
"Although specific DRUGOTHER or food interactions with DRUG1 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG2, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,itraconazole
"Although specific DRUGOTHER or food interactions with DRUG1 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,erythromycin
"Although specific DRUGOTHER or food interactions with DRUG1 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG1). ",negative,mifepristone,mifepristone
"Although specific DRUGOTHER or food interactions with DRUGOTHER have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUG1, DRUG2, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",negative,ketoconazole,itraconazole
"Although specific DRUGOTHER or food interactions with DRUGOTHER have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUG1, DRUGOTHER, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",negative,ketoconazole,erythromycin
"Although specific DRUGOTHER or food interactions with DRUG2 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUG1, DRUGOTHER, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,ketoconazole,mifepristone
"Although specific DRUGOTHER or food interactions with DRUGOTHER have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG1, DRUG2, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUGOTHER). ",negative,itraconazole,erythromycin
"Although specific DRUGOTHER or food interactions with DRUG2 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUG1, DRUGOTHER, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,itraconazole,mifepristone
"Although specific DRUGOTHER or food interactions with DRUG2 have not been studied, on the basis of this DRUGOTHER   s metabolism by CYP 3A4, it is possible that DRUGOTHER, DRUGOTHER, DRUG1, and grapefruit juice may inhibit its metabolism (increasing serum levels of DRUG2). ",mechanism,erythromycin,mifepristone
"Furthermore, DRUG1, DRUG2, St. ",negative,rifampin,dexamethasone
"John   s Wort, and certain DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,anticonvulsants,phenytoin
"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,anticonvulsants,phenobarbital
"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,anticonvulsants,carbamazepine
"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,anticonvulsants,mifepristone
"John   s Wort, and certain DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,anticonvulsants,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,phenytoin,phenobarbital
"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,phenytoin,carbamazepine
"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,phenytoin,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,phenytoin,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) may induce DRUGOTHER metabolism (lowering serum levels of DRUGOTHER). ",negative,phenobarbital,carbamazepine
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,phenobarbital,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,phenobarbital,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",mechanism,carbamazepine,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) may induce DRUG2 metabolism (lowering serum levels of DRUG2). ",negative,carbamazepine,mifepristone
"John   s Wort, and certain DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) may induce DRUG1 metabolism (lowering serum levels of DRUG1). ",negative,mifepristone,mifepristone
"In addition to bleeding associated with DRUG1 and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,heparin,vitamin K antagonists
"In addition to bleeding associated with DRUG1 and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUG2, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,heparin,aspirin
"In addition to bleeding associated with DRUG1 and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG2, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,heparin,dipyridamole
"In addition to bleeding associated with DRUG1 and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUG2) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,heparin,abciximab
"In addition to bleeding associated with DRUG1 and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,heparin,Retavase
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUG2, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,vitamin K antagonists,aspirin
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG2, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,vitamin K antagonists,dipyridamole
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUG2) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,vitamin K antagonists,abciximab
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,vitamin K antagonists,Retavase
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUG1, DRUG2, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,aspirin,dipyridamole
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUG1, DRUGOTHER, and DRUG2) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,aspirin,abciximab
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUG1, DRUGOTHER, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,aspirin,Retavase
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG1, and DRUG2) may increase the risk of bleeding if administered prior to or after DRUGOTHER    therapy.",negative,dipyridamole,abciximab
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUG1, and DRUGOTHER) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,dipyridamole,Retavase
"In addition to bleeding associated with DRUGOTHER and DRUGOTHER antagonists, DRUGOTHER that alter platelet function (such as DRUGOTHER, DRUGOTHER, and DRUG1) may increase the risk of bleeding if administered prior to or after DRUG2    therapy.",effect,abciximab,Retavase
"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of DRUG1 and DRUG2. ",effect,selegiline,meperidine
This is typical of the interaction of DRUG1 and DRUG2. ,int,meperidine,MAOIs
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER DRUGOTHER and DRUG2 and DRUGOTHER and DRUG2. ,effect,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER DRUGOTHER and DRUGOTHER and selective DRUGOTHER and DRUGOTHER. ,negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER DRUGOTHER and DRUG2 and DRUGOTHER and DRUG2. ,negative,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG1 and selective DRUGOTHER and DRUG1. ,negative,ELDEPRYL,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG1 and DRUGOTHER and DRUG1. ,negative,ELDEPRYL,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of DRUGOTHER and DRUG2 and selective DRUGOTHER and DRUG2. ,effect,selective serotonin reuptake inhibitors,ELDEPRYL
One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUG1 and a DRUGOTHER medication (DRUGOTHER).,effect,selegiline,sympathomimetic medication
One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUG1 and a DRUGOTHER (DRUG2).,effect,selegiline,ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of DRUGOTHER and a DRUGOTHER medication (DRUG2).,negative,sympathomimetic medication,ephedrine
Caution should be exercised when administering DRUG1 therapy in combination with other immunomodulating DRUGOTHER. ,advise,ZADAXIN,immunomodulating drugs
Caution should be observed in administering DRUG1 to patients receiving DRUG2 or DRUGOTHER because the extrapyramidal effects of these DRUGOTHER can be expected to be potentiated by inhibition of catecholamine synthesis. ,advise,DEMSER,phenothiazines
Caution should be observed in administering DRUG1 to patients receiving DRUGOTHER or DRUG2 because the extrapyramidal effects of these DRUGOTHER can be expected to be potentiated by inhibition of catecholamine synthesis. ,advise,DEMSER,haloperidol
Caution should be observed in administering DRUGOTHER to patients receiving DRUG1 or DRUG2 because the extrapyramidal effects of these DRUGOTHER can be expected to be potentiated by inhibition of catecholamine synthesis. ,negative,phenothiazines,haloperidol
Concurrent use of DRUG1 with DRUG2 or other DRUGOTHER can increase their DRUGOTHER effects.,effect,DEMSER,alcohol
Concurrent use of DRUG1 with DRUGOTHER or other DRUG2 can increase their DRUGOTHER effects.,effect,DEMSER,CNS depressants
Concurrent use of DRUGOTHER with DRUG1 or other DRUG2 can increase their DRUGOTHER effects.,negative,alcohol,CNS depressants
The metabolism of DRUG1 is accelerated by DRUG2; ,mechanism,Metopirone,phenytoin
DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,mechanism,Metopirone,acetaminophen
DRUG1 inhibits the glucuronidation of DRUG2 and could possibly potentiate DRUG2 toxicity.,effect,Metopirone,acetaminophen
DRUGOTHER inhibits the glucuronidation of DRUG1 and could possibly potentiate DRUG1 toxicity.,negative,acetaminophen,acetaminophen
"DRUGOTHER antagonists, such as the DRUG2 (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,Dopamine antagonists,neuroleptics
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,Dopamine antagonists,phenothiazines
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,Dopamine antagonists,butyrophenones
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,Dopamine antagonists,thioxanthines
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,Dopamine antagonists,metoclopramide
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,Dopamine antagonists,Permax
"DRUGOTHER antagonists, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,Dopamine antagonists,dopamine agonist
"DRUGOTHER, such as the DRUG1 (DRUG2, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,neuroleptics,phenothiazines
"DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUG2, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,neuroleptics,butyrophenones
"DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUG2 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,neuroleptics,thioxanthines
"DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,neuroleptics,metoclopramide
"DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,neuroleptics,Permax
"DRUGOTHER, such as the DRUG1 (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,neuroleptics,dopamine agonist
"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUG2, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,phenothiazines,butyrophenones
"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUG2 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,phenothiazines,thioxanthines
"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,phenothiazines,metoclopramide
"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,phenothiazines,Permax
"DRUGOTHER, such as the DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,phenothiazines,dopamine agonist
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUG2 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,butyrophenones,thioxanthines
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,butyrophenones,metoclopramide
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,butyrophenones,Permax
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,butyrophenones,dopamine agonist
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 ) or DRUG2, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER); ",negative,thioxanthines,metoclopramide
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,thioxanthines,Permax
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1 ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,thioxanthines,dopamine agonist
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG1, ordinarily should not be administered concurrently with DRUG2 (a DRUGOTHER); ",advise,metoclopramide,Permax
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUG1, ordinarily should not be administered concurrently with DRUGOTHER (a DRUGOTHER agonist); ",negative,metoclopramide,dopamine agonist
"DRUGOTHER, such as the DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER ) or DRUGOTHER, ordinarily should not be administered concurrently with DRUG1 (a DRUGOTHER agonist); ",negative,Permax,dopamine agonist
"Because DRUG1 is approximately 90% bound to plasma proteins, caution should be exercised if DRUG1 is coadministered with other DRUGOTHER known to affect protein binding.",negative,pergolide mesylate,pergolide mesylate
"DRUGOTHER-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",negative,ketoconazole,retapamulin
"DRUGOTHER-administration of oral DRUG1 200 mg twice daily increased DRUG2 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG2 ointment, 1% on the abraded skin of healthy adult males. ",mechanism,ketoconazole,retapamulin
"DRUGOTHER-administration of oral DRUGOTHER 200 mg twice daily increased DRUG1 geometric mean AUC(0-24) and Cmax by 81% after topical application of DRUG1 ointment, 1% on the abraded skin of healthy adult males. ",negative,retapamulin,retapamulin
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when DRUGOTHER-administered with DRUGOTHER inhibitors, such as DRUGOTHER. ",negative,retapamulin,retapamulin
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when DRUGOTHER-administered with DRUGOTHER inhibitors, such as DRUG2. ",negative,retapamulin,ketoconazole
"Due to low systemic exposure to DRUG1 following topical application in patients, dosage adjustments for DRUG1 are unnecessary when DRUGOTHER-administered with DRUGOTHER inhibitors, such as DRUG2. ",negative,retapamulin,ketoconazole
"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of DRUG1, DRUG2 is unlikely to affect the metabolism of other P450 substrates. ",negative,ALTABAX,retapamulin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",mechanism,ketoconazole,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,ketoconazole,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,paricalcitol,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,paricalcitol,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,paricalcitol,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,paricalcitol,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,paricalcitol,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUG2 AUC0-   . Since DRUG2 is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG2 with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,paricalcitol
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,ketoconazole,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG2 approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUG2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUG2 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,ketoconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",advise,paricalcitol,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",advise,paricalcitol,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUG1 AUC0-   . Since DRUG1 is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUG1 with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",advise,paricalcitol,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,atazanavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,ketoconazole,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,ketoconazole,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUG1 approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUG1 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUG1 and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,ketoconazole,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,clarithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,atazanavir,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,atazanavir,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,atazanavir,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,indinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,clarithromycin,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,clarithromycin,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,clarithromycin,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,indinavir,itraconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,indinavir,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,indinavir,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,indinavir,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,indinavir,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,indinavir,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,indinavir,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,itraconazole,nefazodone
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,itraconazole,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,itraconazole,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,itraconazole,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,itraconazole,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,itraconazole,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,nefazodone,nelfinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,nefazodone,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,nefazodone,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,nefazodone,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,nefazodone,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",negative,nelfinavir,ritonavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,nelfinavir,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,nelfinavir,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,nelfinavir,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER. ",negative,ritonavir,saquinavir
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER. ",negative,ritonavir,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2. ",negative,ritonavir,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER. ",negative,saquinavir,telithromycin
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2. ",negative,saquinavir,voriconazole
"A multiple dose DRUGOTHER-DRUGOTHER interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2. ",negative,telithromycin,voriconazole
"Dose adjustment of DRUG1 Capsules may be required, and iPTH and serum DRUGOTHER concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong DRUGOTHER inhibitor such as DRUG2. ",advise,Zemplar,ketoconazole
"DRUGOTHER that impair intestinal absorption of fat-soluble DRUGOTHER, such as DRUG2, may interfere with the absorption of DRUGOTHER Capsules.",mechanism,fat-soluble vitamins,cholestyramine
"DRUGOTHER that impair intestinal absorption of fat-soluble DRUGOTHER, such as DRUGOTHER, may interfere with the absorption of DRUG2 Capsules.",negative,fat-soluble vitamins,Zemplar
"DRUGOTHER that impair intestinal absorption of DRUGOTHER, such as DRUG1, may interfere with the absorption of DRUG2 Capsules.",mechanism,cholestyramine,Zemplar
"Caution is advised for patients receiving high-dose DRUG1 and DRUG2 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUGOTHER.",advise,aspirin,methazolamide
"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUGOTHER.",negative,aspirin,aspirin
"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",negative,aspirin,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose DRUG2 and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG2 and DRUGOTHER.",negative,methazolamide,aspirin
"Caution is advised for patients receiving high-dose DRUGOTHER and DRUG1 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUGOTHER and DRUG2.",negative,methazolamide,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose DRUG1 and DRUGOTHER concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose DRUG1 and DRUG2.",effect,aspirin,carbonic anhydrase inhibitors
DRUGOTHER-DRUGOTHER Interactions: The pharmacokinetic and pharmacodynamic interactions between DRUG1 capsules and other alpha-DRUGOTHER blocking agents have not been determined. ,negative,FLOMAX,alpha-adrenergic blocking agents
"However, interactions may be expected and DRUG1 capsules should NOT be used in combination with other alpha-DRUGOTHER blocking agents. ",advise,FLOMAX,alpha-adrenergic blocking agents
The pharmacokinetic interaction between DRUG1 and DRUG2 capsules was investigated. ,negative,cimetidine,FLOMAX
"Therefore, DRUG1 capsules should be used with caution in combination with DRUG2, particularly at doses higher than 0.4 mg. ",advise,FLOMAX,cimetidine
Results from limited in vitro and in vivo DRUGOTHER-DRUGOTHER interaction studies between DRUGOTHER HCI and DRUG2 are inconclusive. ,negative,tamsulosin HCI,warfarin
"Therefore, caution should be exercised with concomitant administration of DRUG1 and DRUG2 capsules.        ",advise,warfarin,FLOMAX
"If DRUG1 replacement is required, the DRUG1 dose should be carefully adjusted. ",negative,glucocorticoid,glucocorticoid
Limited published data indicate that DRUG1 treatment increases cytochrome P450 (CP450) mediated DRUG2 clearance in man. ,mechanism,GH,antipyrine
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,GH,corticosteroids
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, sex DRUGOTHER, DRUGOTHER, DRUGOTHER). ",mechanism,GH,sex steroids
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER). ",mechanism,GH,anticonvulsants
"These data suggest that DRUG1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2). ",mechanism,GH,cyclosporin
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, sex DRUGOTHER, DRUGOTHER, DRUGOTHER). ",negative,corticosteroids,sex steroids
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER). ",negative,corticosteroids,anticonvulsants
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2). ",negative,corticosteroids,cyclosporin
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, sex DRUGOTHER, DRUG2, DRUGOTHER). ",negative,sex steroids,anticonvulsants
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, sex DRUGOTHER, DRUGOTHER, DRUG2). ",negative,sex steroids,cyclosporin
"These data suggest that DRUGOTHER administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2). ",negative,anticonvulsants,cyclosporin
The DRUGOTHER effects of DRUGOTHER hydrochloride may be additive with that of other DRUG2..,effect,oxycodone hydrochloride,CNS depressants
"Use with Other DRUG1: The depressant effects of DRUG2 are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,Central Nervous System Depressants,morphine
"Use with Other DRUG1: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG2 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,Central Nervous System Depressants,CNS depressants
"Use with Other DRUG1: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,Central Nervous System Depressants,alcohol
"Use with Other DRUG1: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,Central Nervous System Depressants,sedatives
"Use with Other DRUG1: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,Central Nervous System Depressants,antihistaminics
"Use with Other DRUG1: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or psychotropic DRUGOTHER. ",negative,Central Nervous System Depressants,psychotropic drugs
"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUG2 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",effect,morphine,CNS depressants
"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUGOTHER such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",effect,morphine,alcohol
"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",effect,morphine,sedatives
"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",effect,morphine,antihistaminics
"Use with Other DRUGOTHER: The depressant effects of DRUG1 are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or psychotropic DRUGOTHER. ",effect,morphine,psychotropic drugs
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,CNS depressants,alcohol
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,CNS depressants,sedatives
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,CNS depressants,antihistaminics
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUG1 such as DRUGOTHER, DRUGOTHER, DRUGOTHER, or psychotropic DRUGOTHER. ",negative,CNS depressants,psychotropic drugs
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,alcohol,sedatives
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,alcohol,antihistaminics
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, or psychotropic DRUGOTHER. ",negative,alcohol,psychotropic drugs
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,sedatives,antihistaminics
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUG1, DRUGOTHER, or psychotropic DRUGOTHER. ",negative,sedatives,psychotropic drugs
"Use with Other DRUGOTHER: The depressant effects of DRUGOTHER are potentiated by the presence of other DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, or psychotropic DRUGOTHER. ",negative,antihistaminics,psychotropic drugs
"Use of DRUG1 in conjunction with oral DRUG2 may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",effect,neuroleptics,morphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,pentazocine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,butorphanol
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Agonist/antagonist analgesics,pentazocine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Agonist/antagonist analgesics,nalbuphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Agonist/antagonist analgesics,butorphanol
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,Agonist/antagonist analgesics,buprenorphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",advise,Agonist/antagonist analgesics,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,pentazocine,nalbuphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,pentazocine,butorphanol
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,pentazocine,buprenorphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUG1, DRUGOTHER, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",advise,pentazocine,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,nalbuphine,butorphanol
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,nalbuphine,buprenorphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",advise,nalbuphine,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",negative,butorphanol,buprenorphine
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUG1, or DRUGOTHER) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",advise,butorphanol,opioid agonist analgesic
"Interaction with Mixed Agonist/Antagonist DRUGOTHER DRUGOTHER: Agonist/antagonist DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG1) should NOT be administered to patients who have received or are receiving a course of therapy with a proof DRUGOTHER agonist DRUGOTHER. ",advise,buprenorphine,opioid agonist analgesic
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER-type medications (like DRUGOTHER or DRUGOTHER) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,ergotamine,ergot-type medications
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like DRUG2 or DRUGOTHER) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,ergotamine,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like DRUGOTHER or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,ergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUGOTHER (like DRUGOTHER or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",advise,ergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER-type medications (like DRUG2 or DRUGOTHER) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,ergot-type medications,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER-type medications (like DRUGOTHER or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,ergot-type medications,methysergide
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER-type medications (like DRUGOTHER or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",advise,ergot-type medications,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUG2) and DRUGOTHER within 24 hours of each other should be avoided. ",negative,dihydroergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUG1 or DRUGOTHER) and DRUG2 within 24 hours of each other should be avoided. ",advise,dihydroergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like DRUGOTHER or DRUG1) and DRUG2 within 24 hours of each other should be avoided. ",advise,methysergide,sumatriptan
"DRUG1 reduce DRUG2 clearance, significantly increasing systemic exposure. ",mechanism,MAO-A inhibitors,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG2 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",advise,sumatriptan succinate,MAO-A inhibitors
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,Selective serotonin reuptake inhibitors
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG2) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,SSRIs
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,fluoxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,fluvoxamine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,sumatriptan succinate,sertraline
"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",negative,sumatriptan succinate,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,Selective serotonin reuptake inhibitors
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUG2) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,SSRIs
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,fluoxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,fluvoxamine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,MAO-A inhibitors,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUG1 is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",negative,MAO-A inhibitors,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUG2) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,Selective serotonin reuptake inhibitors,SSRIs
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,Selective serotonin reuptake inhibitors,fluoxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,Selective serotonin reuptake inhibitors,fluvoxamine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,Selective serotonin reuptake inhibitors,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,Selective serotonin reuptake inhibitors,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . Selective DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,Selective serotonin reuptake inhibitors,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG1) (e.g., DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,SSRIs,fluoxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG1) (e.g., DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,SSRIs,fluvoxamine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG1) (e.g., DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,SSRIs,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG1) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,SSRIs,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUG1) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,SSRIs,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,fluoxetine,fluvoxamine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,fluoxetine,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,fluoxetine,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,fluoxetine,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,fluvoxamine,paroxetine
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,fluvoxamine,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,fluvoxamine,sumatriptan
"Therefore, the use of DRUGOTHER succinate tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUGOTHER. ",negative,paroxetine,sertraline
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,paroxetine,sumatriptan
"Therefore, the use of DRUGOTHER tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",effect,sertraline,sumatriptan
"If concomitant treatment with DRUG1 and an DRUG2 is clinically warranted, appropriate observation of the patient is advised.",advise,sumatriptan,SSRI
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,Antacids,Myfortic
"DRUG1: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUG2-DRUGOTHER containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,Antacids,magnesium
"DRUG1: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUG2 containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,Antacids,aluminum
"DRUG1: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,Antacids,antacids
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,Antacids,Myfortic
"DRUGOTHER: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUG2-DRUGOTHER containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",mechanism,Myfortic,magnesium
"DRUGOTHER: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUG2 containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",mechanism,Myfortic,aluminum
"DRUG2: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",negative,Myfortic,antacids
"DRUGOTHER: Absorption of a single dose of DRUG1 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG1 was administered alone under fasting conditions. ",negative,Myfortic,Myfortic
"DRUGOTHER: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUG1-DRUG2 containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,magnesium,aluminum
"DRUG2: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUG1-DRUGOTHER containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,magnesium,antacids
"DRUGOTHER: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUG1-DRUGOTHER containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,magnesium,Myfortic
"DRUG2: Absorption of a single dose of DRUGOTHER was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUG1 containing DRUG2 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUGOTHER was administered alone under fasting conditions. ",negative,aluminum,antacids
"DRUGOTHER: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUG1 containing DRUGOTHER (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,aluminum,Myfortic
"DRUG1: Absorption of a single dose of DRUG2 was decreased when administered to 12 stable renal transplant patients also taking DRUGOTHER-DRUGOTHER containing DRUG1 (30 mL): the mean Cmax and AUC(0-t) values for DRUGOTHER were 25% and 37% lower, respectively, than when DRUG2 was administered alone under fasting conditions. ",negative,antacids,Myfortic
It is recommended that DRUG1 and DRUG2 not be administered simultaneously. ,advise,Myfortic,antacids
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUGOTHER. ",negative,Cyclosporine,cyclosporine
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",negative,Cyclosporine,Myfortic
"DRUG1: When studied in stable renal transplant patients, DRUG1, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of DRUG2. ",negative,cyclosporine,Myfortic
DRUG1/DRUG2: may be taken with DRUGOTHER; ,negative,Acyclovir,Ganciclovir
DRUG1/DRUGOTHER: may be taken with DRUG2; ,negative,Acyclovir,Myfortic
DRUGOTHER/DRUG1: may be taken with DRUG2; ,negative,Ganciclovir,Myfortic
"Both DRUG1/DRUG2 and DRUGOTHER concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,acyclovir,ganciclovir
"Both DRUG1/DRUGOTHER and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,acyclovir,MPAG
"Both DRUGOTHER/DRUG1 and DRUG2 concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",negative,ganciclovir,MPAG
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,Azathioprine,Mycophenolate Mofetil
"DRUG1/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER. ",negative,Azathioprine,azathioprine
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,Azathioprine,mycophenolate mofetil
"DRUG1/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUG1 or DRUGOTHER. ",negative,Azathioprine,Myfortic
"DRUG1/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER. ",negative,Azathioprine,azathioprine
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,Azathioprine,mycophenolate mofetil
"DRUG2/DRUGOTHER Mofetil: Given that DRUG2 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER mofetil. ",negative,Mycophenolate Mofetil,azathioprine
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",negative,Mycophenolate Mofetil,mycophenolate mofetil
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",negative,Mycophenolate Mofetil,Myfortic
"DRUG2/DRUGOTHER Mofetil: Given that DRUG2 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER mofetil. ",negative,Mycophenolate Mofetil,azathioprine
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",negative,Mycophenolate Mofetil,mycophenolate mofetil
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,azathioprine,mycophenolate mofetil
"DRUG1/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUG1 or DRUGOTHER. ",negative,azathioprine,Myfortic
"DRUG1/DRUGOTHER: Given that DRUG1 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER. ",negative,azathioprine,azathioprine
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,azathioprine,mycophenolate mofetil
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUG2 not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",negative,mycophenolate mofetil,Myfortic
"DRUG2/DRUGOTHER Mofetil: Given that DRUG2 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG2 or DRUGOTHER mofetil. ",negative,mycophenolate mofetil,azathioprine
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",negative,mycophenolate mofetil,mycophenolate mofetil
"DRUG2/DRUGOTHER: Given that DRUG2 and DRUGOTHER inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with DRUG2 or DRUGOTHER. ",advise,Myfortic,azathioprine
"DRUGOTHER/DRUGOTHER Mofetil: Given that DRUGOTHER and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUG1 not be administered concomitantly with DRUGOTHER or DRUGOTHER mofetil. ",advise,Myfortic,mycophenolate mofetil
"DRUG1/DRUGOTHER Mofetil: Given that DRUG1 and DRUGOTHER mofetil inhibit purine metabolism, it is recommended that DRUGOTHER not be administered concomitantly with DRUG1 or DRUGOTHER mofetil. ",negative,azathioprine,mycophenolate mofetil
DRUG1 and DRUGOTHER that Bind Bile Acids: These DRUGOTHER interrupt enterohepatic recirculation and reduce DRUG2 exposure when coadministered with DRUGOTHER. ,negative,Cholestyramine,MPA
DRUG1 and DRUGOTHER that Bind Bile Acids: These DRUGOTHER interrupt enterohepatic recirculation and reduce DRUGOTHER exposure when coadministered with DRUGOTHER mofetil. ,negative,Cholestyramine,mycophenolate mofetil
DRUGOTHER and DRUGOTHER that Bind Bile Acids: These DRUGOTHER interrupt enterohepatic recirculation and reduce DRUG1 exposure when coadministered with DRUGOTHER mofetil. ,negative,MPA,mycophenolate mofetil
"Therefore, do not administer DRUG1 with DRUG2 or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUG1. ",advise,Myfortic,cholestyramine
"Therefore, do not administer DRUG1 with DRUGOTHER or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUG1. ",advise,Myfortic,activated charcoal
"Therefore, do not administer DRUG1 with DRUGOTHER or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUG1. ",negative,Myfortic,Myfortic
"Therefore, do not administer DRUGOTHER with DRUG1 or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUGOTHER. ",negative,cholestyramine,activated charcoal
"Therefore, do not administer DRUG2 with DRUG1 or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUG2. ",negative,cholestyramine,Myfortic
"Therefore, do not administer DRUG2 with DRUGOTHER or other agents that may interfere with enterohepatic recirculation or DRUGOTHER that may bind bile acids, for example bile acid sequestrates or oral activated DRUGOTHER, because of the potential to reduce the efficacy of DRUG2. ",negative,activated charcoal,Myfortic
"Oral DRUG1: Given the different metabolism of DRUG2 and oral DRUG1, no DRUGOTHER interaction between these two classes of DRUGOTHER is expected. ",negative,Contraceptives,Myfortic
"Oral DRUG1: Given the different metabolism of DRUGOTHER and oral DRUG1, no DRUGOTHER interaction between these two classes of DRUGOTHER is expected. ",negative,Contraceptives,contraceptives
"Oral DRUG2: Given the different metabolism of DRUG1 and oral DRUG2, no DRUGOTHER interaction between these two classes of DRUGOTHER is expected. ",negative,Myfortic,contraceptives
"However, in a DRUGOTHER-DRUGOTHER interaction study, mean DRUG1 AUC was decreased by 15% when coadministered with DRUGOTHER mofetil. ",mechanism,levonorgesterol,mycophenolate mofetil
"Therefore, it is recommended that oral DRUG1 are DRUGOTHER- administered with DRUG2 with caution and additional birth control methods be considered. ",advise,contraceptives,Myfortic
"Live DRUGOTHER: During treatment with DRUG2, the use of live attenuated DRUGOTHER should be avoided and patients should be advised that vaccinations may be less effective. ",negative,Live Vaccines,Myfortic
"Live DRUGOTHER: During treatment with DRUGOTHER, the use of live attenuated DRUGOTHER should be avoided and patients should be advised that vaccinations may be less effective. ",negative,Live Vaccines,live attenuated vaccines
"Live DRUGOTHER: During treatment with DRUG1, the use of live attenuated DRUGOTHER should be avoided and patients should be advised that vaccinations may be less effective. ",advise,Myfortic,live attenuated vaccines
Interference of DRUG1 hydrolysis may DRUGOTHER to less DRUG2 available for absorption.,negative,MPAG,MPA
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUGOTHER since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUGOTHER to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUGOTHER since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUGOTHER to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",int,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG2 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUGOTHER since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUGOTHER to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,FELDENE,FELDENE
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",negative,FELDENE,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with DRUGOTHER-type DRUGOTHER, interactions with DRUGOTHER-type DRUGOTHER have been reported with DRUG1 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering DRUG1 to patients on DRUGOTHER-type DRUGOTHER and other highly protein-bound DRUGOTHER. ",advise,FELDENE,coumarin-type anticoagulants
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,aspirin
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG2 has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,antacids
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,piroxicam
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUG2 levels. ",negative,piroxicam,lithium
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUG2 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",mechanism,FELDENE,aspirin
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG2 has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,FELDENE,antacids
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG2 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,FELDENE,piroxicam
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,FELDENE,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,FELDENE,FELDENE
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUG2 levels. ",negative,FELDENE,lithium
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUG2 has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,aspirin,antacids
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG2 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,aspirin,piroxicam
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,aspirin,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,aspirin,FELDENE
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUG1 (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUG2 levels. ",negative,aspirin,lithium
"Plasma levels of DRUG2 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG1 has no effect on DRUG2 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,antacids,piroxicam
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG1 has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,antacids,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG1 has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,antacids,FELDENE
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUG1 has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUG2 levels. ",negative,antacids,lithium
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,piroxicam,FELDENE
"Plasma levels of DRUG1 are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUG1 plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUG2 levels. ",negative,piroxicam,lithium
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG2 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG2, have been reported to increase steady state plasma DRUGOTHER levels. ",negative,Nonsteroidal anti-inflammatory agents,FELDENE
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUGOTHER is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUGOTHER, have been reported to increase steady state plasma DRUG2 levels. ",mechanism,Nonsteroidal anti-inflammatory agents,lithium
"Plasma levels of DRUGOTHER are depressed to approximately 80% of their normal values when DRUG1 is administered in conjunction with DRUGOTHER (3900 mg/day), but concomitant administration of DRUGOTHER has no effect on DRUGOTHER plasma levels . Nonsteroidal DRUGOTHER agents, including DRUG1, have been reported to increase steady state plasma DRUG2 levels. ",mechanism,FELDENE,lithium
"It is recommended that plasma DRUG1 levels be monitored when initiating, adjusting and discontinuing DRUG2.",advise,lithium,FELDENE
"DRUG1, particularly DRUG2, may cause serious cardiac arrhythmias during DRUGOTHER DRUGOTHER and therefore should be used only with great caution or not at all. ",negative,Vasopressors,metaraminol
"DRUG1, particularly DRUGOTHER, may cause serious cardiac arrhythmias during DRUG2 DRUGOTHER and therefore should be used only with great caution or not at all. ",effect,Vasopressors,halothane
"DRUGOTHER, particularly DRUG1, may cause serious cardiac arrhythmias during DRUG2 DRUGOTHER and therefore should be used only with great caution or not at all. ",effect,metaraminol,halothane
DRUG1 - The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUGOTHER (DRUGOTHER). ,negative,MAO Inhibitors,sympathomimetic pressor amines
DRUG1 - The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,negative,MAO Inhibitors,monoamine oxidase inhibitors
DRUG1 - The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUGOTHER (DRUG2). ,negative,MAO Inhibitors,MAOI
DRUGOTHER - The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUG2 (DRUGOTHER). ,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
DRUGOTHER - The pressor effect of DRUGOTHER pressor amines is markedly potentiated in patients receiving DRUGOTHER (DRUG2). ,effect,sympathomimetic pressor amines,MAOI
DRUGOTHER - The pressor effect of DRUGOTHER is markedly potentiated in patients receiving DRUG1 (DRUG2). ,negative,monoamine oxidase inhibitors,MAOI
The pressor response of DRUGOTHER agents may also be potentiated by DRUGOTHER DRUGOTHER.,effect,adrenergic agents,tricyclic antidepressants
Acromegalic patients with diabetes mellitus being treated with DRUG1 and/or oral DRUGOTHER may require dose reductions of these therapeutic agents after the initiation of therapy with DRUGOTHER. ,negative,insulin,hypoglycemic
Acromegalic patients with diabetes mellitus being treated with DRUG1 and/or oral DRUGOTHER may require dose reductions of these therapeutic agents after the initiation of therapy with DRUG2. ,advise,insulin,SOMAVERT
Acromegalic patients with diabetes mellitus being treated with DRUGOTHER and/or oral DRUGOTHER may require dose reductions of these therapeutic agents after the initiation of therapy with DRUG2. ,advise,hypoglycemic,SOMAVERT
"In clinical studies, patients on DRUG1 often needed higher serum DRUG2 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG1. ",mechanism,opioids,pegvisomant
"In clinical studies, patients on DRUG1 often needed higher serum DRUGOTHER concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG1. ",negative,opioids,opioids
"In clinical studies, patients on DRUG2 often needed higher serum DRUG1 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving DRUG2. ",negative,pegvisomant,opioids
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak DRUGOTHER concentration (Cmax, 18%) of DRUG1 with the DRUGOTHER-administration of 100 mg DRUGOTHER for 10 days. ",negative,Digoxin,digoxin
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak DRUGOTHER concentration (Cmax, 18%) of DRUG1 with the DRUGOTHER-administration of 100 mg DRUG2 for 10 days. ",negative,Digoxin,sitagliptin
"DRUG1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak DRUGOTHER concentration (Cmax, 18%) of DRUG1 with the DRUGOTHER-administration of 100 mg DRUG2 for 10 days. ",mechanism,digoxin,sitagliptin
No dosage adjustment of DRUG1 or DRUG2 is recommended.,negative,digoxin,JANUVIA
Limited evidence suggests that DRUG1 may influence the intensity and duration of action of DRUG2.,mechanism,ascorbic acid,bishydroxycoumarin
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG2: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",int,Vindesine,Phenytoin
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",int,Vindesine,Live virus vaccines
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Vindesine,vaccine
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUG2: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",int,Vindesine,Mitomycin-C
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",int,Vindesine,Killed virus vaccines
"DRUG1 can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Vindesine,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Phenytoin,Live virus vaccines
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Phenytoin,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUG2: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Phenytoin,Mitomycin-C
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Phenytoin,Killed virus vaccines
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUG1: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Phenytoin,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Live virus vaccines,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUG2: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Live virus vaccines,Mitomycin-C
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Live virus vaccines,Killed virus vaccines
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Live virus vaccines,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - DRUG2: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG1",negative,vaccine,Mitomycin-C
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG1",negative,vaccine,Killed virus vaccines
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG1 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG1 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG1",negative,vaccine,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUGOTHER virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUGOTHER - DRUG1: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUGOTHER",negative,Mitomycin-C,Killed virus vaccines
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUG1: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Mitomycin-C,vaccine
"DRUGOTHER can interact with the DRUGOTHER of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - DRUGOTHER: can increase seizure activity - Live virus DRUGOTHER: may potentiate the replication of the DRUG2 virus, may increase the side effects of the vaccination, and decrease patient's response to the DRUG2 - DRUGOTHER: may cause shortness of breath and bronchospasm - Killed virus DRUGOTHER: may decrease patient's response to the DRUG2",negative,Killed virus vaccines,vaccine
DRUG1: Excessive reductions in blood pressure may occur in patients on DRUGOTHER therapy when DRUG2 are started. ,negative,Diuretics,ACE inhibitors
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing DRUGOTHER therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUGOTHER should be reduced.. ",negative,UNIVASC,UNIVASC
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing DRUGOTHER therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUG2 should be reduced.. ",negative,UNIVASC,moexpril
"The possibility of hypotensive effects with DRUG1    can be minimized by discontinuing DRUGOTHER therapy for several days or cautiously increasing salt intake before initiation of treatment with DRUG1   . If this is not possible, the starting dose of DRUG2 should be reduced.. ",negative,UNIVASC,moexpril
DRUG1 Supplements and DRUG1-Sparing DRUGOTHER: DRUGOTHER    can increase serum DRUG1 because it decreases aldosterone secretion. ,negative,Potassium,Potassium-Sparing Diuretics
DRUG1 Supplements and DRUG1-Sparing DRUGOTHER: DRUG2    can increase serum DRUG1 because it decreases aldosterone secretion. ,negative,Potassium,UNIVASC
DRUGOTHER Supplements and DRUGOTHER-Sparing DRUGOTHER: DRUG2    can increase serum DRUGOTHER because it decreases aldosterone secretion. ,negative,Potassium-Sparing Diuretics,UNIVASC
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,spironolactone
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,triamterene
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,amiloride
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG2 supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,potassium-sparing diuretics,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,potassium-sparing diuretics,ACE inhibitors
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUG2, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,spironolactone,triamterene
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,spironolactone,amiloride
"Use of DRUG2-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUG2 supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,spironolactone,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,spironolactone,ACE inhibitors
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUG2) or DRUGOTHER supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,triamterene,amiloride
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) or DRUG2 supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,triamterene,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER) or DRUGOTHER supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,triamterene,ACE inhibitors
"Use of DRUG2-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) or DRUG2 supplements concomitantly with DRUGOTHER can increase the risk of hyperkalemia. ",negative,amiloride,potassium
"Use of DRUGOTHER-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1) or DRUGOTHER supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,amiloride,ACE inhibitors
"Use of DRUG1-sparing DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER) or DRUG1 supplements concomitantly with DRUG2 can increase the risk of hyperkalemia. ",effect,potassium,ACE inhibitors
Oral DRUG1: Interaction studies with DRUG2 failed to identify any clinically important effect on the serum concentrations of the DRUGOTHER or on its DRUGOTHER effect. ,negative,Anticoagulants,warfarin
Oral DRUG1: Interaction studies with DRUGOTHER failed to identify any clinically important effect on the serum concentrations of the DRUG2 or on its DRUG2 effect. ,negative,Anticoagulants,anticoagulant
Oral DRUGOTHER: Interaction studies with DRUG1 failed to identify any clinically important effect on the serum concentrations of the DRUG2 or on its DRUG2 effect. ,negative,warfarin,anticoagulant
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,Lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,Lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,lithium,lithium
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUG2 during therapy with DRUG1. ,negative,lithium,ACE inhibitors
DRUG1: Increased serum DRUG1 levels and symptoms of DRUG1 toxicity have been reported in patients receiving DRUGOTHER during therapy with DRUG1. ,negative,lithium,lithium
DRUG2: Increased serum DRUG2 levels and symptoms of DRUG2 toxicity have been reported in patients receiving DRUG1 during therapy with DRUG2. ,effect,ACE inhibitors,lithium
"If a DRUG1 is also used, the risk of DRUG2 toxicity may be increased. ",effect,diuretic,lithium
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,UNIVASC,hydrochlorothiazide
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,UNIVASC,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUG1    was administered concomitantly with DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,UNIVASC,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUG2, or DRUGOTHER. ",negative,hydrochlorothiazide,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUG1, DRUGOTHER, or DRUG2. ",negative,hydrochlorothiazide,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when DRUGOTHER    was administered concomitantly with DRUGOTHER, DRUG1, or DRUG2. ",negative,digoxin,cimetidine
"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,UNIVASC,calcium-channel-blocking agents
"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,UNIVASC,diuretics
"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,UNIVASC,H2 blockers
"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,UNIVASC,digoxin
"DRUG1    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER agents, and cholesterol-lowering agents. ",negative,UNIVASC,hypoglycemic agents
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUG2, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,diuretics
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUG2, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,H2 blockers
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,digoxin
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER agents, and cholesterol-lowering agents. ",negative,calcium-channel-blocking agents,hypoglycemic agents
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUG1, DRUG2, DRUGOTHER, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,diuretics,H2 blockers
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUG1, DRUGOTHER, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,diuretics,digoxin
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUG1, DRUGOTHER, DRUGOTHER, oral DRUGOTHER agents, and cholesterol-lowering agents. ",negative,diuretics,hypoglycemic agents
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUG1, DRUG2, oral DRUGOTHER, and cholesterol-lowering agents. ",negative,H2 blockers,digoxin
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUG1, DRUGOTHER, oral DRUGOTHER agents, and cholesterol-lowering agents. ",negative,H2 blockers,hypoglycemic agents
"DRUGOTHER    has been used in clinical trials concomitantly with DRUGOTHER-channel-blocking agents, DRUGOTHER, DRUGOTHER, DRUG1, oral DRUGOTHER agents, and cholesterol-lowering agents. ",negative,digoxin,hypoglycemic agents
"DRUG1 may interact with the following DRUGOTHER: DRUG2 and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,aspirin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG2 (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,NSAIDs
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,fluvoxamine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,beta blockers
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,fluoxetine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",int,Melatonin,benzodiazepenes
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",int,Melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,Melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,Melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,Melatonin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUG2 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,NSAIDs
"DRUG2 may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUG2 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,fluvoxamine
"DRUG2 may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG2 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,beta blockers
"DRUG2 may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,fluoxetine
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,progestin
"DRUG2 may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,aspirin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUG1 and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,aspirin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUG2 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,fluvoxamine
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG2 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,beta blockers
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,fluoxetine
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,progestin
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,NSAIDs,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUG1 (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,NSAIDs,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUG2 (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,fluvoxamine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,beta blockers
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG2 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,beta blockers
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,fluoxetine
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,progestin
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUG1 (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluvoxamine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUG1 (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluvoxamine,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUG2 (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,beta blockers
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,fluoxetine
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,progestin
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUG1 (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,beta blockers,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUG1 (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,beta blockers,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUG2 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,fluoxetine
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluoxetine,progestin
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluoxetine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUGOTHER with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluoxetine,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluoxetine,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,fluoxetine,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUG1 (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,fluoxetine,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,progestin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG2 (coadministration of DRUG1 with DRUG2 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",effect,melatonin,progestin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,benzodiazepenes
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,melatonin,melatonin
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUG2 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUGOTHER and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,benzodiazepenes
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUG2 with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,progestin,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUG1 (coadministration of DRUGOTHER with DRUG1 can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,progestin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG1 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUG1 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",negative,benzodiazepenes,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG1 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUG1 and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUGOTHER and DRUG2 may interfere with the efficacy of the DRUG2).",negative,benzodiazepenes,corticosteroids
"DRUG2 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUG2 and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,melatonin
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",effect,melatonin,corticosteroids
"DRUG1 may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG2 (coadministration of DRUG1 and DRUG2 may interfere with the efficacy of the DRUG2).",negative,melatonin,corticosteroids
"DRUGOTHER may interact with the following DRUGOTHER: DRUGOTHER and other DRUGOTHER (may lower DRUGOTHER levels), DRUGOTHER (bioavailability of oral DRUGOTHER is increased with coadministration), DRUGOTHER (may decrease DRUGOTHER levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUGOTHER with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating DRUGOTHER (may result in additive sedation and an increased incidence of adverse effects), and DRUG1 (coadministration of DRUGOTHER and DRUG1 may interfere with the efficacy of the DRUG1).",negative,corticosteroids,corticosteroids
DRUGOTHER Affecting Hepatic Metabolism The metabolism and pharmacokinetics of DRUGOTHER SolTab    (DRUG2) Orally Disintegrating Tablets may be affected by the induction or inhibition of DRUGOTHER-metab-olizing enzymes. ,negative,REMERON SolTab,mirtazapine
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other DRUGOTHER that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUGOTHER SolTab with most other DRUGOTHER metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,mirtazapine
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other DRUGOTHER that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUGOTHER SolTab with most other DRUGOTHER metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,REMERON SolTab
"While in vitro studies have shown that DRUG1 is not a potent inhibitor of any of these enzymes, an indication that DRUG1 is not likely to have a clinically significant inhibitory effect on the metabolism of other DRUGOTHER that are substrates for these cytochrome P450 enzymes, the concomitant use of DRUGOTHER SolTab with most other DRUGOTHER metabolized by these enzymes has not been formally studied. ",negative,mirtazapine,REMERON SolTab
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 6 healthy male subjects. ,negative,Alcohol,alcohol
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,negative,Alcohol,mirtazapine
DRUG1: Concomitant administration of DRUG1 (equivalent to 60 g) had a minimal effect on plasma levels of DRUG2 (15 mg) in 6 healthy male subjects. ,mechanism,alcohol,mirtazapine
"However, the impairment of cognitive and motor skills produced by DRUG1    were shown to be additive with those produced by DRUG2. ",effect,REMERON,alcohol
"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER SolTab. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",advise,alcohol,REMERON SolTab
"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",negative,alcohol,Diazepam
"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",negative,alcohol,diazepam
"Accordingly, patients should be advised to avoid DRUG1 while taking DRUGOTHER SolTab. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,alcohol,mirtazapine
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,Diazepam
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUG2: Concomitant administration of DRUG2 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,diazepam
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUGOTHER: Concomitant administration of DRUGOTHER (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,REMERON SolTab,mirtazapine
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUGOTHER (15 mg) in 12 healthy subjects. ",negative,Diazepam,diazepam
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",negative,Diazepam,mirtazapine
"Accordingly, patients should be advised to avoid DRUGOTHER while taking DRUGOTHER SolTab. DRUG1: Concomitant administration of DRUG1 (15 mg) had a minimal effect on plasma levels of DRUG2 (15 mg) in 12 healthy subjects. ",mechanism,diazepam,mirtazapine
"However, the impairment of motor skills produced by DRUG1 has been shown to be additive with those caused by DRUG2. ",effect,REMERON,diazepam
"Accordingly, patients should be advised to avoid DRUG1 and other similar DRUGOTHER while taking DRUGOTHER SolTab.",advise,diazepam,REMERON SolTab
"Interaction with Other DRUG1: DRUG2 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,MEPERIDINE
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,NARCOTIC ANALGESICS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG2, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,ANESTHETICS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG2, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,PHENOTHIAZINES
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG2, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,TRANQUILIZERS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,SEDATIVE-HYPNOTICS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,BARBITURATES
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,Central Nervous System Depressants,CNS DEPRESSANTS
"Interaction with Other DRUG1: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,Central Nervous System Depressants,ALCOHOL
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,NARCOTIC ANALGESICS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG2, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,ANESTHETICS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG2, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,PHENOTHIAZINES
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG2, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,TRANQUILIZERS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,SEDATIVE-HYPNOTICS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,BARBITURATES
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",advise,MEPERIDINE,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUG1 SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",advise,MEPERIDINE,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG2, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,ANESTHETICS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG2, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,PHENOTHIAZINES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG2, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,TRANQUILIZERS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,SEDATIVE-HYPNOTICS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,BARBITURATES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,NARCOTIC ANALGESICS,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,NARCOTIC ANALGESICS,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUG2, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,PHENOTHIAZINES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUG2, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,TRANQUILIZERS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,SEDATIVE-HYPNOTICS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,BARBITURATES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,ANESTHETICS,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUG1, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,ANESTHETICS,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUG2, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,PHENOTHIAZINES,TRANQUILIZERS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,PHENOTHIAZINES,SEDATIVE-HYPNOTICS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,PHENOTHIAZINES,BARBITURATES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,PHENOTHIAZINES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,PHENOTHIAZINES,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUG1, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,PHENOTHIAZINES,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG1, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,TRANQUILIZERS,SEDATIVE-HYPNOTICS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG1, DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,TRANQUILIZERS,BARBITURATES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG1, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,TRANQUILIZERS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG1, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,TRANQUILIZERS,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUG1, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,TRANQUILIZERS,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUG2), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,SEDATIVE-HYPNOTICS,BARBITURATES
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,SEDATIVE-HYPNOTICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,SEDATIVE-HYPNOTICS,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER-DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,SEDATIVE-HYPNOTICS,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG1), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUGOTHER). ",negative,BARBITURATES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG1), DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,BARBITURATES,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUG1), DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,BARBITURATES,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUG2 (INCLUDING DRUGOTHER). ",negative,TRICYCLIC ANTIDEPRESSANTS,CNS DEPRESSANTS
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER DRUGOTHER AND OTHER DRUGOTHER (INCLUDING DRUG2). ",negative,TRICYCLIC ANTIDEPRESSANTS,ALCOHOL
"Interaction with Other DRUGOTHER: DRUGOTHER SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER DRUGOTHER DRUGOTHER, GENERAL DRUGOTHER, DRUGOTHER, OTHER DRUGOTHER, DRUGOTHER (INCLUDING DRUGOTHER), DRUGOTHER AND OTHER DRUG1 (INCLUDING DRUG2). ",negative,CNS DEPRESSANTS,ALCOHOL
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUG2, DRUGOTHER) may diminish the bactericidal effects of DRUGOTHER by slowing the rate of bacterial growth. ",negative,bacteriostatic antibiotics,erythromycin
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUGOTHER, DRUG2) may diminish the bactericidal effects of DRUGOTHER by slowing the rate of bacterial growth. ",negative,bacteriostatic antibiotics,tetracycline
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,bacteriostatic antibiotics,penicillins
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUG1, DRUG2) may diminish the bactericidal effects of DRUGOTHER by slowing the rate of bacterial growth. ",negative,erythromycin,tetracycline
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUG1, DRUGOTHER) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,erythromycin,penicillins
"Concurrent administration of bacteriostatic DRUGOTHER (e.g., DRUGOTHER, DRUG1) may diminish the bactericidal effects of DRUG2 by slowing the rate of bacterial growth. ",effect,tetracycline,penicillins
DRUG1 blood levels may be prolonged by concurrent administration of DRUG2 which blocks the renal tubular secretion of DRUGOTHER. ,mechanism,Penicillin,probenecid
DRUG1 blood levels may be prolonged by concurrent administration of DRUGOTHER which blocks the renal tubular secretion of DRUG2. ,negative,Penicillin,penicillins
DRUGOTHER blood levels may be prolonged by concurrent administration of DRUG1 which blocks the renal tubular secretion of DRUG2. ,negative,probenecid,penicillins
Displacement of DRUG1 from plasma protein binding sites will elevate the level of free DRUG1 in the serum.,negative,penicillin,penicillin
DRUGOTHER Interactions: Women on oral DRUG1 have shown a significant increase in plasma DRUG2 levels.,mechanism,contraceptives,vitamin A
DRUG1 is not known to interact with other DRUGOTHER including DRUGOTHER; ,negative,CHEMET,iron
"Concomitant administration of DRUG1 with other chelation therapy, such as DRUG2 is not recommended. ",advise,CHEMET,CaNa 2 EDTA
"When DRUG1 is used with other DRUGOTHER DRUGOTHER, potentiation of DRUGOTHER effect may occur. ",effect,methyldopa,antihypertensive drugs
Patients may require reduced doses of DRUG1 when on DRUG2. ,advise,anesthetics,methyldopa
When DRUG1 and DRUG2 are given concomitantly the patient should be carefully monitored for symptoms of DRUG2 toxicity. ,advise,methyldopa,lithium
When DRUG1 and DRUG2 are given concomitantly the patient should be carefully monitored for symptoms of DRUG2 toxicity. ,negative,methyldopa,lithium
When DRUGOTHER and DRUG1 are given concomitantly the patient should be carefully monitored for symptoms of DRUG1 toxicity. ,negative,lithium,lithium
Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with DRUG2 or DRUGOTHER. ,mechanism,methyldopa,ferrous sulfate
Several studies demonstrate a decrease in the bioavailability of DRUG1 when it is ingested with DRUGOTHER or DRUG2. ,mechanism,methyldopa,ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of DRUGOTHER when it is ingested with DRUG1 or DRUG2. ,negative,ferrous sulfate,ferrous gluconate
Coadministration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ,advise,methyldopa,ferrous sulfate
Coadministration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ,advise,methyldopa,ferrous gluconate
Coadministration of DRUGOTHER with DRUG1 or DRUG2 is not recommended. ,negative,ferrous sulfate,ferrous gluconate
"DRUG1 does not interfere with measurement of DRUG2 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",negative,Methyldopa,VMA
"DRUG1 does not interfere with measurement of DRUGOTHER (DRUG2), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUGOTHER. ",negative,Methyldopa,vanillylmandelic acid
"DRUG1 does not interfere with measurement of DRUG2 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",negative,Methyldopa,VMA
"DRUG1 does not interfere with measurement of DRUGOTHER (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUG2. ",negative,Methyldopa,vanillin
"DRUGOTHER does not interfere with measurement of DRUG1 (DRUG2), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUGOTHER. ",negative,VMA,vanillylmandelic acid
"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUGOTHER. ",negative,VMA,VMA
"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",negative,VMA,vanillin
"DRUGOTHER does not interfere with measurement of DRUG2 (DRUG1), a test for pheochromocytoma, by those methods which convert DRUG2 to DRUGOTHER. ",negative,vanillylmandelic acid,VMA
"DRUGOTHER does not interfere with measurement of DRUGOTHER (DRUG1), a test for pheochromocytoma, by those methods which convert DRUGOTHER to DRUG2. ",negative,vanillylmandelic acid,vanillin
"DRUGOTHER does not interfere with measurement of DRUG1 (DRUGOTHER), a test for pheochromocytoma, by those methods which convert DRUG1 to DRUG2. ",negative,VMA,vanillin
DRUG1 and DRUG2 are incompatible with DRUGOTHER solution. ,negative,norepinephrine,dobutamine
DRUG1 and DRUGOTHER are incompatible with DRUG2 solution. ,int,norepinephrine,sodium bicarbonate
DRUGOTHER and DRUG1 are incompatible with DRUG2 solution. ,int,dobutamine,sodium bicarbonate
"The addition of DRUG1 to parenteral solutions containing DRUG2 should be avoided, except where compatibility has been previously established. ",negative,sodium bicarbonate,calcium
"The bioavailability of DRUG1 is decreased 80% by DRUG2, when DRUG2 and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",mechanism,SKELID,calcium
"The bioavailability of DRUG1 is decreased 80% by DRUG2, when DRUG2 and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,calcium
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUG2- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,aluminum
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUG2-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,magnesium
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUG2, when administered 1 hour before DRUG1. ",negative,SKELID,antacids
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,calcium,calcium
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUG2- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,calcium,aluminum
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUG2-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,calcium,magnesium
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUG2, when administered 1 hour before DRUGOTHER. ",negative,calcium,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUG2- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,calcium,aluminum
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUG2-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,calcium,magnesium
"The bioavailability of DRUGOTHER is decreased 80% by DRUG1, when DRUG1 and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUG2, when administered 1 hour before DRUGOTHER. ",negative,calcium,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUG1, when DRUG1 and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG2. ",negative,calcium,SKELID
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUG2- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,aluminum
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUG2-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,magnesium
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUG2, when administered 1 hour before DRUG1. ",negative,SKELID,antacids
"The bioavailability of DRUG1 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG1 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG1. ",negative,SKELID,SKELID
"The bioavailability of DRUGOTHER is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUGOTHER are administered at the same time, and 60% by some DRUG1- or DRUG2-containing DRUGOTHER, when administered 1 hour before DRUGOTHER. ",negative,aluminum,magnesium
"The bioavailability of DRUGOTHER is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUGOTHER are administered at the same time, and 60% by some DRUG1- or DRUGOTHER-containing DRUG2, when administered 1 hour before DRUGOTHER. ",negative,aluminum,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG2 are administered at the same time, and 60% by some DRUG1- or DRUGOTHER-containing DRUGOTHER, when administered 1 hour before DRUG2. ",mechanism,aluminum,SKELID
"The bioavailability of DRUGOTHER is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUGOTHER are administered at the same time, and 60% by some DRUGOTHER- or DRUG1-containing DRUG2, when administered 1 hour before DRUGOTHER. ",negative,magnesium,antacids
"The bioavailability of DRUG2 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUG1-containing DRUGOTHER, when administered 1 hour before DRUG2. ",mechanism,magnesium,SKELID
"The bioavailability of DRUG2 is decreased 80% by DRUGOTHER, when DRUGOTHER and DRUG2 are administered at the same time, and 60% by some DRUGOTHER- or DRUGOTHER-containing DRUG1, when administered 1 hour before DRUG2. ",negative,antacids,SKELID
DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,mechanism,Aspirin,SKELID
DRUG1 may decrease bioavailability of DRUG2 by up to 50% when taken 2 hours after DRUG2. ,negative,Aspirin,SKELID
DRUGOTHER may decrease bioavailability of DRUG1 by up to 50% when taken 2 hours after DRUG1. ,negative,SKELID,SKELID
The bioavailability of DRUG1 is increased 2-4 fold by DRUG2 but is not significantly altered by coadministration of DRUGOTHER. ,mechanism,SKELID,indomethacin
The bioavailability of DRUG1 is increased 2-4 fold by DRUGOTHER but is not significantly altered by coadministration of DRUG2. ,negative,SKELID,diclofenac
The bioavailability of DRUGOTHER is increased 2-4 fold by DRUG1 but is not significantly altered by coadministration of DRUG2. ,negative,indomethacin,diclofenac
The pharmacokinetic parameters of DRUG1 are not significantly modified by DRUG2 coadministration. ,negative,digoxin,SKELID
In vitro studies show that DRUG1 does not displace DRUG2 from its binding site on protein.,negative,tiludronate,warfarin
"DRUG1, a DRUGOTHER, may antagonize the bactericidal effect of DRUGOTHER and concurrent use of these DRUGOTHER should be avoided.",negative,Tetracycline,antibiotic
"DRUG1, a bacteriostatic DRUGOTHER, may antagonize the bactericidal effect of DRUG2 and concurrent use of these DRUGOTHER should be avoided.",effect,Tetracycline,penicillin
"DRUGOTHER, a DRUGOTHER, may antagonize the bactericidal effect of DRUG2 and concurrent use of these DRUGOTHER should be avoided.",negative,antibiotic,penicillin
"DRUG1 should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUG2, DRUGOTHER, or DRUGOTHER. ",advise,Scopolamine,sedatives
"DRUG1 should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUGOTHER, DRUG2, or DRUGOTHER. ",advise,Scopolamine,tranquilizers
"DRUG1 should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUGOTHER, DRUGOTHER, or DRUG2. ",advise,Scopolamine,alcohol
"DRUGOTHER should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUG1, DRUG2, or DRUGOTHER. ",negative,sedatives,tranquilizers
"DRUGOTHER should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUG1, DRUGOTHER, or DRUG2. ",negative,sedatives,alcohol
"DRUGOTHER should be used with care in patients taking other DRUGOTHER that are capable of causing CNS effects such as DRUGOTHER, DRUG1, or DRUG2. ",negative,tranquilizers,alcohol
"e.g., other DRUG1, DRUG2 (including DRUGOTHER), DRUGOTHER, and DRUGOTHER. ",negative,belladonna alkaloids,antihistamines
"e.g., other DRUG1, DRUGOTHER (including DRUG2), DRUGOTHER, and DRUGOTHER. ",negative,belladonna alkaloids,meclizine
"e.g., other DRUG1, DRUGOTHER (including DRUGOTHER), DRUGOTHER DRUGOTHER, and DRUGOTHER. ",negative,belladonna alkaloids,tricyclic antidepressants
"e.g., other DRUG1, DRUGOTHER (including DRUGOTHER), DRUGOTHER, and DRUG2. ",negative,belladonna alkaloids,muscle relaxants
"e.g., other DRUGOTHER, DRUG1 (including DRUG2), DRUGOTHER, and DRUGOTHER. ",negative,antihistamines,meclizine
"e.g., other DRUGOTHER, DRUG1 (including DRUGOTHER), DRUGOTHER DRUGOTHER, and DRUGOTHER. ",negative,antihistamines,tricyclic antidepressants
"e.g., other DRUGOTHER, DRUG1 (including DRUGOTHER), DRUGOTHER, and DRUG2. ",negative,antihistamines,muscle relaxants
"e.g., other DRUGOTHER, DRUGOTHER (including DRUG1), DRUGOTHER DRUGOTHER, and DRUGOTHER. ",negative,meclizine,tricyclic antidepressants
"e.g., other DRUGOTHER, DRUGOTHER (including DRUG1), DRUGOTHER, and DRUG2. ",negative,meclizine,muscle relaxants
"e.g., other DRUGOTHER, DRUGOTHER (including DRUGOTHER), DRUGOTHER DRUGOTHER, and DRUG2. ",negative,tricyclic antidepressants,muscle relaxants
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG2 (eg, DRUGOTHER, DRUGOTHER, and DRUGOTHER, etc.) ",effect,DIPRIVAN,narcotics
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG2, DRUGOTHER, and DRUGOTHER, etc.) ",effect,DIPRIVAN,morphine
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG2, and DRUGOTHER, etc.) ",effect,DIPRIVAN,meperidine
"The induction dose requirements of DRUG1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, and DRUG2, etc.) ",effect,DIPRIVAN,fentanyl
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, DRUG2, DRUGOTHER, and DRUGOTHER, etc.) ",negative,narcotics,morphine
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, DRUGOTHER, DRUG2, and DRUGOTHER, etc.) ",negative,narcotics,meperidine
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUG1 (eg, DRUGOTHER, DRUGOTHER, and DRUG2, etc.) ",negative,narcotics,fentanyl
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUG2, and DRUGOTHER, etc.) ",negative,morphine,meperidine
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUG1, DRUGOTHER, and DRUG2, etc.) ",negative,morphine,fentanyl
"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG1, and DRUG2, etc.) ",negative,meperidine,fentanyl
"and combinations of DRUG1 and DRUG2 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.). ",negative,opioids,sedatives
"and combinations of DRUG1 and DRUGOTHER (eg, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.). ",negative,opioids,benzodiazepines
"and combinations of DRUG1 and DRUGOTHER (eg, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.). ",negative,opioids,barbiturates
"and combinations of DRUG1 and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.). ",negative,opioids,chloral hydrate
"and combinations of DRUG1 and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.). ",negative,opioids,droperidol
"and combinations of DRUGOTHER and DRUG1 (eg, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, etc.). ",negative,sedatives,benzodiazepines
"and combinations of DRUGOTHER and DRUG1 (eg, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, etc.). ",negative,sedatives,barbiturates
"and combinations of DRUGOTHER and DRUG1 (eg, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, etc.). ",negative,sedatives,chloral hydrate
"and combinations of DRUGOTHER and DRUG1 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, etc.). ",negative,sedatives,droperidol
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, etc.). ",negative,benzodiazepines,barbiturates
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, etc.). ",negative,benzodiazepines,chloral hydrate
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, etc.). ",negative,benzodiazepines,droperidol
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, etc.). ",negative,barbiturates,chloral hydrate
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, etc.). ",negative,barbiturates,droperidol
"and combinations of DRUGOTHER and DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, etc.). ",negative,chloral hydrate,droperidol
"During maintenance of DRUGOTHER or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUGOTHER or DRUGOTHER). ",advise,DIPRIVAN,analgesic agents
"During maintenance of DRUGOTHER or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUG2 or DRUGOTHER). ",advise,DIPRIVAN,nitrous oxide
"During maintenance of DRUGOTHER or sedation, the rate of DRUG1 Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUGOTHER or DRUG2). ",advise,DIPRIVAN,opioids
"During maintenance of DRUGOTHER or sedation, the rate of DRUGOTHER Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUG2 or DRUGOTHER). ",negative,analgesic agents,nitrous oxide
"During maintenance of DRUGOTHER or sedation, the rate of DRUGOTHER Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUGOTHER or DRUG2). ",negative,analgesic agents,opioids
"During maintenance of DRUGOTHER or sedation, the rate of DRUGOTHER Injectable Emulsion administration should be adjusted according to the desired level of DRUGOTHER or sedation and may be reduced in the presence of supplemental DRUGOTHER agents (eg, DRUG1 or DRUG2). ",negative,nitrous oxide,opioids
"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUG2, and DRUGOTHER) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,enflurane
"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUGOTHER, and DRUG2) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,halothane
"The concurrent administration of potent inhalational agents (eg, DRUG1, DRUGOTHER, and DRUGOTHER) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,isoflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUG1, and DRUG2) during maintenance with DRUGOTHER Injectable Emulsion has not been extensively evaluated. ",negative,enflurane,halothane
"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUG1, and DRUGOTHER) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,enflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg, DRUGOTHER, DRUGOTHER, and DRUG1) during maintenance with DRUG2 Injectable Emulsion has not been extensively evaluated. ",negative,halothane,DIPRIVAN
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG2 (eg, DRUGOTHER and DRUGOTHER). ",negative,DIPRIVAN,neuromuscular blocking agents
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUGOTHER (eg, DRUG2 and DRUGOTHER). ",negative,DIPRIVAN,succinylcholine
"DRUG1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUGOTHER (eg, DRUGOTHER and nondepolarizing DRUGOTHER). ",negative,DIPRIVAN,nondepolarizing muscle relaxants
"DRUGOTHER Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG1 (eg, DRUG2 and DRUGOTHER). ",negative,neuromuscular blocking agents,succinylcholine
"DRUGOTHER Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUG1 (eg, DRUGOTHER and nondepolarizing DRUGOTHER). ",negative,neuromuscular blocking agents,nondepolarizing muscle relaxants
"DRUGOTHER Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used DRUGOTHER (eg, DRUG1 and nondepolarizing DRUGOTHER). ",negative,succinylcholine,nondepolarizing muscle relaxants
"No significant adverse interactions with commonly used premedications or DRUGOTHER used during DRUGOTHER or sedation (including a range of DRUG1, inhalational agents, DRUGOTHER agents, and local DRUGOTHER) have been observed.",negative,muscle relaxants,analgesic agents
"No significant adverse interactions with commonly used premedications or DRUGOTHER used during DRUGOTHER or sedation (including a range of DRUG1, inhalational agents, DRUGOTHER agents, and local DRUGOTHER agents) have been observed.",negative,muscle relaxants,anesthetic agents
"No significant adverse interactions with commonly used premedications or DRUGOTHER used during DRUGOTHER or sedation (including a range of DRUGOTHER, inhalational agents, DRUGOTHER agents, and local DRUGOTHER agents) have been observed.",negative,analgesic agents,anesthetic agents
"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",negative,warfarin,tolmetin
"The in vitro binding of DRUG1 to human plasma proteins is unaffected by DRUG2, and DRUG2 does not alter the prothrombin time of normal volunteers. ",negative,warfarin,tolmetin
"The in vitro binding of DRUGOTHER to human plasma proteins is unaffected by DRUG1, and DRUG1 does not alter the prothrombin time of normal volunteers. ",negative,tolmetin,tolmetin
"However, increased prothrombin time and bleeding have been reported in patients on concomitant DRUG1 and DRUG2 therapy. ",effect,TOLECTIN,warfarin
"Therefore, caution should be exercised when administering DRUG1 to patients on DRUG2. ",advise,TOLECTIN,anticoagulants
In adult diabetic patients under treatment with either DRUG1 or DRUG2 there is no change in the clinical effects of either DRUGOTHER or the DRUGOTHER. ,negative,sulfonylureas,insulin
In adult diabetic patients under treatment with either DRUG1 or DRUGOTHER there is no change in the clinical effects of either DRUG2 or the DRUGOTHER. ,negative,sulfonylureas,TOLECTIN
In adult diabetic patients under treatment with either DRUG1 or DRUGOTHER there is no change in the clinical effects of either DRUGOTHER or the DRUGOTHER agents. ,negative,sulfonylureas,hypoglycemic agents
In adult diabetic patients under treatment with either DRUGOTHER or DRUG1 there is no change in the clinical effects of either DRUG2 or the DRUGOTHER. ,negative,insulin,TOLECTIN
In adult diabetic patients under treatment with either DRUGOTHER or DRUG1 there is no change in the clinical effects of either DRUGOTHER or the DRUGOTHER agents. ,negative,insulin,hypoglycemic agents
In adult diabetic patients under treatment with either DRUGOTHER or DRUGOTHER there is no change in the clinical effects of either DRUG1 or the DRUGOTHER agents. ,negative,TOLECTIN,hypoglycemic agents
Caution should be used if DRUG1 is administered concomitantly with DRUG2. ,advise,TOLECTIN,methotrexate
"DRUG1 and other nonsteroidal DRUGOTHER DRUGOTHER have been reported to reduce the tubular secretion of DRUGOTHER in an animal model, possibly enhancing the toxicity of DRUGOTHER. ",negative,TOLECTIN,nonsteroidal anti-inflammatory drugs
"DRUG1 and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",mechanism,TOLECTIN,methotrexate
"DRUG1 and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",negative,TOLECTIN,methotrexate
"DRUGOTHER and other nonsteroidal DRUGOTHER DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",mechanism,nonsteroidal anti-inflammatory drugs,methotrexate
"DRUGOTHER and other nonsteroidal DRUGOTHER DRUGOTHER have been reported to reduce the tubular secretion of DRUG2 in an animal model, possibly enhancing the toxicity of DRUG2. ",negative,nonsteroidal anti-inflammatory drugs,methotrexate
"DRUGOTHER and other DRUGOTHER have been reported to reduce the tubular secretion of DRUG1 in an animal model, possibly enhancing the toxicity of DRUG1. ",negative,methotrexate,methotrexate
DRUGOTHER DRUGOTHER may accentuate the orthostatic hypotension that may occur with DRUG2. ,effect,Thiazide diuretics,phenothiazines
DRUGOTHER effects of DRUG1 and related compounds may be counteracted when DRUG2 are used concomitantly. ,effect,guanethidine,phenothiazines
Concomitant administration of DRUG1 with DRUG2 results in increased plasma levels of both DRUGOTHER.,mechanism,propranolol,phenothiazines
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,TOBI
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUG2 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,dornase alfa
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUG2   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,PULMOZYME
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,(beta)-agonists
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,corticosteroids
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,anti-pseudomonal antibiotics
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,TOBI,aminoglycosides
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUG2 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,dornase alfa
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUG2   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,PULMOZYME
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,(beta)-agonists
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,corticosteroids
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,anti-pseudomonal antibiotics
"In clinical studies of DRUG1, patients taking DRUG1 concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",effect,TOBI,aminoglycosides
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUG1 (DRUG2   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,PULMOZYME
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUG1 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,(beta)-agonists
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUG1 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,corticosteroids
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUG1 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,anti-pseudomonal antibiotics
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUG1 (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,dornase alfa,aminoglycosides
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUG1   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,(beta)-agonists
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUG1   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,corticosteroids
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUG1   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,anti-pseudomonal antibiotics
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUG1   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,PULMOZYME,aminoglycosides
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG2, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,corticosteroids
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,anti-pseudomonal antibiotics
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,(beta)-agonists,aminoglycosides
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG1, other anti-pseudomonal DRUGOTHER, or parenteral DRUGOTHER demonstrated adverse experience profiles similar to the study population as a whole. ",negative,corticosteroids,anti-pseudomonal antibiotics
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUG1, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,corticosteroids,aminoglycosides
"In clinical studies of DRUGOTHER, patients taking DRUGOTHER concomitantly with DRUGOTHER (DRUGOTHER   , Genentech), (beta)-agonists, inhaled DRUGOTHER, other anti-pseudomonal DRUGOTHER, or parenteral DRUG2 demonstrated adverse experience profiles similar to the study population as a whole. ",negative,anti-pseudomonal antibiotics,aminoglycosides
Some DRUG1 can enhance DRUG2 toxicity by altering DRUGOTHER concentrations in serum and tissue. ,effect,diuretics,aminoglycoside
Some DRUG1 can enhance DRUGOTHER toxicity by altering DRUG2 concentrations in serum and tissue. ,negative,diuretics,antibiotic
Some DRUGOTHER can enhance DRUG1 toxicity by altering DRUG2 concentrations in serum and tissue. ,negative,aminoglycoside,antibiotic
"DRUG1 should not be administered concomitantly with DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",advise,TOBI,ethacrynic acid
"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER.",advise,TOBI,furosemide
"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",advise,TOBI,urea
"DRUG1 should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2.",advise,TOBI,mannitol
"DRUGOTHER should not be administered concomitantly with DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER.",negative,ethacrynic acid,furosemide
"DRUGOTHER should not be administered concomitantly with DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER.",negative,ethacrynic acid,urea
"DRUGOTHER should not be administered concomitantly with DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2.",negative,ethacrynic acid,mannitol
"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER.",negative,furosemide,urea
"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2.",negative,furosemide,mannitol
"DRUGOTHER should not be administered concomitantly with DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2.",negative,urea,mannitol
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG2. ,mechanism,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUGOTHER and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of DRUGOTHER. ,negative,gemfibrozil,rifampin
An inhibitor of CYP2C8 (such as DRUG1) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG2. ,negative,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as DRUG2) may decrease the AUC of DRUG1. ,negative,rosiglitazone,rifampin
An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG1 and an inducer of CYP2C8 (such as DRUGOTHER) may decrease the AUC of DRUG1. ,negative,rosiglitazone,rosiglitazone
An inhibitor of CYP2C8 (such as DRUGOTHER) may increase the AUC of DRUG2 and an inducer of CYP2C8 (such as DRUG1) may decrease the AUC of DRUG2. ,mechanism,rifampin,rosiglitazone
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUGOTHER. ,negative,Cholestyramine,Cholestyramine
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with DRUGOTHER. ,negative,Cholestyramine,raloxifene
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUG2. ,negative,Cholestyramine,EVISTA
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUG2 and should not be coadministered with DRUGOTHER. ,mechanism,Cholestyramine,raloxifene
DRUG1: DRUG1 causes a 60% reduction in the absorption and enterohepatic cycling of DRUGOTHER and should not be coadministered with DRUG2. ,advise,Cholestyramine,EVISTA
DRUGOTHER: DRUGOTHER causes a 60% reduction in the absorption and enterohepatic cycling of DRUG1 and should not be coadministered with DRUG2. ,negative,raloxifene,EVISTA
DRUG1: The coadministration of DRUG2 and DRUG1 has not been assessed under chronic conditions. ,negative,Warfarin,EVISTA
DRUG1: The coadministration of DRUGOTHER and DRUG1 has not been assessed under chronic conditions. ,negative,Warfarin,warfarin
DRUG2: The coadministration of DRUG1 and DRUG2 has not been assessed under chronic conditions. ,negative,EVISTA,warfarin
"If DRUG1 is given concurrently with DRUG2, prothrombin time should be monitored. ",advise,EVISTA,warfarin
"In vitro, DRUG1 did not affect the binding of DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,raloxifene,warfarin
"In vitro, DRUG1 did not affect the binding of DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,raloxifene,phenytoin
"In vitro, DRUG1 did not affect the binding of DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,raloxifene,tamoxifen
"In vitro, DRUGOTHER did not affect the binding of DRUG1, DRUG2, or DRUGOTHER. ",negative,warfarin,phenytoin
"In vitro, DRUGOTHER did not affect the binding of DRUG1, DRUGOTHER, or DRUG2. ",negative,warfarin,tamoxifen
"In vitro, DRUGOTHER did not affect the binding of DRUGOTHER, DRUG1, or DRUG2. ",negative,phenytoin,tamoxifen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",advise,EVISTA,clofibrate
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",advise,EVISTA,indomethacin
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",advise,EVISTA,naproxen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",advise,EVISTA,ibuprofen
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",advise,EVISTA,diazepam
"Caution should be used when DRUG1 is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",advise,EVISTA,diazoxide
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clofibrate,indomethacin
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,clofibrate,naproxen
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,clofibrate,ibuprofen
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,clofibrate,diazepam
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,clofibrate,diazoxide
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,indomethacin,naproxen
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,indomethacin,ibuprofen
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,indomethacin,diazepam
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,indomethacin,diazoxide
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,naproxen,ibuprofen
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,naproxen,diazepam
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,naproxen,diazoxide
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,ibuprofen,diazepam
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,ibuprofen,diazoxide
"Caution should be used when DRUGOTHER is coadministered with other highly protein-bound DRUGOTHER, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,diazepam,diazoxide
DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,mechanism,Probenecid,meropenem
DRUG1 competes with DRUG2 for active tubular secretion and thus inhibits the renal excretion of DRUG2. ,negative,Probenecid,meropenem
DRUGOTHER competes with DRUG1 for active tubular secretion and thus inhibits the renal excretion of DRUG1. ,negative,meropenem,meropenem
"Therefore, the coadministration of DRUG1 with DRUG2 is not recommended. ",advise,probenecid,meropenem
There is evidence that DRUG1 may reduce serum levels of DRUG2 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUGOTHER).,mechanism,meropenem,valproic acid
There is evidence that DRUG1 may reduce serum levels of DRUGOTHER to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,negative,meropenem,valproate
There is evidence that DRUGOTHER may reduce serum levels of DRUG1 to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total DRUG2).,negative,valproic acid,valproate
Other beta DRUGOTHER aerosol DRUGOTHER should not be used concomitantly with DRUG2    (DRUGOTHER USP) because they may have additive effects. ,advise,beta adrenergic aerosol bronchodilators,Alupent
Other beta DRUGOTHER aerosol DRUGOTHER should not be used concomitantly with DRUGOTHER    (DRUG2 USP) because they may have additive effects. ,advise,beta adrenergic aerosol bronchodilators,metaproterenol sulfate
Other DRUGOTHER should not be used concomitantly with DRUG1    (DRUG2 USP) because they may have additive effects. ,negative,Alupent,metaproterenol sulfate
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUG2 or DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",advise,Beta adrenergic agonists,monoamine oxidase inhibitors
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUGOTHER or DRUGOTHER DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",advise,Beta adrenergic agonists,tricyclic antidepressants
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUGOTHER or DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",negative,Beta adrenergic agonists,beta adrenergic agonists
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUG1 or DRUGOTHER DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,tricyclic antidepressants
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUG1 or DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,beta adrenergic agonists
"Beta DRUGOTHER should be administered with caution to patients being treated with DRUGOTHER or DRUGOTHER DRUGOTHER, since the action of beta DRUGOTHER on the vascular system may be potentiated.",negative,tricyclic antidepressants,beta adrenergic agonists
"DRUGOTHER Interactions: The use of DRUG1    (DRUGOTHER bromide) Injection before DRUGOTHER, for the purpose of attenuating some of the side effects of DRUGOTHER, has not been studied. ",negative,ZEMURON,rocuronium bromide
"DRUGOTHER Interactions: The use of DRUG1    (DRUGOTHER bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,ZEMURON,succinylcholine
"DRUGOTHER Interactions: The use of DRUG1    (DRUGOTHER bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,ZEMURON,succinylcholine
"DRUGOTHER Interactions: The use of DRUGOTHER    (DRUGOTHER bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,rocuronium bromide,succinylcholine
"DRUGOTHER Interactions: The use of DRUGOTHER    (DRUGOTHER bromide) Injection before DRUG2, for the purpose of attenuating some of the side effects of DRUG2, has not been studied. ",negative,rocuronium bromide,succinylcholine
"DRUGOTHER Interactions: The use of DRUGOTHER    (DRUGOTHER bromide) Injection before DRUG1, for the purpose of attenuating some of the side effects of DRUG1, has not been studied. ",negative,succinylcholine,succinylcholine
"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",advise,ZEMURON,succinylcholine
"If DRUG1    is administered following administration of DRUG2, it should not be given until recovery from DRUG2 has been observed. ",negative,ZEMURON,succinylcholine
"If DRUGOTHER    is administered following administration of DRUG1, it should not be given until recovery from DRUG1 has been observed. ",negative,succinylcholine,succinylcholine
"The median duration of action of DRUG1    0.6 mg/kg administered after a 1 mg/kg dose of DRUG2 when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",negative,ZEMURON,succinylcholine
There are no controlled studies documenting the use of DRUG1    before or after other nondepolarizing DRUGOTHER. ,negative,ZEMURON,nondepolarizing muscle relaxants
"Because DRUG1 is metabolized by hepatic cytochrome P-450 DRUGOTHER-metabolizing enzymes (DRUGOTHER, DRUGOTHER, DRUGOTHER), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of DRUG1. ",negative,ondansetron,ondansetron
"DRUG1, DRUG2, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Phenytoin,Carbamazepine
"DRUG1, DRUGOTHER, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Phenytoin,Rifampicin
"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Phenytoin,phenytoin
"DRUG1, DRUG2, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Phenytoin,carbamazepine
"DRUG1, DRUGOTHER, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Phenytoin,rifampicin
"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Phenytoin,ondansetron
"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Phenytoin,ondansetron
"DRUGOTHER, DRUG1, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Carbamazepine,Rifampicin
"DRUG2, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG2, DRUG1, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Carbamazepine,phenytoin
"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Carbamazepine,carbamazepine
"DRUGOTHER, DRUG1, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Carbamazepine,rifampicin
"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Carbamazepine,ondansetron
"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Carbamazepine,ondansetron
"DRUG2, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG2, DRUGOTHER, and DRUG1), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Rifampicin,phenytoin
"DRUGOTHER, DRUG2, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG2, and DRUG1), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Rifampicin,carbamazepine
"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,Rifampicin,rifampicin
"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Rifampicin,ondansetron
"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",negative,Rifampicin,ondansetron
"DRUG1, DRUG2, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUG2, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,phenytoin,carbamazepine
"DRUG1, DRUGOTHER, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,phenytoin,rifampicin
"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,phenytoin,ondansetron
"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUG1, DRUGOTHER, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,phenytoin,ondansetron
"DRUGOTHER, DRUG1, and DRUG2: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUG2), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",negative,carbamazepine,rifampicin
"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,carbamazepine,ondansetron
"DRUGOTHER, DRUG1, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUG1, and DRUGOTHER), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,carbamazepine,ondansetron
"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,rifampicin,ondansetron
"DRUGOTHER, DRUGOTHER, and DRUG1: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUG1), the clearance of DRUG2 was significantly increased and DRUG2 blood concentrations were decreased. ",mechanism,rifampicin,ondansetron
"DRUGOTHER, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of DRUGOTHER (i.e., DRUGOTHER, DRUGOTHER, and DRUGOTHER), the clearance of DRUG1 was significantly increased and DRUG1 blood concentrations were decreased. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,Tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUGOTHER and DRUG1 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUGOTHER and DRUG1 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUGOTHER is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUGOTHER and DRUG1 has been observed, data from 2 small studies indicate that DRUGOTHER may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUGOTHER. ",negative,tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUG2: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUG2 has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUG2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",effect,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for DRUG1 is recommended for patients on these DRUGOTHER.1,3  DRUGOTHER: Although no pharmacokinetic DRUGOTHER interaction between DRUG1 and DRUGOTHER has been observed, data from 2 small studies indicate that DRUG1 may be associated with an increase in patient controlled administration of DRUGOTHER.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG1. ",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for DRUG2 is recommended for patients on these DRUGOTHER.1,3  DRUG1: Although no pharmacokinetic DRUGOTHER interaction between DRUG2 and DRUG1 has been observed, data from 2 small studies indicate that DRUG2 may be associated with an increase in patient controlled administration of DRUG1.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by DRUG2. ",negative,tramadol,ondansetron
"In humans, DRUG1, DRUG2, and DRUGOTHER do not affect the pharmacokinetics of DRUGOTHER.  ",negative,carmustine,etoposide
"In humans, DRUG1, DRUGOTHER, and DRUG2 do not affect the pharmacokinetics of DRUGOTHER.  ",negative,carmustine,cisplatin
"In humans, DRUG1, DRUGOTHER, and DRUGOTHER do not affect the pharmacokinetics of DRUG2.  ",negative,carmustine,ondansetron
"In humans, DRUGOTHER, DRUG1, and DRUG2 do not affect the pharmacokinetics of DRUGOTHER.  ",negative,etoposide,cisplatin
"In humans, DRUGOTHER, DRUG1, and DRUGOTHER do not affect the pharmacokinetics of DRUG2.  ",negative,etoposide,ondansetron
"In humans, DRUGOTHER, DRUGOTHER, and DRUG1 do not affect the pharmacokinetics of DRUG2.  ",negative,cisplatin,ondansetron
DRUG1 did not increase blood levels of high-dose DRUG2.,negative,ondansetron,methotrexate
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,mechanism,paclitaxel,HERCEPTIN
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of DRUG1 in combination with DRUG2 resulted in a two-fold decrease in DRUG2 clearance in a non-human primate study and in a 1.5-fold increase in DRUG2 serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of DRUGOTHER in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of DRUGOTHER in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of DRUGOTHER in combination with DRUG1 resulted in a two-fold decrease in DRUG1 clearance in a non-human primate study and in a 1.5-fold increase in DRUG1 serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain DRUGOTHER interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  - DRUG1 and DRUGOTHER: Certain DRUG2 interact with DRUG1 and DRUGOTHER leading to increased serum concentrations of the latter. ,negative,Terfenadine,macrolides
Concomitant administrations not recommended:  - DRUG1 and DRUGOTHER: Certain DRUGOTHER interact with DRUG1 and DRUGOTHER leading to increased serum concentrations of the latter. ,negative,Terfenadine,terfenadine
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain DRUGOTHER interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  - DRUGOTHER and DRUG1: Certain DRUG2 interact with DRUGOTHER and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,macrolides
Concomitant administrations not recommended:  - DRUG2 and DRUG1: Certain DRUGOTHER interact with DRUG2 and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,terfenadine
Concomitant administrations not recommended:  - DRUGOTHER and DRUG1: Certain DRUGOTHER interact with DRUGOTHER and DRUG1 leading to increased serum concentrations of the latter. ,negative,astemizole,astemizole
Concomitant administrations not recommended:  - DRUG2 and DRUGOTHER: Certain DRUG1 interact with DRUG2 and DRUGOTHER leading to increased serum concentrations of the latter. ,int,macrolides,terfenadine
Concomitant administrations not recommended:  - DRUGOTHER and DRUG2: Certain DRUG1 interact with DRUGOTHER and DRUG2 leading to increased serum concentrations of the latter. ,int,macrolides,astemizole
Concomitant administrations not recommended:  - DRUG1 and DRUG2: Certain DRUGOTHER interact with DRUG1 and DRUG2 leading to increased serum concentrations of the latter. ,negative,terfenadine,astemizole
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUGOTHER is not recommended. ",negative,roxithromycin,roxithromycin
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ",negative,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ",negative,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUG2 or DRUGOTHER is not recommended. ",advise,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with DRUG1, concomitant administration of DRUG1 with DRUGOTHER or DRUG2 is not recommended. ",advise,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with DRUGOTHER, concomitant administration of DRUGOTHER with DRUG1 or DRUG2 is not recommended. ",negative,terfenadine,astemizole
"- DRUG1, DRUG2: Other DRUGOTHER such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,Cisapride,pimozide
"- DRUG1, DRUGOTHER: Other DRUGOTHER such as DRUG1 or DRUGOTHER, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,Cisapride,cisapride
"- DRUG1, DRUG2: Other DRUGOTHER such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,Cisapride,pimozide
"- DRUG1, DRUGOTHER: Other DRUGOTHER such as DRUG1 or DRUGOTHER, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",negative,Cisapride,macrolide antibacterials
"- DRUG2, DRUG1: Other DRUGOTHER such as DRUG2 or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,pimozide,cisapride
"- DRUGOTHER, DRUG1: Other DRUGOTHER such as DRUGOTHER or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,pimozide,pimozide
"- DRUGOTHER, DRUG1: Other DRUGOTHER such as DRUGOTHER or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",mechanism,pimozide,macrolide antibacterials
"- DRUG1, DRUG2: Other DRUGOTHER such as DRUG1 or DRUG2, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUGOTHER. ",negative,cisapride,pimozide
"- DRUG1, DRUGOTHER: Other DRUGOTHER such as DRUG1 or DRUGOTHER, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",mechanism,cisapride,macrolide antibacterials
"- DRUGOTHER, DRUG1: Other DRUGOTHER such as DRUGOTHER or DRUG1, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some DRUG2. ",negative,pimozide,macrolide antibacterials
"Although such a risk is not verified for DRUG1, combination of DRUG1 with such DRUGOTHER is not recommended.",negative,roxithromycin,roxithromycin
Some DRUG1 may interact with DRUG2. ,int,anticonvulsants,Mephenytoin
"Those DRUG1 include DRUGOTHER sodium, DRUGOTHER, and DRUGOTHER. ",negative,anticonvulsants,divalproex sodium
"Those DRUG1 include DRUGOTHER sodium, DRUG2, and DRUGOTHER. ",negative,anticonvulsants,valproic acid
"Those DRUG1 include DRUGOTHER sodium, DRUGOTHER, and DRUG2. ",negative,anticonvulsants,phenobarbital
"Those DRUGOTHER include DRUGOTHER sodium, DRUG2, and DRUGOTHER. ",negative,divalproex sodium,valproic acid
"Those DRUGOTHER include DRUGOTHER sodium, DRUGOTHER, and DRUG2. ",negative,divalproex sodium,phenobarbital
"Those DRUGOTHER include DRUGOTHER sodium, DRUG1, and DRUG2. ",negative,valproic acid,phenobarbital
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",effect,Mephenytoin,steroid medications
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUG2, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",effect,Mephenytoin,warfarin
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUG2, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",effect,Mephenytoin,anti-infective medicines
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",effect,Mephenytoin,furosemide
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",effect,Mephenytoin,theophylline
"DRUG1 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG1 may interact with other DRUGOTHER that are not listed here.",negative,Mephenytoin,Mephenytoin
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUG2, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,steroid medications,warfarin
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUGOTHER, certain heart medicines, birth control pills, DRUG2, DRUGOTHER and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,steroid medications,anti-infective medicines
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,steroid medications,furosemide
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,steroid medications,theophylline
"DRUG2 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER medications, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG2 may interact with other DRUGOTHER that are not listed here.",negative,steroid medications,Mephenytoin
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUG2, DRUGOTHER and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,warfarin,anti-infective medicines
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUG2 and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,warfarin,furosemide
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG2 Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,warfarin,theophylline
"DRUG2 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUG1, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUGOTHER Please note that DRUG2 may interact with other DRUGOTHER that are not listed here.",negative,warfarin,Mephenytoin
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUG1, DRUG2 and DRUGOTHER Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,anti-infective medicines,furosemide
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUG1, DRUGOTHER and DRUG2 Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,anti-infective medicines,theophylline
"DRUG2 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUG1, DRUGOTHER and DRUGOTHER Please note that DRUG2 may interact with other DRUGOTHER that are not listed here.",negative,anti-infective medicines,Mephenytoin
"DRUGOTHER may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUG2 Please note that DRUGOTHER may interact with other DRUGOTHER that are not listed here.",negative,furosemide,theophylline
"DRUG2 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUGOTHER Please note that DRUG2 may interact with other DRUGOTHER that are not listed here.",negative,furosemide,Mephenytoin
"DRUG2 may also affect the effects of other DRUGOTHER, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUGOTHER and DRUG1 Please note that DRUG2 may interact with other DRUGOTHER that are not listed here.",negative,theophylline,Mephenytoin
"The interaction of DRUG1, DRUG2, with other DRUGOTHER has not been well studied. ",negative,Streptase,Streptokinase
"Use of DRUG1 and DRUG2 -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUG2 and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Antiplatelet Agents
"Use of DRUG1 and DRUGOTHER -- DRUG2, DRUGOTHER, alone or in combination with DRUGOTHER and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Streptase
"Use of DRUG1 and DRUGOTHER -- DRUGOTHER, DRUG2, alone or in combination with DRUGOTHER and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,Streptokinase
"Use of DRUG1 and DRUG2 -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUG2 and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,antiplatelet agents
"Use of DRUG1 and DRUGOTHER -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUGOTHER and DRUG1, may cause bleeding complications. ",negative,Anticoagulants,anticoagulants
"Use of DRUGOTHER and DRUG1 -- DRUG2, DRUGOTHER, alone or in combination with DRUG1 and DRUGOTHER, may cause bleeding complications. ",negative,Antiplatelet Agents,Streptase
"Use of DRUGOTHER and DRUG1 -- DRUGOTHER, DRUG2, alone or in combination with DRUG1 and DRUGOTHER, may cause bleeding complications. ",negative,Antiplatelet Agents,Streptokinase
"Use of DRUGOTHER and DRUG1 -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUG1 and DRUGOTHER, may cause bleeding complications. ",negative,Antiplatelet Agents,antiplatelet agents
"Use of DRUG2 and DRUG1 -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUG1 and DRUG2, may cause bleeding complications. ",negative,Antiplatelet Agents,anticoagulants
"Use of DRUGOTHER and DRUGOTHER -- DRUG1, DRUG2, alone or in combination with DRUGOTHER and DRUGOTHER, may cause bleeding complications. ",negative,Streptase,Streptokinase
"Use of DRUGOTHER and DRUG2 -- DRUG1, DRUGOTHER, alone or in combination with DRUG2 and DRUGOTHER, may cause bleeding complications. ",effect,Streptase,antiplatelet agents
"Use of DRUG2 and DRUGOTHER -- DRUG1, DRUGOTHER, alone or in combination with DRUGOTHER and DRUG2, may cause bleeding complications. ",effect,Streptase,anticoagulants
"Use of DRUGOTHER and DRUG2 -- DRUGOTHER, DRUG1, alone or in combination with DRUG2 and DRUGOTHER, may cause bleeding complications. ",effect,Streptokinase,antiplatelet agents
"Use of DRUG2 and DRUGOTHER -- DRUGOTHER, DRUG1, alone or in combination with DRUGOTHER and DRUG2, may cause bleeding complications. ",effect,Streptokinase,anticoagulants
"Use of DRUG2 and DRUG1 -- DRUGOTHER, DRUGOTHER, alone or in combination with DRUG1 and DRUG2, may cause bleeding complications. ",negative,antiplatelet agents,anticoagulants
"In the treatment of acute MI, DRUG1, when not otherwise contraindicated, should be administered with DRUG2 ( see below ). ",negative,aspirin,Streptokinase
"Anticoagulation and DRUG1 After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of DRUG2 has been shown to reduce the incidence of reinfarction and stroke. ",negative,Antiplatelets,aspirin
"The addition of DRUG1 to DRUG2 causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",effect,aspirin,Streptokinase
DRUG1 and beta DRUGOTHER increase the effects of DRUGOTHER. ,negative,MAO inhibitors,beta adrenergic blockers
DRUG1 and beta DRUGOTHER increase the effects of DRUG2. ,effect,MAO inhibitors,pseudoephedrine
DRUGOTHER and beta DRUGOTHER increase the effects of DRUG2. ,effect,beta adrenergic blockers,pseudoephedrine
"DRUG1 may reduce the DRUGOTHER effects of DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER.",effect,Sympathomimetics,methyldopa
"DRUG1 may reduce the DRUGOTHER effects of DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER.",effect,Sympathomimetics,mecamylamine
"DRUG1 may reduce the DRUGOTHER effects of DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER.",effect,Sympathomimetics,reserpine
"DRUG1 may reduce the DRUGOTHER effects of DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2.",effect,Sympathomimetics,veratrum alkaloids
"DRUGOTHER may reduce the DRUGOTHER effects of DRUG1, DRUG2, DRUGOTHER and DRUGOTHER.",negative,methyldopa,mecamylamine
"DRUGOTHER may reduce the DRUGOTHER effects of DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER.",negative,methyldopa,reserpine
"DRUGOTHER may reduce the DRUGOTHER effects of DRUG1, DRUGOTHER, DRUGOTHER and DRUG2.",negative,methyldopa,veratrum alkaloids
"DRUGOTHER may reduce the DRUGOTHER effects of DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER.",negative,mecamylamine,reserpine
"DRUGOTHER may reduce the DRUGOTHER effects of DRUGOTHER, DRUG1, DRUGOTHER and DRUG2.",negative,mecamylamine,veratrum alkaloids
"DRUGOTHER may reduce the DRUGOTHER effects of DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2.",negative,reserpine,veratrum alkaloids
"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",advise,tetracyclines,anticoagulant
"Because DRUG1 have been shown to depress plasma prothrombin activity, patients who are on DRUG2 therapy may require downward adjustment of their DRUG2 dosage. ",negative,tetracyclines,anticoagulant
"Because DRUGOTHER have been shown to depress plasma prothrombin activity, patients who are on DRUG1 therapy may require downward adjustment of their DRUG1 dosage. ",negative,anticoagulant,anticoagulant
"Since bacteriostatic DRUGOTHER may interfere with the bactericidal action of DRUG1, it is advisable to avoid giving DRUGOTHER class DRUGOTHER in conjunction with DRUG1. ",negative,penicillin,tetracycline class drugs
"Since bacteriostatic DRUGOTHER may interfere with the bactericidal action of DRUG1, it is advisable to avoid giving DRUGOTHER class DRUGOTHER in conjunction with DRUG1. ",negative,penicillin,penicillin
"Since bacteriostatic DRUGOTHER may interfere with the bactericidal action of DRUG2, it is advisable to avoid giving DRUGOTHER class DRUGOTHER in conjunction with DRUG2. ",advise,tetracycline class drugs,penicillin
"Absorption of DRUG1 is impaired by DRUG2 containing DRUGOTHER, DRUGOTHER or DRUGOTHER, and DRUGOTHER-containing preparations. ",negative,tetracyclines,antacids
"Absorption of DRUG1 is impaired by DRUGOTHER containing DRUG2, DRUGOTHER or DRUGOTHER, and DRUGOTHER-containing preparations. ",mechanism,tetracyclines,aluminum
"Absorption of DRUG1 is impaired by DRUGOTHER containing DRUGOTHER, DRUG2 or DRUGOTHER, and DRUGOTHER-containing preparations. ",mechanism,tetracyclines,calcium
"Absorption of DRUG1 is impaired by DRUGOTHER containing DRUGOTHER, DRUGOTHER or DRUG2, and DRUGOTHER-containing preparations. ",mechanism,tetracyclines,magnesium
"Absorption of DRUG1 is impaired by DRUGOTHER containing DRUGOTHER, DRUGOTHER or DRUGOTHER, and DRUG2-containing preparations. ",mechanism,tetracyclines,iron
"Absorption of DRUGOTHER is impaired by DRUG1 containing DRUG2, DRUGOTHER or DRUGOTHER, and DRUGOTHER-containing preparations. ",negative,antacids,aluminum
"Absorption of DRUGOTHER is impaired by DRUG1 containing DRUGOTHER, DRUG2 or DRUGOTHER, and DRUGOTHER-containing preparations. ",negative,antacids,calcium
"Absorption of DRUGOTHER is impaired by DRUG1 containing DRUGOTHER, DRUGOTHER or DRUG2, and DRUGOTHER-containing preparations. ",negative,antacids,magnesium
"Absorption of DRUGOTHER is impaired by DRUG1 containing DRUGOTHER, DRUGOTHER or DRUGOTHER, and DRUG2-containing preparations. ",negative,antacids,iron
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUG1, DRUG2 or DRUGOTHER, and DRUGOTHER-containing preparations. ",negative,aluminum,calcium
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUG1, DRUGOTHER or DRUG2, and DRUGOTHER-containing preparations. ",negative,aluminum,magnesium
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUG1, DRUGOTHER or DRUGOTHER, and DRUG2-containing preparations. ",negative,aluminum,iron
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUGOTHER, DRUG1 or DRUG2, and DRUGOTHER-containing preparations. ",negative,calcium,magnesium
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUGOTHER, DRUG1 or DRUGOTHER, and DRUG2-containing preparations. ",negative,calcium,iron
"Absorption of DRUGOTHER is impaired by DRUGOTHER containing DRUGOTHER, DRUGOTHER or DRUG1, and DRUG2-containing preparations. ",negative,magnesium,iron
The concurrent use of DRUG1 and DRUG2 has been reported to result in fatal renal toxicity. ,effect,tetracycline,methoxyflurane
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,effect,tetracyclines,contraceptives
Concurrent use of DRUG1 with oral DRUG2 may render oral DRUG2 less effective.,negative,tetracyclines,contraceptives
Concurrent use of DRUGOTHER with oral DRUG1 may render oral DRUG1 less effective.,negative,contraceptives,contraceptives
"The concomitant use of DRUG1 with other DRUGOTHER agents that produce dry mouth, constipation, and other DRUGOTHER pharmacological effects may increase the frequency and/or severity of such effects. ",effect,Sanctura,anticholinergic agents
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,Sanctura
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,digoxin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,procainamide
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,pancuronium
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,morphine
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",negative,Sanctura,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",negative,Sanctura,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",negative,Sanctura,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",mechanism,Sanctura,digoxin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",mechanism,Sanctura,procainamide
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",mechanism,Sanctura,pancuronium
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",mechanism,Sanctura,morphine
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",mechanism,Sanctura,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",mechanism,Sanctura,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUG1 have not been conducted, DRUG1 has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",mechanism,Sanctura,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,digoxin,procainamide
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,digoxin,pancuronium
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,digoxin,morphine
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",negative,digoxin,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",negative,digoxin,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",negative,digoxin,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,procainamide,pancuronium
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,procainamide,morphine
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",negative,procainamide,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",negative,procainamide,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",negative,procainamide,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER). ",negative,pancuronium,morphine
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER). ",negative,pancuronium,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER). ",negative,pancuronium,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2). ",negative,pancuronium,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER). ",negative,morphine,vancomycin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER). ",negative,morphine,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2). ",negative,morphine,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER). ",negative,vancomycin,metformin
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2). ",negative,vancomycin,tenofovir
"DRUGOTHER Eliminated by Active Tubular Secretion: Although studies to assess DRUGOTHER-DRUGOTHER interactions with DRUGOTHER have not been conducted, DRUGOTHER has the potential for pharmacokinetic interactions with other DRUGOTHER that are eliminated by active tubular secretion (e.g. DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2). ",negative,metformin,tenofovir
Coadministration of DRUG1 with DRUGOTHER that are eliminated by active renal tubular secretion may increase the serum concentration of DRUG1 and/or the coadministered DRUGOTHER due to competition for this elimination pathway. ,negative,Sanctura,Sanctura
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUG1  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUGOTHER together with high-dose intravenous DRUGOTHER has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,live organism vaccines
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUG1  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUG2 together with high-dose intravenous DRUGOTHER has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,Nalidixic acid
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUG1  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUGOTHER together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,ALKERAN,melphalan
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUGOTHER  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUG2 together with high-dose intravenous DRUGOTHER has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,live organism vaccines,Nalidixic acid
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUGOTHER  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUGOTHER together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,negative,live organism vaccines,melphalan
DRUGOTHER INTERACTIONS  There are no known DRUGOTHER/DRUGOTHER interactions with oral DRUGOTHER  Vaccinations with live organism DRUGOTHER are not recommended in immunocompromised individuals  DRUG1 together with high-dose intravenous DRUG2 has caused deaths in children due to haemorrhagic enterocolitis.  ,effect,Nalidixic acid,melphalan
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous DRUG1 and who subsequently received DRUG2 to prevent graft-versus-host disease,effect,melphalan,cyclosporin
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUG1 is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUG2, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",advise,midazolam,azole antimycotics
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUG1 is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUG2, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",advise,midazolam,protease inhibitors
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUG1 is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",advise,midazolam,calcium channel antagonists
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUG1 is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",advise,midazolam,macrolide antibiotics
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUG1, DRUG2, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,azole antimycotics,protease inhibitors
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUG1, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,azole antimycotics,calcium channel antagonists
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUG1, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,azole antimycotics,macrolide antibiotics
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUG1, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,protease inhibitors,calcium channel antagonists
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUG1, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,protease inhibitors,macrolide antibiotics
"DRUGOTHER Interactions: Inhibitors of DRUGOTHER Isozymes: Caution is advised when DRUGOTHER is administered concomitantly with DRUGOTHER that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some DRUGOTHER in the DRUGOTHER classes of DRUGOTHER, DRUGOTHER, DRUGOTHER channel antagonists, and macrolide DRUGOTHER). ",negative,calcium channel antagonists,macrolide antibiotics
"DRUGOTHER such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,erythromycin,diltiazem
"DRUGOTHER such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,erythromycin,verapamil
"DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,erythromycin,ketoconazole
"DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,erythromycin,fluconazole
"DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,erythromycin,itraconazole
"DRUGOTHER such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,erythromycin,midazolam
"DRUGOTHER such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,diltiazem,verapamil
"DRUGOTHER such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,diltiazem,ketoconazole
"DRUGOTHER such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,diltiazem,fluconazole
"DRUGOTHER such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,diltiazem,itraconazole
"DRUGOTHER such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,diltiazem,midazolam
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,verapamil,ketoconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,verapamil,fluconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,verapamil,itraconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,verapamil,midazolam
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,ketoconazole,fluconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,ketoconazole,itraconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,ketoconazole,midazolam
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2 were shown to significantly increase the C max and AUC of orally administered DRUGOTHER. ",negative,fluconazole,itraconazole
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,fluconazole,midazolam
"DRUGOTHER such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1 were shown to significantly increase the C max and AUC of orally administered DRUG2. ",mechanism,itraconazole,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUG2 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUGOTHER. ",negative,ritonavir,nelfinavir
"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUG1 and DRUGOTHER may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",mechanism,ritonavir,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors DRUGOTHER and DRUG1 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of DRUG2. ",mechanism,nelfinavir,midazolam
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUG2, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",negative,rifampin,carbamazepine
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUGOTHER, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",negative,rifampin,phenytoin
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUG1, DRUGOTHER, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,rifampin,midazolam
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUG1, and DRUG2, induce metabolism and caused a markedly decreased C max and AUC of oral DRUGOTHER in adult studies. ",negative,carbamazepine,phenytoin
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUG1, and DRUGOTHER, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,carbamazepine,midazolam
"Inducers of DRUGOTHER Isozymes: Cytochrome P450 inducers, such as DRUGOTHER, DRUGOTHER, and DRUG1, induce metabolism and caused a markedly decreased C max and AUC of oral DRUG2 in adult studies. ",mechanism,phenytoin,midazolam
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the DRUG1 due to both the gastrointestinal effects and stimulant effects of DRUG2. ,negative,sedatives,methylphenidate
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG2 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,narcotics
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG2, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,morphine
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG2 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,meperidine
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,fentanyl
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,propofol
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,ketamine
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",effect,VERSED Syrup,nitrous oxide
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",effect,VERSED Syrup,secobarbital
"The DRUGOTHER effect of DRUG1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",effect,VERSED Syrup,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUG2, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,narcotics,morphine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUG2 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,narcotics,meperidine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,narcotics,fentanyl
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,narcotics,propofol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,narcotics,ketamine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,narcotics,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,narcotics,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUG1 (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,narcotics,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUG2 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,morphine,meperidine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,morphine,fentanyl
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,morphine,propofol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,morphine,ketamine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,morphine,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,morphine,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUG1, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,morphine,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,meperidine,fentanyl
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,meperidine,propofol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,meperidine,ketamine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,meperidine,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,meperidine,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,meperidine,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,fentanyl,propofol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,fentanyl,ketamine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,fentanyl,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,fentanyl,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUG1), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,fentanyl,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,propofol,ketamine
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,propofol,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,propofol,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,propofol,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,ketamine,nitrous oxide
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,ketamine,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER and DRUG2. ",negative,ketamine,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER. ",negative,nitrous oxide,secobarbital
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER and DRUG2. ",negative,nitrous oxide,droperidol
"The DRUGOTHER effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUGOTHER and DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2. ",negative,secobarbital,droperidol
"No significant adverse interactions with common premedications (such as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,atropine,scopolamine
"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,atropine,glycopyrrolate
"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,atropine,diazepam
"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,atropine,hydroxyzine
"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUG2) or local DRUGOTHER have been observed.",negative,atropine,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",negative,atropine,anesthetics
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,scopolamine,glycopyrrolate
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,scopolamine,diazepam
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,scopolamine,hydroxyzine
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUG2) or local DRUGOTHER have been observed.",negative,scopolamine,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",negative,scopolamine,anesthetics
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,glycopyrrolate,diazepam
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,glycopyrrolate,hydroxyzine
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and other DRUG2) or local DRUGOTHER have been observed.",negative,glycopyrrolate,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",negative,glycopyrrolate,anesthetics
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and other DRUGOTHER) or local DRUGOTHER have been observed.",negative,diazepam,hydroxyzine
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and other DRUG2) or local DRUGOTHER have been observed.",negative,diazepam,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and other DRUGOTHER) or local DRUG2 have been observed.",negative,diazepam,anesthetics
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and other DRUG2) or local DRUGOTHER have been observed.",negative,hydroxyzine,muscle relaxants
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and other DRUGOTHER) or local DRUG2 have been observed.",negative,hydroxyzine,anesthetics
"No significant adverse interactions with common premedications (such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and other DRUG1) or local DRUG2 have been observed.",negative,muscle relaxants,anesthetics
"DRUGOTHER which may potentiate the myeloproliferative effects of DRUG1, such as DRUG2 and DRUGOTHER, should be used with caution.",effect,Leukine,lithium
"DRUGOTHER which may potentiate the myeloproliferative effects of DRUG1, such as DRUGOTHER and DRUG2, should be used with caution.",effect,Leukine,corticosteroids
"DRUGOTHER which may potentiate the myeloproliferative effects of DRUGOTHER, such as DRUG1 and DRUG2, should be used with caution.",negative,lithium,corticosteroids
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Coumarin-type anticoagulants
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Phenytoin
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Cyclosporine
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Rifampin
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Theophylline
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Terfenadine
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Cisapride
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Astemizole
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Rifabutin
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Tacrolimus
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,hypoglycemics,hypoglycemics
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Phenytoin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Cyclosporine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Rifampin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Theophylline
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Terfenadine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Coumarin-type anticoagulants,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Coumarin-type anticoagulants,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Cyclosporine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Rifampin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Theophylline
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Terfenadine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Phenytoin,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Phenytoin,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Phenytoin,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Rifampin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Theophylline
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Terfenadine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cyclosporine,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Cyclosporine,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Cyclosporine,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Theophylline
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Terfenadine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifampin,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Rifampin,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Rifampin,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Terfenadine
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Theophylline,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Theophylline,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Theophylline,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,Cisapride
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Terfenadine,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Terfenadine,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Terfenadine,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cisapride,Astemizole
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cisapride,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cisapride,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cisapride,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Cisapride,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Cisapride,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Cisapride,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Astemizole,Rifabutin
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Astemizole,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Astemizole,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Astemizole,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Astemizole,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Astemizole,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifabutin,Tacrolimus
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifabutin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Rifabutin,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Rifabutin,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Rifabutin,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Tacrolimus,Short-acting benzodiazepines
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Tacrolimus,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Tacrolimus,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Tacrolimus,hypoglycemic agents
"These are described in greater detail below:  Oral DRUG2, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUG2: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",negative,Short-acting benzodiazepines,hypoglycemics
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,Short-acting benzodiazepines,DIFLUCAN
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Short-acting DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,Short-acting benzodiazepines,hypoglycemic agents
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUG2 with oral DRUGOTHER; ",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral DRUG1, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUG1: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER agents; ",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER-type DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUG1 with oral DRUGOTHER agents; ",effect,DIFLUCAN,hypoglycemic agents
one fatality has been reported from hypoglycemia in association with combined DRUG1 and DRUG2 use. ,effect,DIFLUCAN,glyburide
"DRUG1 reduces the metabolism of DRUG2, DRUGOTHER, and DRUGOTHER and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,tolbutamide
"DRUG1 reduces the metabolism of DRUGOTHER, DRUG2, and DRUGOTHER and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,glyburide
"DRUG1 reduces the metabolism of DRUGOTHER, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",mechanism,DIFLUCAN,glipizide
"DRUGOTHER reduces the metabolism of DRUG1, DRUG2, and DRUGOTHER and increases the plasma concentration of these agents. ",negative,tolbutamide,glyburide
"DRUGOTHER reduces the metabolism of DRUG1, DRUGOTHER, and DRUG2 and increases the plasma concentration of these agents. ",negative,tolbutamide,glipizide
"DRUGOTHER reduces the metabolism of DRUGOTHER, DRUG1, and DRUG2 and increases the plasma concentration of these agents. ",negative,glyburide,glipizide
"When DRUG1 is used concomitantly with these or other DRUGOTHER oral DRUGOTHER, blood DRUGOTHER concentrations should be carefully monitored and the dose of the DRUGOTHER should be adjusted as necessary. ",advise,DIFLUCAN,sulfonylurea oral hypoglycemic agents
"When DRUG1 is used concomitantly with these or other DRUGOTHER, blood DRUGOTHER concentrations should be carefully monitored and the dose of the DRUG2 should be adjusted as necessary. ",negative,DIFLUCAN,sulfonylurea
"When DRUGOTHER is used concomitantly with these or other DRUG2 oral DRUGOTHER, blood DRUGOTHER concentrations should be carefully monitored and the dose of the DRUG2 should be adjusted as necessary. ",negative,sulfonylurea oral hypoglycemic agents,sulfonylurea
DRUGOTHER-type DRUGOTHER: Prothrombin time may be increased in patients receiving concomitant DRUG2 and DRUGOTHER-type DRUGOTHER. ,negative,Coumarin-type anticoagulants,DIFLUCAN
DRUGOTHER-type DRUGOTHER: Prothrombin time may be increased in patients receiving concomitant DRUGOTHER and DRUGOTHER-type DRUGOTHER. ,negative,Coumarin-type anticoagulants,coumarin-type anticoagulants
DRUGOTHER-type DRUGOTHER: Prothrombin time may be increased in patients receiving concomitant DRUG1 and DRUGOTHER-type DRUGOTHER. ,effect,DIFLUCAN,coumarin-type anticoagulants
"In post-marketing experience, as with other azole DRUGOTHER, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG2 concurrently with DRUGOTHER. ",negative,azole antifungals,fluconazole
"In post-marketing experience, as with other azole DRUGOTHER, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUGOTHER concurrently with DRUG2. ",negative,azole antifungals,warfarin
"In post-marketing experience, as with other azole DRUGOTHER, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving DRUG1 concurrently with DRUG2. ",effect,fluconazole,warfarin
Careful monitoring of prothrombin time in patients receiving DRUG1 and DRUGOTHER-type DRUGOTHER is recommended. ,advise,DIFLUCAN,coumarin-type anticoagulants
DRUG1: DRUG2 increases the plasma concentrations of DRUG1. ,negative,Phenytoin,DIFLUCAN
DRUG1: DRUGOTHER increases the plasma concentrations of DRUG1. ,negative,Phenytoin,phenytoin
DRUG2: DRUG1 increases the plasma concentrations of DRUG2. ,mechanism,DIFLUCAN,phenytoin
Careful monitoring of DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,negative,phenytoin,DIFLUCAN
Careful monitoring of DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,negative,phenytoin,phenytoin
Careful monitoring of DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,advise,DIFLUCAN,phenytoin
DRUG1: DRUG2 may significantly increase DRUG1 levels in renal transplant patients with or without renal impairment. ,negative,Cyclosporine,DIFLUCAN
DRUG1: DRUGOTHER may significantly increase DRUG1 levels in renal transplant patients with or without renal impairment. ,negative,Cyclosporine,cyclosporine
DRUG2: DRUG1 may significantly increase DRUG2 levels in renal transplant patients with or without renal impairment. ,mechanism,DIFLUCAN,cyclosporine
Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DRUG2 and DRUG1. ,negative,cyclosporine,DIFLUCAN
Careful monitoring of DRUG1 concentrations and serum creatinine is recommended in patients receiving DRUGOTHER and DRUG1. ,negative,cyclosporine,cyclosporine
Careful monitoring of DRUG2 concentrations and serum creatinine is recommended in patients receiving DRUG1 and DRUG2. ,advise,DIFLUCAN,cyclosporine
DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUGOTHER. ,negative,Rifampin,Rifampin
DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,negative,Rifampin,DIFLUCAN
DRUG1: DRUG1 enhances the metabolism of concurrently administered DRUG2. ,mechanism,Rifampin,DIFLUCAN
"Depending on clinical circumstances, consideration should be given to increasing the dose of DRUG1 when it is administered with DRUG2. ",advise,DIFLUCAN,rifampin
DRUG1: DRUG2 increases the serum concentrations of DRUG1. ,negative,Theophylline,DIFLUCAN
DRUG1: DRUGOTHER increases the serum concentrations of DRUG1. ,negative,Theophylline,theophylline
DRUG2: DRUG1 increases the serum concentrations of DRUG2. ,mechanism,DIFLUCAN,theophylline
Careful monitoring of serum DRUG1 concentrations in patients receiving DRUG2 and DRUG1 is recommended. ,negative,theophylline,DIFLUCAN
Careful monitoring of serum DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,negative,theophylline,theophylline
Careful monitoring of serum DRUG2 concentrations in patients receiving DRUG1 and DRUG2 is recommended. ,advise,DIFLUCAN,theophylline
"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole DRUGOTHER in conjunction with DRUG1, interaction studies have been performed. ",negative,Terfenadine,azole antifungals
"DRUG1: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole DRUGOTHER in conjunction with DRUG1, interaction studies have been performed. ",negative,Terfenadine,terfenadine
"DRUG2: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole DRUGOTHER in conjunction with DRUG2, interaction studies have been performed. ",effect,azole antifungals,terfenadine
Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DRUG2 taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUGOTHER when taken concomitantly. ,negative,fluconazole,DIFLUCAN
Another study at a 400-mg and 800-mg daily dose of DRUG1 demonstrated that DRUGOTHER taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,negative,fluconazole,terfenadine
Another study at a 400-mg and 800-mg daily dose of DRUGOTHER demonstrated that DRUG1 taken in doses of 400 mg per day or greater significantly increases plasma levels of DRUG2 when taken concomitantly. ,mechanism,DIFLUCAN,terfenadine
The combined use of DRUG1 at doses of 400 mg or greater with DRUG2 is contraindicated. ,advise,fluconazole,terfenadine
The coadministration of DRUG1 at doses lower than 400 mg/day with DRUG2 should be carefully monitored. ,advise,fluconazole,terfenadine
"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG2 and DRUG1 were coadministered. ",negative,Cisapride,fluconazole
"DRUG1: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUGOTHER and DRUG1 were coadministered. ",negative,Cisapride,cisapride
"DRUG2: There have been reports of cardiac events, including torsade de pointes in patients to whom DRUG1 and DRUG2 were coadministered. ",effect,fluconazole,cisapride
A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,mechanism,fluconazole,cisapride
A controlled study found that concomitant DRUG1 200 mg once daily and DRUG2 20 mg four times a day yielded a significant increase in DRUG2 plasma levels and prolongation of QTc interval.,negative,fluconazole,cisapride
A controlled study found that concomitant DRUGOTHER 200 mg once daily and DRUG1 20 mg four times a day yielded a significant increase in DRUG1 plasma levels and prolongation of QTc interval.,negative,cisapride,cisapride
The combined use of DRUG1 with DRUG2 is contraindicated. ,advise,fluconazole,cisapride
DRUG1: The use of DRUG2 in patients concurrently taking DRUG1 or other DRUGOTHER metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these DRUGOTHER. ,negative,Astemizole,fluconazole
DRUG1: The use of DRUGOTHER in patients concurrently taking DRUG1 or other DRUGOTHER metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these DRUGOTHER. ,negative,Astemizole,astemizole
DRUG2: The use of DRUG1 in patients concurrently taking DRUG2 or other DRUGOTHER metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these DRUGOTHER. ,mechanism,fluconazole,astemizole
DRUG1: There have been reports of uveitis in patients to whom DRUG2 and DRUG1 were coadministered. ,negative,Rifabutin,fluconazole
DRUG1: There have been reports of uveitis in patients to whom DRUGOTHER and DRUG1 were coadministered. ,negative,Rifabutin,rifabutin
DRUG2: There have been reports of uveitis in patients to whom DRUG1 and DRUG2 were coadministered. ,effect,fluconazole,rifabutin
Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,advise,rifabutin,fluconazole
DRUG1: There have been reports of nephrotoxicity in patients to whom DRUG2 and DRUG1 were coadministered. ,negative,Tacrolimus,fluconazole
DRUG1: There have been reports of nephrotoxicity in patients to whom DRUGOTHER and DRUG1 were coadministered. ,negative,Tacrolimus,tacrolimus
DRUG2: There have been reports of nephrotoxicity in patients to whom DRUG1 and DRUG2 were coadministered. ,effect,fluconazole,tacrolimus
Patients receiving DRUG1 and DRUG2 concomitantly should be carefully monitored. ,advise,tacrolimus,fluconazole
"Short-acting DRUGOTHER: Following oral administration of DRUG2, DRUGOTHER resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,midazolam
"Short-acting DRUGOTHER: Following oral administration of DRUGOTHER, DRUG2 resulted in substantial increases in DRUGOTHER concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,fluconazole
"Short-acting DRUGOTHER: Following oral administration of DRUG2, DRUGOTHER resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,Short-acting Benzodiazepines,midazolam
"DRUGOTHER: Following oral administration of DRUG1, DRUG2 resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",mechanism,midazolam,fluconazole
"DRUGOTHER: Following oral administration of DRUG1, DRUGOTHER resulted in substantial increases in DRUG1 concentrations and psychomotor effects. ",negative,midazolam,midazolam
"DRUGOTHER: Following oral administration of DRUG2, DRUG1 resulted in substantial increases in DRUG2 concentrations and psychomotor effects. ",negative,fluconazole,midazolam
This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,effect,midazolam,fluconazole
This effect on DRUG1 appears to be more pronounced following oral administration of DRUG2 than with DRUG2 administered intravenously. ,negative,midazolam,fluconazole
This effect on DRUGOTHER appears to be more pronounced following oral administration of DRUG1 than with DRUG1 administered intravenously. ,negative,fluconazole,fluconazole
"If short-acting DRUGOTHER, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUG2, consideration should be given to decreasing the DRUGOTHER dosage, and the patients should be appropriately monitored. ",advise,short-acting benzodiazepines,fluconazole
"If short-acting DRUGOTHER, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUGOTHER, consideration should be given to decreasing the DRUG2 dosage, and the patients should be appropriately monitored. ",negative,short-acting benzodiazepines,benzodiazepine
"If DRUGOTHER, which are metabolized by the cytochrome P450 system, are concomitantly administered with DRUG1, consideration should be given to decreasing the DRUG2 dosage, and the patients should be appropriately monitored. ",negative,fluconazole,benzodiazepine
DRUG1 tablets coadministered with ethinyl DRUGOTHER- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUGOTHER levels; ,mechanism,Fluconazole,ethinyl estradiol
DRUG1 tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,mechanism,Fluconazole,levonorgestrel
DRUG1 tablets coadministered with DRUGOTHER- and DRUGOTHER-containing oral DRUG2 produced an overall mean increase in DRUGOTHER and DRUGOTHER levels; ,negative,Fluconazole,contraceptives
DRUG1 tablets coadministered with ethinyl DRUGOTHER- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUGOTHER levels; ,negative,Fluconazole,ethinyl estradiol
DRUG1 tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,negative,Fluconazole,levonorgestrel
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUGOTHER-containing oral DRUG2 produced an overall mean increase in ethinyl DRUGOTHER and DRUGOTHER levels; ,negative,ethinyl estradiol,contraceptives
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUGOTHER-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUGOTHER levels; ,negative,ethinyl estradiol,ethinyl estradiol
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG1-containing oral DRUG2 produced an overall mean increase in DRUGOTHER and DRUG1 levels; ,negative,levonorgestrel,contraceptives
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUG1-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUG1 levels; ,negative,levonorgestrel,ethinyl estradiol
DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG1-containing oral DRUGOTHER produced an overall mean increase in DRUGOTHER and DRUG1 levels; ,negative,levonorgestrel,levonorgestrel
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUGOTHER-containing oral DRUG1 produced an overall mean increase in ethinyl DRUGOTHER and DRUGOTHER levels; ,negative,contraceptives,ethinyl estradiol
DRUGOTHER tablets coadministered with DRUGOTHER- and DRUG2-containing oral DRUG1 produced an overall mean increase in DRUGOTHER and DRUG2 levels; ,negative,contraceptives,levonorgestrel
DRUGOTHER tablets coadministered with ethinyl DRUGOTHER- and DRUG2-containing oral DRUGOTHER produced an overall mean increase in ethinyl DRUGOTHER and DRUG2 levels; ,negative,ethinyl estradiol,levonorgestrel
"however, in some patients there were decreases up to 47% and 33% of ethinyl DRUGOTHER and DRUG2 levels. ",negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual ethinyl DRUGOTHER and DRUG2 AUC values with DRUGOTHER treatment are likely the result of random variation. ,negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual ethinyl DRUGOTHER and DRUGOTHER AUC values with DRUG2 treatment are likely the result of random variation. ,negative,ethinyl estradiol,fluconazole
The data presently available indicate that the decreases in some individual DRUGOTHER and DRUG1 AUC values with DRUG2 treatment are likely the result of random variation. ,negative,levonorgestrel,fluconazole
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl DRUGOTHER and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of ethinyl DRUGOTHER or DRUGOTHER metabolism. ",mechanism,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",mechanism,fluconazole,levonorgestrel
"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUGOTHER metabolism. ",negative,fluconazole,fluconazole
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl DRUGOTHER and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of ethinyl DRUGOTHER or DRUGOTHER metabolism. ",negative,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",negative,fluconazole,levonorgestrel
"While there is evidence that DRUGOTHER can inhibit the metabolism of ethinyl DRUGOTHER and DRUG2, there is no evidence that DRUGOTHER is a net inducer of ethinyl DRUGOTHER or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that DRUG2 can inhibit the metabolism of ethinyl DRUGOTHER and DRUGOTHER, there is no evidence that DRUG2 is a net inducer of ethinyl DRUGOTHER or DRUGOTHER metabolism. ",negative,ethinyl estradiol,fluconazole
"While there is evidence that DRUGOTHER can inhibit the metabolism of ethinyl DRUGOTHER and DRUGOTHER, there is no evidence that DRUGOTHER is a net inducer of ethinyl DRUGOTHER or DRUGOTHER metabolism. ",negative,ethinyl estradiol,ethinyl estradiol
"While there is evidence that DRUGOTHER can inhibit the metabolism of ethinyl DRUGOTHER and DRUG2, there is no evidence that DRUGOTHER is a net inducer of ethinyl DRUGOTHER or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that DRUG2 can inhibit the metabolism of DRUGOTHER and DRUG1, there is no evidence that DRUG2 is a net inducer of DRUGOTHER or DRUG1 metabolism. ",negative,levonorgestrel,fluconazole
"While there is evidence that DRUGOTHER can inhibit the metabolism of ethinyl DRUGOTHER and DRUG1, there is no evidence that DRUGOTHER is a net inducer of ethinyl DRUGOTHER or DRUG1 metabolism. ",negative,levonorgestrel,ethinyl estradiol
"While there is evidence that DRUGOTHER can inhibit the metabolism of DRUGOTHER and DRUG1, there is no evidence that DRUGOTHER is a net inducer of DRUGOTHER or DRUG1 metabolism. ",negative,levonorgestrel,levonorgestrel
"While there is evidence that DRUG1 can inhibit the metabolism of ethinyl DRUGOTHER and DRUGOTHER, there is no evidence that DRUG1 is a net inducer of ethinyl DRUGOTHER or DRUGOTHER metabolism. ",negative,fluconazole,ethinyl estradiol
"While there is evidence that DRUG1 can inhibit the metabolism of DRUGOTHER and DRUG2, there is no evidence that DRUG1 is a net inducer of DRUGOTHER or DRUG2 metabolism. ",negative,fluconazole,levonorgestrel
"While there is evidence that DRUGOTHER can inhibit the metabolism of ethinyl DRUGOTHER and DRUG2, there is no evidence that DRUGOTHER is a net inducer of ethinyl DRUGOTHER or DRUG2 metabolism. ",negative,ethinyl estradiol,levonorgestrel
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with DRUG1 with and without DRUG2 or DRUGOTHER. ",effect,TRENTAL,anticoagulants
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with DRUG1 with and without DRUGOTHER or DRUG2. ",effect,TRENTAL,platelet aggregation inhibitors
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with DRUGOTHER with and without DRUG1 or DRUG2. ",negative,anticoagulants,platelet aggregation inhibitors
Concomitant administration of DRUG1 and DRUG2-containing DRUGOTHER leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,mechanism,TRENTAL,theophylline
Concomitant administration of DRUG1 and DRUG2-containing DRUGOTHER leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,negative,TRENTAL,theophylline
Concomitant administration of DRUG1 and DRUG2-containing DRUGOTHER leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,negative,TRENTAL,theophylline
Concomitant administration of DRUGOTHER and DRUG1-containing DRUGOTHER leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
Concomitant administration of DRUGOTHER and DRUG1-containing DRUGOTHER leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
Concomitant administration of DRUGOTHER and DRUG1-containing DRUGOTHER leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,negative,theophylline,theophylline
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,TRENTAL,antihypertensive drugs
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,TRENTAL,beta blockers
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,TRENTAL,digitalis
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,TRENTAL,diuretics
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",negative,TRENTAL,antidiabetic agents
"DRUG1 has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, without observed problems. ",negative,TRENTAL,antiarrhythmics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,antihypertensive drugs,beta blockers
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,antihypertensive drugs,digitalis
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,antihypertensive drugs,diuretics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",negative,antihypertensive drugs,antidiabetic agents
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, without observed problems. ",negative,antihypertensive drugs,antiarrhythmics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,beta blockers,digitalis
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,beta blockers,diuretics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",negative,beta blockers,antidiabetic agents
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2, without observed problems. ",negative,beta blockers,antiarrhythmics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER, without observed problems. ",negative,digitalis,diuretics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER, without observed problems. ",negative,digitalis,antidiabetic agents
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2, without observed problems. ",negative,digitalis,antiarrhythmics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER, without observed problems. ",negative,diuretics,antidiabetic agents
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2, without observed problems. ",negative,diuretics,antiarrhythmics
"DRUGOTHER has been used concurrently with DRUGOTHER DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2, without observed problems. ",negative,antidiabetic agents,antiarrhythmics
DRUG1 Reports suggest that DRUG2 may diminish the DRUGOTHER effect of DRUGOTHER. ,negative,ACE inhibitors,NSAIDs
DRUG1 Reports suggest that DRUGOTHER may diminish the DRUGOTHER effect of DRUGOTHER-converting enzyme (ACE) inhibitors. ,negative,ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors
DRUGOTHER Reports suggest that DRUG1 may diminish the DRUGOTHER effect of DRUGOTHER-converting enzyme (ACE) inhibitors. ,effect,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors
This interaction should be given consideration in patients taking DRUG1 concomitantly with DRUG2. ,advise,NSAIDs,ACE inhibitors
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUGOTHER. ,negative,Aspirin,aspirin
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,negative,Aspirin,meloxicam
DRUG1: Concomitant administration of DRUG1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of DRUG2. ,mechanism,aspirin,meloxicam
"however, as with other DRUG1, concomitant administration of DRUG2 and DRUGOTHER is not generally recommended because of the potential for increased adverse effects. ",negative,NSAIDs,meloxicam
"however, as with other DRUG1, concomitant administration of DRUGOTHER and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",advise,NSAIDs,aspirin
"however, as with other DRUGOTHER, concomitant administration of DRUG1 and DRUG2 is not generally recommended because of the potential for increased adverse effects. ",advise,meloxicam,aspirin
"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",effect,aspirin,MOBIC
"Concomitant administration of low-dose DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG2 alone. ",negative,aspirin,MOBIC
"Concomitant administration of low-dose DRUGOTHER with DRUG1 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG1 alone. ",negative,MOBIC,MOBIC
DRUG1 is not a substitute for DRUG2 for cardiovascular prophylaxis. ,negative,MOBIC,aspirin
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUGOTHER by 50%. ,negative,Cholestyramine,cholestyramine
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,negative,Cholestyramine,meloxicam
DRUG1: Pretreatment for four days with DRUG1 significantly increased the clearance of DRUG2 by 50%. ,mechanism,cholestyramine,meloxicam
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUGOTHER. ,negative,Cimetidine,cimetidine
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,negative,Cimetidine,meloxicam
DRUG1: Concomitant administration of 200 mg DRUG1 QID did not alter the single-dose pharmacokinetics of 30 mg DRUG2. ,negative,cimetidine,meloxicam
DRUG1: DRUG2 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG1 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Digoxin,Meloxicam
DRUG1: DRUGOTHER 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG1 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Digoxin,digoxin
DRUG2: DRUG1 15 mg once daily for 7 days did not alter the plasma concentration profile of DRUG2 after b-acetyldigoxin administration for 7 days at clinical doses. ,negative,Meloxicam,digoxin
In vitro testing found no protein binding DRUGOTHER interaction between DRUG1 and DRUG2. ,negative,digoxin,meloxicam
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUG2 can reduce the natriuretic effect of DRUG1 and DRUGOTHER DRUGOTHER in some patients. ",negative,Furosemide,NSAIDs
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUGOTHER DRUGOTHER in some patients. ",negative,Furosemide,furosemide
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUGOTHER DRUGOTHER in some patients. ",negative,Furosemide,thiazide diuretics
"DRUG2: Clinical studies, as well as post-marketing observations, have shown that DRUG1 can reduce the natriuretic effect of DRUG2 and DRUGOTHER DRUGOTHER in some patients. ",effect,NSAIDs,furosemide
"DRUGOTHER: Clinical studies, as well as post-marketing observations, have shown that DRUG1 can reduce the natriuretic effect of DRUGOTHER and DRUGOTHER DRUGOTHER in some patients. ",effect,NSAIDs,thiazide diuretics
"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUGOTHER DRUGOTHER in some patients. ",negative,furosemide,thiazide diuretics
Studies with DRUG1 agents and DRUG2 have not demonstrated a reduction in natriuretic effect. ,negative,furosemide,meloxicam
DRUG1: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of DRUG2. ,negative,Furosemide,meloxicam
"Nevertheless, during concomitant therapy with DRUG1 and DRUG2, patients should be observed closely for signs of declining renal function, as well as to assure DRUGOTHER efficacy. ",advise,furosemide,MOBIC
"DRUG1: In clinical trials, DRUG2 have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,NSAIDs
"DRUG1: In clinical trials, DRUGOTHER have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,lithium
"DRUG1: In clinical trials, DRUGOTHER have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,Lithium,lithium
"DRUG2: In clinical trials, DRUG1 have produced an elevation of plasma DRUG2 levels and a reduction in renal DRUG2 clearance. ",mechanism,NSAIDs,lithium
"DRUG2: In clinical trials, DRUG1 have produced an elevation of plasma DRUG2 levels and a reduction in renal DRUG2 clearance. ",negative,NSAIDs,lithium
"DRUG1: In clinical trials, DRUGOTHER have produced an elevation of plasma DRUG1 levels and a reduction in renal DRUG1 clearance. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUGOTHER 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUG2 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUGOTHER 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUG2 15 mg QD as compared to subjects receiving DRUG1 alone. ",mechanism,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose DRUG1 concentration and AUC were increased by 21% in subjects receiving DRUG1 doses ranging from 804 to 1072 mg BID with DRUGOTHER 15 mg QD as compared to subjects receiving DRUG1 alone. ",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose DRUG2 concentration and AUC were increased by 21% in subjects receiving DRUG2 doses ranging from 804 to 1072 mg BID with DRUG1 15 mg QD as compared to subjects receiving DRUG2 alone. ",negative,meloxicam,lithium
Patients on DRUG1 treatment should be closely monitored when DRUG2 is introduced or withdrawn. ,advise,lithium,MOBIC
DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG2 on the pharmacokinetics of DRUG1 taken once weekly. ,negative,Methotrexate,meloxicam
DRUG1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUGOTHER on the pharmacokinetics of DRUG1 taken once weekly. ,negative,Methotrexate,methotrexate
DRUG2: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of DRUG1 on the pharmacokinetics of DRUG2 taken once weekly. ,negative,meloxicam,methotrexate
DRUG1 did not have a significant effect on the pharmacokinetics of single doses of DRUG2. ,negative,Meloxicam,methotrexate
"In vitro, DRUG1 did not displace DRUG2 from its human serum binding sites. ",negative,methotrexate,meloxicam
"DRUG1: DRUGOTHER activity should be monitored, particularly in the first few days after initiating or changing DRUG2 therapy in patients receiving DRUG1 or similar agents, since these patients are at an increased risk of bleeding. ",negative,Warfarin,MOBIC
"DRUG1: DRUGOTHER activity should be monitored, particularly in the first few days after initiating or changing DRUGOTHER therapy in patients receiving DRUG1 or similar agents, since these patients are at an increased risk of bleeding. ",negative,Warfarin,warfarin
"DRUG2: DRUGOTHER activity should be monitored, particularly in the first few days after initiating or changing DRUG1 therapy in patients receiving DRUG2 or similar agents, since these patients are at an increased risk of bleeding. ",advise,MOBIC,warfarin
The effect of DRUG1 on the DRUGOTHER effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,meloxicam,warfarin
The effect of DRUG1 on the DRUGOTHER effect of DRUG2 was studied in a group of healthy subjects receiving daily doses of DRUG2 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,meloxicam,warfarin
The effect of DRUGOTHER on the DRUGOTHER effect of DRUG1 was studied in a group of healthy subjects receiving daily doses of DRUG1 that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,negative,warfarin,warfarin
"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average DRUGOTHER effect of DRUG2 as determined by prothrombin time. ",negative,meloxicam,warfarin
"In these subjects, DRUG1 did not alter DRUG2 pharmacokinetics and the average DRUGOTHER effect of DRUG2 as determined by prothrombin time. ",negative,meloxicam,warfarin
"In these subjects, DRUGOTHER did not alter DRUG1 pharmacokinetics and the average DRUGOTHER effect of DRUG1 as determined by prothrombin time. ",negative,warfarin,warfarin
Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,advise,MOBIC,warfarin
Caution should be used when administering DRUG1 with DRUG2 since patients on DRUG2 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,MOBIC,warfarin
Caution should be used when administering DRUGOTHER with DRUG1 since patients on DRUG1 may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,warfarin,warfarin
"When administered concomitantly with DRUG1   , cardiac DRUGOTHER may enhance or precipitate bradycardia, A.V. ",effect,ProAmatine,cardiac glycosides
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,pseudoephedrine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,ephedrine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,phenylpropanolamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,dihydroergotamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,phenylephrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylephrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,ephedrine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,phenylpropanolamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,dihydroergotamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,pseudoephedrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,pseudoephedrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,phenylpropanolamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,dihydroergotamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,ephedrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,ephedrine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUG2) may enhance or potentiate the pressor effects of DRUGOTHER   . Therefore, caution should be used when DRUGOTHER    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylpropanolamine,dihydroergotamine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,phenylpropanolamine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,phenylpropanolamine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",effect,dihydroergotamine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUG1) may enhance or potentiate the pressor effects of DRUG2   . Therefore, caution should be used when DRUG2    is administered concomitantly with agents that cause vasoconstriction. ",negative,dihydroergotamine,ProAmatine
"The use of DRUGOTHER that stimulate alpha-DRUGOTHER receptors (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER or DRUGOTHER) may enhance or potentiate the pressor effects of DRUG1   . Therefore, caution should be used when DRUG1    is administered concomitantly with agents that cause vasoconstriction. ",negative,ProAmatine,ProAmatine
"DRUG1    has been used in patients concomitantly treated with salt-retaining DRUGOTHER therapy (i.e., DRUG2), with or without salt supplementation. ",negative,ProAmatine,fludrocortisone acetate
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,Alpha-adrenergic blocking agents
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUG2, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,prazosin
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG2, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,terazosin
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG2, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,doxazosin
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,ProAmatine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,desglymidodrine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,metformin
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,cimetidine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,ranitidine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,procainamide
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,triamterene
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,ProAmatine,flecainide
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,ProAmatine,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG2, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,prazosin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG2, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,terazosin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,doxazosin
"DRUG2. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,Alpha-adrenergic blocking agents,ProAmatine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,desglymidodrine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,metformin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,Alpha-adrenergic blocking agents,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,Alpha-adrenergic blocking agents,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUG2, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,terazosin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,doxazosin
"DRUG2. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,prazosin,ProAmatine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,desglymidodrine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,metformin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,prazosin,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,prazosin,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUG1, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,prazosin,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUG2, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,doxazosin
"DRUG2. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUG2. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,terazosin,ProAmatine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,desglymidodrine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,metformin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,terazosin,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,terazosin,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUG1, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,terazosin,quinidine
"DRUG2. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUG2. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",effect,doxazosin,ProAmatine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,desglymidodrine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,metformin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,doxazosin,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,doxazosin,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUG1, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,doxazosin,quinidine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG2 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,desglymidodrine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,metformin
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,cimetidine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,ranitidine
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,procainamide
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,ProAmatine,triamterene
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,ProAmatine,flecainide
"DRUG1. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUG1. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,ProAmatine,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,desglymidodrine,metformin
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,desglymidodrine,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,desglymidodrine,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",mechanism,desglymidodrine,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",mechanism,desglymidodrine,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",mechanism,desglymidodrine,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUG1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",mechanism,desglymidodrine,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,metformin,cimetidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,metformin,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,metformin,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,metformin,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,metformin,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,metformin,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cimetidine,ranitidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,cimetidine,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,cimetidine,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,cimetidine,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,cimetidine,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",negative,ranitidine,procainamide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,ranitidine,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,ranitidine,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,ranitidine,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER. ",negative,procainamide,triamterene
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER. ",negative,procainamide,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2. ",negative,procainamide,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER. ",negative,triamterene,flecainide
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUG2. ",negative,triamterene,quinidine
"DRUGOTHER. Alpha-DRUGOTHER blocking agents, such as DRUGOTHER, DRUGOTHER, and DRUGOTHER, can antagonize the effects of DRUGOTHER. Potential for DRUGOTHER Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of DRUGOTHER (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such DRUGOTHER as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2. ",negative,flecainide,quinidine
Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,mechanism,cimetidine,mebendazole
Preliminary evidence suggests that DRUG1 inhibits DRUG2 metabolism and may result in an increase in plasma concentrations of DRUG2.,negative,cimetidine,mebendazole
Preliminary evidence suggests that DRUGOTHER inhibits DRUG1 metabolism and may result in an increase in plasma concentrations of DRUG1.,negative,mebendazole,mebendazole
Interactions for DRUG1 (DRUG2):  DRUGOTHER - impairs the intestinal absorption of DRUG2,negative,Vitamin B2,Riboflavin
Interactions for DRUG1 (DRUGOTHER):  DRUG2 - impairs the intestinal absorption of DRUGOTHER,negative,Vitamin B2,Alcohol
Interactions for DRUG1 (DRUG2):  DRUGOTHER - impairs the intestinal absorption of DRUG2,negative,Vitamin B2,riboflavin
Interactions for DRUGOTHER (DRUG1):  DRUG2 - impairs the intestinal absorption of DRUG1,negative,Riboflavin,Alcohol
Interactions for DRUGOTHER (DRUG1):  DRUGOTHER - impairs the intestinal absorption of DRUG1,negative,Riboflavin,riboflavin
Interactions for DRUGOTHER (DRUG2):  DRUG1 - impairs the intestinal absorption of DRUG2,mechanism,Alcohol,riboflavin
DRUG1 - concurrent use decreases gastrointestinal absorption of DRUG2; ,mechanism,Probenecid,riboflavin
requirements for DRUG1 may be increased in patients receiving DRUG2.,effect,riboflavin,probenecid
"The concomitant use of other DRUG1 including DRUG2, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,sedatives
"The concomitant use of other DRUG1 including DRUGOTHER, DRUG2, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,hypnotics
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUG2, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,tranquilizers
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG2, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,anesthetics
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,phenothiazines
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,opioids
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,tricyclic antidepressants
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,CNS depressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUG1 including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,CNS depressants,alcohol
"The concomitant use of other DRUGOTHER including DRUG1, DRUG2, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,hypnotics
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUG2, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,tranquilizers
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUG2, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,anesthetics
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,phenothiazines
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,opioids
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,sedatives,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUG1, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,sedatives,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUG2, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,tranquilizers
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUG2, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,anesthetics
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUGOTHER, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,phenothiazines
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,opioids
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,hypnotics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUG1, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,hypnotics,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUG2, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tranquilizers,anesthetics
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tranquilizers,phenothiazines
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tranquilizers,opioids
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tranquilizers,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tranquilizers,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUG1, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,tranquilizers,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUG2, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,anesthetics,phenothiazines
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,anesthetics,opioids
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,anesthetics,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,anesthetics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUG1, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,anesthetics,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,phenothiazines,opioids
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,phenothiazines,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,phenothiazines,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUG1, other DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,phenothiazines,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,opioids,tricyclic antidepressants
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,opioids,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUG1, DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,opioids,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUG2, and DRUGOTHER may produce additive DRUGOTHER effects. ",negative,tricyclic antidepressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER DRUGOTHER, DRUGOTHER, and DRUG2 may produce additive DRUGOTHER effects. ",negative,tricyclic antidepressants,alcohol
"The concomitant use of other DRUGOTHER including DRUGOTHER, DRUGOTHER, DRUGOTHER, general DRUGOTHER, DRUGOTHER, other DRUGOTHER, DRUGOTHER, DRUG1, and DRUG2 may produce additive DRUGOTHER effects. ",negative,monoamine oxidase (MAO) inhibitors,alcohol
"DRUG1 or other medications with DRUGOTHER activity when used concurrently with DRUGOTHER DRUGOTHER may result in increased risk of urinary retention and/or severe constipation, which may DRUGOTHER to paralytic ileus. ",effect,Anticholinergics,opioid analgesics
It has been reported that the incidence of bradycardia was increased when DRUG1 was combined with DRUG2 for induction of DRUGOTHER. ,effect,oxymorphone,propofol
"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of DRUG1 with DRUGOTHER DRUGOTHER; ",effect,cimetidine,opioid analgesics
"Since DRUG1 (DRUG2) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG2 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",negative,Celontin,methsuximide
"Since DRUG1 (DRUGOTHER) may interact with concurrently administered antiepileptic DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",advise,Celontin,antiepileptic drugs
"Since DRUG1 (DRUG2) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG2 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",negative,Celontin,methsuximide
"Since DRUG1 (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUG2 and DRUGOTHER).",negative,Celontin,phenytoin
"Since DRUG1 (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUGOTHER and DRUG2).",negative,Celontin,phenobarbital
"Since DRUGOTHER (DRUG1) may interact with concurrently administered antiepileptic DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",advise,methsuximide,antiepileptic drugs
"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",negative,methsuximide,methsuximide
"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",negative,methsuximide,phenytoin
"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUG2).",negative,methsuximide,phenobarbital
"Since DRUGOTHER (DRUG2) may interact with concurrently administered antiepileptic DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG2 may increase the plasma concentrations of DRUGOTHER and DRUGOTHER).",negative,antiepileptic drugs,methsuximide
"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered antiepileptic DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUG2 and DRUGOTHER).",negative,antiepileptic drugs,phenytoin
"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered antiepileptic DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUGOTHER and DRUG2).",negative,antiepileptic drugs,phenobarbital
"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUG2 and DRUGOTHER).",mechanism,methsuximide,phenytoin
"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUG1 may increase the plasma concentrations of DRUGOTHER and DRUG2).",mechanism,methsuximide,phenobarbital
"Since DRUGOTHER (DRUGOTHER) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these DRUGOTHER may be necessary (eg DRUGOTHER may increase the plasma concentrations of DRUG1 and DRUG2).",negative,phenytoin,phenobarbital
"When DRUG1 and DRUG2 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",effect,atropine,pralidoxime
"When DRUG1 and DRUGOTHER are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG1 is used alone. ",negative,atropine,atropine
"When DRUG2 and DRUG1 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when DRUG2 is used alone. ",negative,pralidoxime,atropine
This is especially true if the total dose of DRUG1 has been large and the administration of DRUG2 has been delayed. ,negative,atropine,pralidoxime
"2 - 4 The following precautions should be kept in mind in the treatment of DRUGOTHER poisoning, although they do not bear directly on the use of DRUG1: since DRUG2 are potentiated by the DRUGOTHER, they should be used cautiously in the treatment of convulsions; ",negative,pralidoxime,barbiturates
"2 - 4 The following precautions should be kept in mind in the treatment of DRUGOTHER poisoning, although they do not bear directly on the use of DRUG1: since DRUGOTHER are potentiated by the DRUG2, they should be used cautiously in the treatment of convulsions; ",negative,pralidoxime,anticholinesterases
"2 - 4 The following precautions should be kept in mind in the treatment of DRUGOTHER poisoning, although they do not bear directly on the use of DRUGOTHER: since DRUG1 are potentiated by the DRUG2, they should be used cautiously in the treatment of convulsions; ",effect,barbiturates,anticholinesterases
"DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,morphine,theophylline
"DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,morphine,aminophylline
"DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,morphine,succinylcholine
"DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,morphine,reserpine
"DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER-type DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,morphine,phenothiazine-type tranquilizers
"DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,theophylline,aminophylline
"DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,theophylline,succinylcholine
"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,theophylline,reserpine
"DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER-type DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,theophylline,phenothiazine-type tranquilizers
"DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,aminophylline,succinylcholine
"DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,aminophylline,reserpine
"DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER-type DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,aminophylline,phenothiazine-type tranquilizers
"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, and DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,reserpine
"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER-type DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,phenothiazine-type tranquilizers
"DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, and DRUGOTHER-type DRUGOTHER should be avoided in patients with organophosphate poisoning.",negative,reserpine,phenothiazine-type tranquilizers
Reduced absorption of DRUG1 and DRUG2 have been reported when those agents were administered concomitantly with DRUGOTHER. ,negative,folic acid,digoxin
Reduced absorption of DRUG1 and DRUGOTHER have been reported when those agents were administered concomitantly with DRUG2. ,mechanism,folic acid,sulfasalazine
Reduced absorption of DRUGOTHER and DRUG1 have been reported when those agents were administered concomitantly with DRUG2. ,mechanism,digoxin,sulfasalazine
"When daily doses of DRUG1 2 g and weekly doses of DRUG2 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a DRUGOTHER-DRUGOTHER interaction study, the pharmacokinetic disposition of the DRUGOTHER was not altered. ",negative,sulfasalazine,methotrexate
Daily doses of DRUG1 2 g (maximum 3 g) and weekly doses of DRUG2 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ,negative,sulfasalazine,methotrexate
DRUG1 Anabolic DRUGOTHER may increase sensitivity to oral DRUG1. ,negative,Anticoagulants,Anabolic steroids
DRUG1 DRUGOTHER may increase sensitivity to oral DRUG1. ,negative,Anticoagulants,anticoagulants
DRUG2 Anabolic DRUGOTHER may increase sensitivity to oral DRUG2. ,effect,Anabolic steroids,anticoagulants
"DRUG1: A multidose study of DRUG2, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUGOTHER half-life and AUC were also detected. ",negative,Warfarin,oxandrolone
"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUGOTHER half-life and AUC were also detected. ",negative,Warfarin,warfarin
"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUGOTHER half-life and AUC were also detected. ",negative,Warfarin,S-warfarin
"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,Warfarin,R-warfarin
"DRUG2: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG2, resulted in a mean increase in DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUGOTHER half-life and AUC were also detected. ",mechanism,oxandrolone,warfarin
"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",negative,oxandrolone,S-warfarin
"DRUGOTHER: A multidose study of DRUG1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",negative,oxandrolone,R-warfarin
"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in S-DRUG1 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in DRUGOTHER half-life and AUC were also detected. ",negative,warfarin,S-warfarin
"DRUG1: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUG1, resulted in a mean increase in DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUG1 half-life and AUC were also detected. ",negative,warfarin,R-warfarin
"DRUGOTHER: A multidose study of DRUGOTHER, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with DRUGOTHER, resulted in a mean increase in S-DRUGOTHER half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-DRUGOTHER half-life and AUC were also detected. ",negative,S-warfarin,R-warfarin
"A 5.5-fold decrease in the mean DRUG1 dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of DRUG1 dose), was necessary to maintain a target INR of 1.5. ",negative,warfarin,warfarin
"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",advise,oxandrolone,warfarin
"When DRUG1 therapy is initiated in a patient already receiving treatment with DRUG2, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG2 adjusted as necessary until a stable target INR or PT has been achieved. ",negative,oxandrolone,warfarin
"When DRUGOTHER therapy is initiated in a patient already receiving treatment with DRUG1, the INR or prothrombin time (PT) should be monitored closely and the dose of DRUG1 adjusted as necessary until a stable target INR or PT has been achieved. ",negative,warfarin,warfarin
"Furthermore, in patients receiving both DRUGOTHER, careful monitoring of the INR or PT, and adjustment of the DRUG1 dosage if indicated are recommended when the DRUG2 dose is changed or discontinued. ",advise,warfarin,oxandrolone
Oral DRUGOTHER agents DRUG2 may inhibit the metabolism of oral DRUGOTHER agents. ,negative,hypoglycemic agents,Oxandrolone
Oral DRUGOTHER agents DRUGOTHER may inhibit the metabolism of oral DRUGOTHER agents. ,negative,hypoglycemic agents,hypoglycemic agents
Oral DRUGOTHER agents DRUG1 may inhibit the metabolism of oral DRUGOTHER agents. ,mechanism,Oxandrolone,hypoglycemic agents
"Adrenal DRUGOTHER or DRUG2 In patients with edema, concomitant administration with DRUGOTHER or DRUG2 may increase the edema. ",negative,Adrenal steroids,ACTH
"Adrenal DRUGOTHER or DRUGOTHER In patients with edema, concomitant administration with adrenal cortical DRUGOTHER or DRUGOTHER may increase the edema. ",negative,Adrenal steroids,adrenal cortical steroids
"Adrenal DRUGOTHER or DRUG2 In patients with edema, concomitant administration with DRUGOTHER or DRUG2 may increase the edema. ",negative,Adrenal steroids,ACTH
"DRUGOTHER or DRUG1 In patients with edema, concomitant administration with adrenal cortical DRUGOTHER or DRUG1 may increase the edema. ",negative,ACTH,adrenal cortical steroids
"DRUGOTHER or DRUG1 In patients with edema, concomitant administration with DRUGOTHER or DRUG1 may increase the edema. ",negative,ACTH,ACTH
"DRUGOTHER or DRUG2 In patients with edema, concomitant administration with adrenal cortical DRUGOTHER or DRUG2 may increase the edema. ",negative,adrenal cortical steroids,ACTH
DRUG1 may reverse the DRUGOTHER activity of DRUGOTHER DRUGOTHER. ,effect,Methysergide,narcotic analgesics
"Concurrent use with DRUG1 including DRUGOTHER alkaloids, DRUGOTHER, and DRUGOTHER (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,ergot alkaloids
"Concurrent use with DRUG1 including DRUGOTHER, DRUG2, and DRUGOTHER (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,sumatriptan
"Concurrent use with DRUG1 including DRUGOTHER, DRUGOTHER, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,nicotine
"Concurrent use with DRUGOTHER including DRUGOTHER alkaloids, DRUG2, and DRUGOTHER (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,sumatriptan
"Concurrent use with DRUGOTHER including DRUGOTHER alkaloids, DRUGOTHER, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,nicotine
"Concurrent use with DRUGOTHER including DRUGOTHER, DRUG1, and DRUG2 (e.g. smoking) may result in enhanced vasoconstriction.",negative,sumatriptan,nicotine
DRUG1 competitively inhibits the intracellular phosphorylation of DRUG2. ,effect,Zidovudine,stavudine
"Therefore, use of DRUG1 in combination with DRUG2 should be avoided. ",advise,zidovudine,ZERIT
In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by DRUG2 and DRUGOTHER. ,effect,stavudine,doxorubicin
In vitro data indicate that the phosphorylation of DRUG1 is also inhibited at relevant concentrations by DRUGOTHER and DRUG2. ,effect,stavudine,ribavirin
In vitro data indicate that the phosphorylation of DRUGOTHER is also inhibited at relevant concentrations by DRUG1 and DRUG2. ,negative,doxorubicin,ribavirin
"When administered concurrently, DRUG1 may increase the effects of oral DRUG2; ",effect,testolactone,anticoagulants
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total DRUGOTHER approximately 55%. ,negative,Cholestyramine,cholestyramine
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total DRUG2 approximately 55%. ,negative,Cholestyramine,ezetimibe
DRUG1: Concomitant DRUG1 administration decreased the mean AUC of total DRUG2 approximately 55%. ,mechanism,cholestyramine,ezetimibe
The incremental LDL-C reduction due to adding DRUG1 to DRUG2 may be reduced by this interaction. ,effect,ezetimibe,cholestyramine
DRUG1: The safety and effectiveness of DRUG2 administered with DRUG1 have not been established. ,negative,Fibrates,ezetimibe
DRUG1: The safety and effectiveness of DRUGOTHER administered with DRUG1 have not been established. ,negative,Fibrates,fibrates
DRUG2: The safety and effectiveness of DRUG1 administered with DRUG2 have not been established. ,negative,ezetimibe,fibrates
DRUGOTHER-administration of DRUG1 with DRUG2 is not recommended until use in patients is studied. ,advise,ZETIA,fibrates
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUGOTHER concentrations approximately 1.5-fold. ",negative,Fenofibrate,fenofibrate
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.5-fold. ",negative,Fenofibrate,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.5-fold. ",mechanism,fenofibrate,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUGOTHER concentrations approximately 1.7-fold. ",negative,Gemfibrozil,gemfibrozil
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.7-fold. ",negative,Gemfibrozil,ezetimibe
"DRUG1: In a pharmacokinetic study, concomitant DRUG1 administration increased total DRUG2 concentrations approximately 1.7-fold. ",negative,gemfibrozil,ezetimibe
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUG2 was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,HMG-CoA reductase inhibitors,ezetimibe
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,HMG-CoA reductase inhibitors,atorvastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,HMG-CoA reductase inhibitors,simvastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,HMG-CoA reductase inhibitors,pravastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,HMG-CoA reductase inhibitors,lovastatin
"DRUG1: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,HMG-CoA reductase inhibitors,fluvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was DRUGOTHER-administered with DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ezetimibe,atorvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was DRUGOTHER-administered with DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,ezetimibe,simvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,ezetimibe,pravastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,ezetimibe,lovastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUG1 was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,ezetimibe,fluvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,atorvastatin,simvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,atorvastatin,pravastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,atorvastatin,lovastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,atorvastatin,fluvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,simvastatin,pravastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,simvastatin,lovastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,simvastatin,fluvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,pravastatin,lovastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",negative,pravastatin,fluvastatin
"DRUGOTHER: No clinically significant pharmacokinetic interactions were seen when DRUGOTHER was DRUGOTHER-administered with DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",negative,lovastatin,fluvastatin
"DRUG1: The total DRUG2 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG1. ",negative,Cyclosporine,ezetimibe
"DRUG1: The total DRUGOTHER level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG1. ",negative,Cyclosporine,cyclosporine
"DRUG2: The total DRUG1 level increased 12-fold in one renal transplant patient receiving multiple medications, including DRUG2. ",mechanism,ezetimibe,cyclosporine
Patients who take both DRUG1 and DRUG2 should be carefully monitored. ,advise,ezetimibe,cyclosporine
"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with DRUG1 was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
A 104-week dietary carcinogenicity study with DRUG1 was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ,negative,ezetimibe,ezetimibe
"In oral (gavage) fertility studies of DRUG1 conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
"In rabbits treated with DRUG1, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total DRUG1). ",negative,ezetimibe,ezetimibe
Multiple dose studies of DRUG1 given in combination with DRUG2 (DRUGOTHER) in rats and rabbits during organogenesis result in higher DRUG1 and DRUGOTHER exposures. ,negative,ezetimibe,HMG-CoA reductase inhibitors
Multiple dose studies of DRUG1 given in combination with DRUGOTHER (DRUG2) in rats and rabbits during organogenesis result in higher DRUG1 and DRUGOTHER exposures. ,negative,ezetimibe,statins
Multiple dose studies of DRUG1 given in combination with DRUGOTHER (DRUGOTHER) in rats and rabbits during organogenesis result in higher DRUG1 and DRUGOTHER exposures. ,negative,ezetimibe,ezetimibe
Multiple dose studies of DRUGOTHER given in combination with DRUG1 (DRUG2) in rats and rabbits during organogenesis result in higher DRUGOTHER and DRUGOTHER exposures. ,negative,HMG-CoA reductase inhibitors,statins
Multiple dose studies of DRUG2 given in combination with DRUG1 (DRUGOTHER) in rats and rabbits during organogenesis result in higher DRUG2 and DRUGOTHER exposures. ,negative,HMG-CoA reductase inhibitors,ezetimibe
Multiple dose studies of DRUG2 given in combination with DRUGOTHER (DRUG1) in rats and rabbits during organogenesis result in higher DRUG2 and DRUGOTHER exposures. ,negative,statins,ezetimibe
"When DRUG1 is administered with an DRUG2 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG2. ",negative,ZETIA,HMG-CoA reductase inhibitor
"When DRUG1 is administered with an DRUG2 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG2. ",negative,ZETIA,HMG-CoA reductase inhibitor
"When DRUGOTHER is administered with an DRUG1 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the DRUG1. ",negative,HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor
"However, DRUG1, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of DRUG2 during concomitant dosing.",mechanism,ketoconazole,mometasone furoate
"DRUG1 may enhance the effects of DRUG2, DRUGOTHER and other DRUGOTHER.",effect,SKELAXIN,alcohol
"DRUG1 may enhance the effects of DRUGOTHER, DRUG2 and other DRUGOTHER.",effect,SKELAXIN,barbiturates
"DRUG1 may enhance the effects of DRUGOTHER, DRUGOTHER and other DRUG2.",effect,SKELAXIN,CNS depressants
"DRUGOTHER may enhance the effects of DRUG1, DRUG2 and other DRUGOTHER.",negative,alcohol,barbiturates
"DRUGOTHER may enhance the effects of DRUG1, DRUGOTHER and other DRUG2.",negative,alcohol,CNS depressants
"DRUGOTHER may enhance the effects of DRUGOTHER, DRUG1 and other DRUG2.",negative,barbiturates,CNS depressants
"The DRUG1 (DRUG2), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",negative,3-Deazaneplanocin A,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",effect,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in DRUG1 insensitive cells, and cotreatment with DRUG1 and DRUGOTHER, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG1 insensitive MM cells. ",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in DRUG2 insensitive cells, and cotreatment with DRUG2 and DRUGOTHER-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DRUG2 insensitive MM cells. ",negative,ABT-737,DZNep
"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUGOTHER-737 and DRUG1 could synergistically induced apoptosis. ",negative,DZNep,ABT-737
"In addition, DRUG1 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUGOTHER and DRUG1 could synergistically induced apoptosis. ",negative,DZNep,DZNep
"In addition, DRUG2 insensitivity might be associated with overexpression of Bcl-2, and the combination of DRUGOTHER-737 and DRUG2 could synergistically induced apoptosis. ",effect,ABT-737,DZNep
"DRUG1 enhances the antinociceptive effect of DRUG2 in mice.
",effect,Ephedrine,dexmedetomidine
The purpose of this study was to evaluate whether the psychostimulant DRUGOTHER DRUG1 has any effect on DRUG2-induced antinociception and locomotor inhibitor activity in mice in acute application.,negative,ephedrine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUGOTHER (15     g/kg) and DRUG1 (10   mg/kg) + DRUGOTHER (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,ephedrine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"saline + saline, DRUG2 (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and DRUG2 (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,dexmedetomidine,ephedrine
"saline + saline, DRUGOTHER (10   mg/kg) + saline, saline + DRUG1 (15     g/kg) and DRUGOTHER (10   mg/kg) + DRUG1 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,dexmedetomidine,dexmedetomidine
"saline + saline, DRUG1 (10   mg/kg) + saline, saline + DRUG2 (15     g/kg) and DRUG1 (10   mg/kg) + DRUG2 (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",negative,ephedrine,dexmedetomidine
"In the hot plate test in mice, DRUGOTHER-administration of 15     g/kg DRUG1 with 10   mg/kg DRUG2 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",effect,dexmedetomidine,ephedrine
"In the hot plate test in mice, DRUGOTHER-administration of 15     g/kg DRUG1 with 10   mg/kg DRUGOTHER intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG1. ",negative,dexmedetomidine,dexmedetomidine
"In the hot plate test in mice, DRUGOTHER-administration of 15     g/kg DRUG2 with 10   mg/kg DRUG1 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by DRUG2. ",negative,ephedrine,dexmedetomidine
"At the same time, the locomotor inhibitory effect of DRUG1 was counteracted by DRUG2. ",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of DRUG1 with DRUG2 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUGOTHER in humans.",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of DRUG1 with DRUGOTHER may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUGOTHER in humans.",negative,dexmedetomidine,dexmedetomidine
"We concluded that the combined administration of DRUG1 with DRUGOTHER may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUG2 in humans.",negative,dexmedetomidine,analgesic
"We concluded that the combined administration of DRUG2 with DRUG1 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG2 as an DRUGOTHER in humans.",negative,ephedrine,dexmedetomidine
"We concluded that the combined administration of DRUGOTHER with DRUG1 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUGOTHER as an DRUG2 in humans.",negative,ephedrine,analgesic
"We concluded that the combined administration of DRUG1 with DRUGOTHER may have beneficial effects in the treatment of pain without causing sedation, which limits the use of DRUG1 as an DRUG2 in humans.",negative,dexmedetomidine,analgesic
Protective effect of DRUG1 and  DRUG2 against the acute toxicity of diepoxybutane to human lymphocytes.,negative,acetyl-l-carnitine,alpha lipoic acid
"(ii) DRUG1 elicits a significant protective effect on DEB induced toxicity, which was potentiated by  DRUG2.",effect,acetyl-l-carnitine,alpha-lipoic acid
"The role of p27(Kip1) in DRUG1-enhanced DRUG2 cytotoxicity in human ovarian cancer cells.
",effect,dasatinib,paclitaxel
"The effect of DRUG1, an inhibitor of Src and Abl kinases, on DRUG2 sensitivity was measured in ovarian cancer cells and HEY xenografts. ",negative,dasatinib,paclitaxel
"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by DRUG1 and DRUG2 were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",negative,dasatinib,paclitaxel
HEY cells treated with DRUG1 plus DRUG2 formed fewer colonies than did cells treated with either agent alone. ,effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUGOTHER inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUGOTHER vs DRUGOTHER: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,dasatinib
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG2 plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG2 + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,dasatinib
"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUG2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUG2 vs DRUG2: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with DRUGOTHER plus DRUG1 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUGOTHER + DRUG1 vs DRUG1: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",negative,paclitaxel,paclitaxel
DRUG1 + DRUG2 vs. ,negative,dasatinib,paclitaxel
"The siRNA knockdown of p27(Kip1) decreased DRUG1- and DRUG2-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",negative,dasatinib,paclitaxel
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that DRUG1-mediated induction of p27(Kip1) enhanced DRUG2-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,effect,dasatinib,paclitaxel
Inhibition of Src family and Abl kinases with either siRNAs or DRUG1 enhances DRUG2 sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,effect,dasatinib,paclitaxel
"Interaction of DRUG1 with different anti-cancer DRUGOTHER is antagonistic in breast but not in other cancer cells.
",effect,celecoxib,anti-cancer drugs
This study investigates the ability of DRUG1 to sensitize cells from different origins to several DRUG2. ,negative,cyclooxygenase-2 inhibitors,chemotherapeutic agents
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUG2, DRUGOTHER and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",negative,5-FU,cisplatin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",negative,5-FU,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUGOTHER and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",negative,5-FU,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUG1, DRUGOTHER, DRUGOTHER and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",negative,5-FU,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER   DRUGOTHER following different incubation schedules were analyzed.",negative,cisplatin,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUGOTHER and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",negative,cisplatin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUG1, DRUGOTHER and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",negative,cisplatin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2   DRUGOTHER following different incubation schedules were analyzed.",negative,doxorubicin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUG1 and DRUGOTHER   DRUG2 following different incubation schedules were analyzed.",negative,doxorubicin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1   DRUG2 following different incubation schedules were analyzed.",negative,etoposide,celecoxib
We found antagonism between DRUG1 and the four DRUGOTHER in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUGOTHER in all cell lines except for two combinations in HCT116 cells. ,negative,celecoxib,celecoxib
We found antagonism between DRUG1 and the four DRUGOTHER in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,negative,celecoxib,doxorubicin
We found antagonism between DRUG1 and the four DRUGOTHER in the breast cancer cells MCF7 following all incubation schedules and between DRUG1 and DRUG2 in all cell lines except for two combinations in HCT116 cells. ,effect,celecoxib,doxorubicin
"These results, if confirmed in-vivo, indicate that DRUG1 is not a suitable chemosensitizer for breast cancer or with DRUG2 for other cancers. ",negative,celecoxib,doxorubicin
The authors report the case of an infant with confirmed congenital hypothyroidism on DRUG1 who experienced a possible DRUGOTHER interaction with DRUG2. ,int,levothyroxine,simeticone
Questioning revealed the child was taking DRUG1 drops before feeds while on DRUG2. ,negative,Infacol,levothyroxine
DRUGOTHER interaction of DRUG1 with DRUG2 has not been reported previously and is not listed in the British National Formulary for Children. ,negative,thyroxine,simeticone
"In vivo CYP3A activity is significantly lower in DRUG1-treated as compared with DRUG2-treated renal allograft recipients.
",negative,cyclosporine,tacrolimus
In vitro studies have identified DRUG1 and DRUG2 as CYP3A inhibitors. ,negative,cyclosporine,tacrolimus
"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG2-treated patients (n = 20) than in matched DRUGOTHER-treated patients (n = 20). ",mechanism,midazolam,cyclosporine
"Systemic and apparent oral DRUG1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUGOTHER-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",negative,midazolam,tacrolimus
"Systemic and apparent oral DRUGOTHER clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in DRUG1-treated patients (n = 20) than in matched DRUG2-treated patients (n = 20). ",negative,cyclosporine,tacrolimus
The latter displayed DRUG1 clearances similar to those in two larger cohorts of nonmatched DRUG2-treated patients (n = 58 and n = 80) and to those receiving a DRUGOTHER-free regimen (n = 6). ,negative,midazolam,tacrolimus
The latter displayed DRUG1 clearances similar to those in two larger cohorts of nonmatched DRUGOTHER-treated patients (n = 58 and n = 80) and to those receiving a DRUG2-free regimen (n = 6). ,negative,midazolam,calcineurin inhibitor
The latter displayed DRUGOTHER clearances similar to those in two larger cohorts of nonmatched DRUG1-treated patients (n = 58 and n = 80) and to those receiving a DRUG2-free regimen (n = 6). ,negative,tacrolimus,calcineurin inhibitor
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving DRUG2, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",negative,cyclosporine,tacrolimus
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG1 than in those receiving DRUGOTHER, indicating that, at the doses generally used in clinical practice, DRUG1 is the stronger of the two with respect to CYP3A inhibition. ",negative,cyclosporine,cyclosporine
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving DRUG2 than in those receiving DRUG1, indicating that, at the doses generally used in clinical practice, DRUG2 is the stronger of the two with respect to CYP3A inhibition. ",negative,tacrolimus,cyclosporine
DRUG1   failure in an HIV-positive woman on DRUG2 therapy resulting in two ectopic pregnancies.,effect,Implanon,antiretroviral
We present an interesting case of an HIV-positive woman on DRUG1 therapy having tubal pregnancies on two separate occasions with DRUG2 in place.,effect,antiretroviral,Implanon
Synergistic interaction between DRUG1 and DRUG2 is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,int,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUGOTHER in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,sunitinib
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of DRUG1 and that of concurrent or sequential administration of DRUG1 and DRUG2 in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either DRUG1 or DRUG2 or both based on various sequential administrations. ,negative,sunitinib,docetaxel
"DRUG1 exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas DRUG2 arrested at S phase. ",negative,Sunitinib,docetaxel
"Although single or concurrent use of DRUG1 and DRUG2 has some anti-proliferative effects, the sequential administrations of both DRUGOTHER remarkably enhanced anti-tumor activity. ",effect,sunitinib,docetaxel
"When cells were exposed to DRUG1 followed by DRUG2, synergism was observed. ",effect,docetaxel,sunitinib
The molecular basis of this synergism is that the signaling pathways that were initially activated by DRUG1 exposure were efficiently suppressed by the subsequent exposure to DRUG2. ,effect,docetaxel,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,Sunitinib,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG1 is superior to DRUG1 followed by DRUGOTHER and concurrent administration.,negative,Sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG1 is superior to DRUG1 followed by DRUGOTHER and concurrent administration.,negative,Sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,Sunitinib,docetaxel
DRUG2 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,effect,docetaxel,sunitinib
DRUG2 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUG2 is superior to DRUG2 followed by DRUG1 and concurrent administration.,negative,docetaxel,sunitinib
DRUGOTHER as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG1 followed by DRUGOTHER is superior to DRUGOTHER followed by DRUG1 and concurrent administration.,negative,docetaxel,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUGOTHER followed by DRUG1 is superior to DRUG1 followed by DRUGOTHER and concurrent administration.,negative,sunitinib,sunitinib
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,sunitinib,docetaxel
DRUG1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of DRUG2 followed by DRUG1 is superior to DRUG1 followed by DRUG2 and concurrent administration.,negative,sunitinib,docetaxel
"In the present study, we tested whether the highly specific metabotropic DRUGOTHER DRUGOTHER 5 antagonist, DRUG1, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of DRUG2. ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUGOTHER injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUGOTHER/DRUG1 versus DRUGOTHER/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG2 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUG2 versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular DRUG2 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUG1 or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG2/DRUG1 versus DRUG2/vehicle). ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUG2-treated monkeys were significantly affected. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography DRUGOTHER transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of DRUGOTHER transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/DRUG2-treated animals than in DRUG1/vehicle-treated monkeys. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography DRUGOTHER transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of DRUGOTHER transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/DRUGOTHER-treated animals than in DRUG1/vehicle-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"These behavioural observations were consistent with in vivo positron emission tomography DRUGOTHER transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of DRUGOTHER transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG2/DRUG1-treated animals than in DRUG2/vehicle-treated monkeys. ",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
The DRUG1 treatment also had a significant effect on the DRUG2-induced loss of DRUGOTHER neurons in the locus coeruleus and adjoining A5 and A7 DRUGOTHER cell groups. ,effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive DRUGOTHER neurons was found in locus coeruleus/A5/A7 DRUGOTHER cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUGOTHER-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive DRUGOTHER neurons was found in locus coeruleus/A5/A7 DRUGOTHER cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUG2-treated monkeys. ",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive DRUGOTHER neurons was found in locus coeruleus/A5/A7 DRUGOTHER cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUG2-treated monkeys. ",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Our data demonstrate that chronic treatment with the metabotropic DRUGOTHER DRUGOTHER 5 antagonist, DRUG1, significantly reduces DRUG2 toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ",effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"[Interaction between DRUG1 and DRUG2].
",negative,clopidogrel,proton pump inhibitors
The DRUGOTHER interaction between DRUG1 and DRUG2 has been the subject of much study in recent years. ,negative,proton pump inhibitors,clopidogrel
Contradictory results regarding the effect of DRUG1 on platelet reactivity and on clinical outcome in DRUG2-treated patients have been reported in literature. ,negative,proton pump inhibitors,clopidogrel
"Concomitant use of DRUG1 and DRUG2 was found to decrease the exposure (AUC) to DRUG2's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",mechanism,omeprazole,clopidogrel
"Concomitant use of DRUG1 and DRUGOTHER was found to decrease the exposure (AUC) to DRUGOTHER's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG1 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",negative,omeprazole,omeprazole
"Concomitant use of DRUG2 and DRUG1 was found to decrease the exposure (AUC) to DRUG1's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by DRUG2 of CYP2C19, a cytochrome P450 (CYP) enzyme. ",negative,clopidogrel,omeprazole
DRUG1 has a much weaker effect on DRUG2's pharmacokinetics and on platelet reactivity during concomitant use. ,mechanism,Pantoprazole,clopidogrel
The influence of the other DRUG1 when used simultaneously with DRUG2 has not yet been investigated in adequately randomized studies. ,negative,proton pump inhibitors,clopidogrel
Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors DRUG2 and DRUGOTHER should be avoided. ,advise,clopidogrel,omeprazole
Regulatory agencies state that the combination of DRUG1 and the CYP2C19 inhibitors DRUGOTHER and DRUG2 should be avoided. ,advise,clopidogrel,esomeprazole
Regulatory agencies state that the combination of DRUGOTHER and the CYP2C19 inhibitors DRUG1 and DRUG2 should be avoided. ,negative,omeprazole,esomeprazole
"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the DRUG1 and DRUG2.",negative,proton pump inhibitors,clopidogrel
"Effect of DRUG1-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUG2 (DRUGOTHER), an orally active DRUGOTHER.
",negative,ketoconazole,panobinostat
"Effect of DRUG1-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUGOTHER (DRUG2), an orally active DRUGOTHER.
",negative,ketoconazole,LBH589
"Effect of DRUG1-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUGOTHER (DRUGOTHER), an orally active DRUG2.
",negative,ketoconazole,histone deacetylase inhibitor
"Effect of DRUGOTHER-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUG1 (DRUG2), an orally active DRUGOTHER.
",negative,panobinostat,LBH589
"Effect of DRUGOTHER-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUG1 (DRUGOTHER), an orally active DRUG2.
",negative,panobinostat,histone deacetylase inhibitor
"Effect of DRUGOTHER-mediated DRUGOTHER inhibition on clinical pharmacokinetics of DRUGOTHER (DRUG1), an orally active DRUG2.
",negative,LBH589,histone deacetylase inhibitor
"This study evaluated the effect of a potent CYP3A inhibitor, DRUG1, on the pharmacokinetics and safety of DRUG2.",negative,ketoconazole,panobinostat
"On day 8, a single DRUG1 dose was DRUGOTHER-administered with DRUG2. ",negative,panobinostat,ketoconazole
"In the presence of DRUG1, there was 1.6- and 1.8-fold increase in C (max) and AUC of DRUG2, respectively. ",mechanism,ketoconazole,panobinostat
DRUGOTHER-administration of DRUG1 with CYP3A inhibitors is feasible as the observed increase in DRUG1 PK parameters was not considered clinically relevant. ,negative,panobinostat,panobinostat
"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of DRUG1 was not studied with CYP3A inhibitors, close monitoring of DRUG1-related adverse events is necessary.",negative,panobinostat,panobinostat
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
"Phase I trial of DRUG1 and DRUGOTHER in patients with relapsed multiple myeloma: evidence for DRUG1-DRUGOTHER interaction via P-glycoprotein.
",negative,lenalidomide,lenalidomide
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
"Phase I trial of DRUG2 and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUG2-DRUG1 interaction via P-glycoprotein.
",negative,CCI-779,lenalidomide
"Phase I trial of DRUGOTHER and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUGOTHER-DRUG1 interaction via P-glycoprotein.
",negative,CCI-779,CCI-779
"Phase I trial of DRUG1 and DRUG2 in patients with relapsed multiple myeloma: evidence for DRUG1-DRUG2 interaction via P-glycoprotein.
",negative,lenalidomide,CCI-779
The preclinical combination of DRUG1 with the mTOR inhibitor DRUG2 has displayed synergy in vitro and represents a novel combination in MM.,effect,lenalidomide,CCI-779
DRUG1 (DRUG2)--better than DRUGOTHER (DRUGOTHER),negative,Ticagrelor,Brilinta
DRUG1 (DRUGOTHER)--better than DRUG2 (DRUGOTHER),negative,Ticagrelor,clopidogrel
DRUG1 (DRUGOTHER)--better than DRUGOTHER (DRUG2),negative,Ticagrelor,Plavix
DRUGOTHER (DRUG1)--better than DRUG2 (DRUGOTHER),negative,Brilinta,clopidogrel
DRUGOTHER (DRUG1)--better than DRUGOTHER (DRUG2),negative,Brilinta,Plavix
DRUGOTHER (DRUGOTHER)--better than DRUG1 (DRUG2),negative,clopidogrel,Plavix
"The FDA has approved DRUG1 (DRUG2-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,ticagrelor,Brilinta
"The FDA has approved DRUG1 (DRUGOTHER-AstraZeneca), an oral antiplatelet DRUGOTHER, for use with low-dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,ticagrelor,antiplatelet drug
"The FDA has approved DRUG1 (DRUGOTHER-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",effect,ticagrelor,aspirin
"The FDA has approved DRUGOTHER (DRUG1-AstraZeneca), an oral antiplatelet DRUGOTHER, for use with low-dose DRUGOTHER to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,Brilinta,antiplatelet drug
"The FDA has approved DRUGOTHER (DRUG1-AstraZeneca), an oral DRUGOTHER, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",effect,Brilinta,aspirin
"The FDA has approved DRUGOTHER (DRUGOTHER-AstraZeneca), an oral antiplatelet DRUGOTHER, for use with low-dose DRUG2 to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",negative,antiplatelet drug,aspirin
It will compete with DRUG1 (DRUG2) and DRUGOTHER (DRUGOTHER) for such use. ,negative,clopidogrel,Plavix
It will compete with DRUG1 (DRUGOTHER) and DRUG2 (DRUGOTHER) for such use. ,negative,clopidogrel,prasugrel
It will compete with DRUG1 (DRUGOTHER) and DRUGOTHER (DRUG2) for such use. ,negative,clopidogrel,Effient
It will compete with DRUGOTHER (DRUG1) and DRUG2 (DRUGOTHER) for such use. ,negative,Plavix,prasugrel
It will compete with DRUGOTHER (DRUG1) and DRUGOTHER (DRUG2) for such use. ,negative,Plavix,Effient
It will compete with DRUGOTHER (DRUGOTHER) and DRUG1 (DRUG2) for such use. ,negative,prasugrel,Effient
"Exposure to oral S-DRUGOTHER is unaffected by DRUG2 but greatly increased by DRUGOTHER.
",negative,S-ketamine,itraconazole
"Exposure to oral S-DRUGOTHER is unaffected by DRUGOTHER but greatly increased by DRUG2.
",effect,S-ketamine,ticlopidine
"Exposure to oral S-DRUGOTHER is unaffected by DRUG1 but greatly increased by DRUG2.
",negative,itraconazole,ticlopidine
This study examined DRUGOTHER-DRUGOTHER interactions of oral S-DRUGOTHER with the cytochrome P450 (CYP) 2B6 inhibitor DRUG2 and the CYP3A inhibitor DRUGOTHER. ,negative,S-ketamine,ticlopidine
This study examined DRUGOTHER-DRUGOTHER interactions of oral S-DRUGOTHER with the cytochrome P450 (CYP) 2B6 inhibitor DRUGOTHER and the CYP3A inhibitor DRUG2. ,negative,S-ketamine,itraconazole
This study examined DRUGOTHER-DRUGOTHER interactions of oral S-DRUGOTHER with the cytochrome P450 (CYP) 2B6 inhibitor DRUG1 and the CYP3A inhibitor DRUG2. ,negative,ticlopidine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-DRUGOTHER after pretreatments with oral DRUG2 (250 mg twice daily), DRUGOTHER (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,S-ketamine,ticlopidine
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-DRUGOTHER after pretreatments with oral DRUGOTHER (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,S-ketamine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-DRUGOTHER after pretreatments with oral DRUG1 (250 mg twice daily), DRUG2 (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",negative,ticlopidine,itraconazole
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG2 by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to DRUGOTHER. ",mechanism,Ticlopidine,ketamine
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to S-DRUGOTHER. ",negative,Ticlopidine,itraconazole
"DRUG1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to S-DRUGOTHER. ",negative,Ticlopidine,S-ketamine
"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas DRUG2 treatment did not increase the exposure to DRUGOTHER. ",negative,ketamine,itraconazole
"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUG1 by 2.4-fold, whereas DRUGOTHER treatment did not increase the exposure to S-DRUG1. ",negative,ketamine,S-ketamine
"DRUGOTHER treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral DRUGOTHER by 2.4-fold, whereas DRUG1 treatment did not increase the exposure to S-DRUGOTHER. ",negative,itraconazole,S-ketamine
The ratio of DRUG1 AUC(0-   ) to DRUG2 AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,negative,norketamine,ketamine
The ratio of DRUG1 AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,negative,norketamine,ticlopidine
The ratio of DRUG1 AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,norketamine,itraconazole
The ratio of DRUGOTHER AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the DRUG2 (P &lt; 0.001) and DRUGOTHER phases (P = 0.006) as compared to placebo. ,negative,ketamine,ticlopidine
The ratio of DRUGOTHER AUC(0-   ) to DRUG1 AUC(0-   ) was significantly decreased in the DRUGOTHER (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,ketamine,itraconazole
The ratio of DRUGOTHER AUC(0-   ) to DRUGOTHER AUC(0-   ) was significantly decreased in the DRUG1 (P &lt; 0.001) and DRUG2 phases (P = 0.006) as compared to placebo. ,negative,ticlopidine,itraconazole
"In the DRUG1 and DRUG2 phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",negative,ticlopidine,itraconazole
The findings suggest that the dosage of S-DRUGOTHER should be reduced in patients receiving DRUG2.,advise,S-ketamine,ticlopidine
"Improved parathyroid hormone control by DRUG1 is associated with reduction in DRUG2 requirement in patients with end-stage renal disease.
",negative,cinacalcet,darbepoetin
"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to DRUG1 (DRUG2) resistance. ",negative,erythropoietin,EPO
"Medical treatment with DRUG1 is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on DRUG2 dosing is unknown. ",negative,cinacalcet,darbepoetin
The primary objective of the study was to ascertain the difference in DRUG1 responsiveness before and after 12 months of DRUG2 therapy. ,negative,darbepoetin,cinacalcet
Reduction of PTH by DRUG1 is associated with a decrease in DRUG2 requirement. ,effect,cinacalcet,darbepoetin
"DRUG1-DRUG2 interaction and associated gastrointestinal bleeding risk in a case-control study.
",negative,Antidepressant,warfarin
We sought to evaluate whether initiation of an DRUG1 increases the risk of hospitalization for gastrointestinal bleeding in DRUG2 users.,negative,antidepressant,warfarin
"In total, 430,455 DRUG1 users contributed 407,370 person-years of DRUG1 use. ",negative,warfarin,warfarin
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG2 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,citalopram
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,fluoxetine
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,paroxetine
"DRUG1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",effect,Warfarin,amitriptyline
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG2 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,fluoxetine
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,paroxetine
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUG1 (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,citalopram,amitriptyline
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG2 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUGOTHER (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,fluoxetine,paroxetine
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUG1 (OR   =   1.63 [95% CI, 1.11-2.38]), DRUGOTHER (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,fluoxetine,amitriptyline
"DRUGOTHER users had an increased odds ratio of gastrointestinal bleeding upon initiation of DRUGOTHER (OR   =   1.73 [95% CI, 1.25-2.38]), DRUGOTHER (OR   =   1.63 [95% CI, 1.11-2.38]), DRUG1 (OR   =   1.64 [95% CI, 1.27-2.12]), DRUG2 (OR   =   1.47 [95% CI, 1.02-2.11]). ",negative,paroxetine,amitriptyline
"Also DRUG1, which is not believed to interact with DRUG2, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",effect,mirtazapine,warfarin
"DRUG1 users who initiated DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,citalopram
"DRUG1 users who initiated DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,fluoxetine
"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,paroxetine
"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,amitriptyline
"DRUG1 users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",effect,Warfarin,mirtazapine
"DRUGOTHER users who initiated DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,fluoxetine
"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,paroxetine
"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,amitriptyline
"DRUGOTHER users who initiated DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,citalopram,mirtazapine
"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,paroxetine
"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,amitriptyline
"DRUGOTHER users who initiated DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,fluoxetine,mirtazapine
"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,paroxetine,amitriptyline
"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,paroxetine,mirtazapine
"DRUGOTHER users who initiated DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2 had an increased risk of hospitalization for gastrointestinal bleeding. ",negative,amitriptyline,mirtazapine
"Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza DRUGOTHER by oral administration of DRUGOTHER stem-and-leaf saponins in chickens.
",negative,avian influenza vaccines,ginseng stem-and-leaf saponins
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUG2) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,ginseng stem-and-leaf saponins,GSLS
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUGOTHER) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,ginseng stem-and-leaf saponins,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUGOTHER) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,ginseng stem-and-leaf saponins,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUG1) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,GSLS,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUG1) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,GSLS,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of DRUGOTHER stem-and-leaf saponins (DRUGOTHER) on the humoral immune responses of chickens to inactivated ND and AI DRUGOTHER. ,negative,inactivated ND vaccines,inactivated AI vaccines
"In experiment 1, oral administration of DRUG1 at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND DRUGOTHER was evaluated. ",negative,GSLS,inactivated ND vaccine
"In experiment 2, the same regimen of DRUG1 was administered to chickens inoculated with inactivated AI DRUGOTHER, and an enhanced serum antibody response to AI vaccination was also observed. ",effect,GSLS,inactivated AI vaccines
"Considering the safety of DRUG1, because no adverse effect was found throughout the experiments, DRUG1 may be a promising oral adjuvant to improve immunization in poultry.",negative,GSLS,GSLS
DRUG1 does not inhibit the absorption of 5 milligrams of nonheme or DRUGOTHER at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,nonheme iron
DRUG1 does not inhibit the absorption of 5 milligrams of nonheme or heme DRUGOTHER at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,heme iron
DRUGOTHER does not inhibit the absorption of 5 milligrams of nonheme or heme DRUGOTHER at doses less than 800 milligrams in nonpregnant women.,negative,nonheme iron,heme iron
DRUG1 is the only known component in the diet that may affect absorption of both nonheme and DRUGOTHER. ,mechanism,Calcium,nonheme iron
DRUG1 is the only known component in the diet that may affect absorption of both nonheme and heme DRUGOTHER. ,mechanism,Calcium,heme iron
DRUGOTHER is the only known component in the diet that may affect absorption of both nonheme and heme DRUGOTHER. ,negative,nonheme iron,heme iron
"However, the evidence for a DRUG1 effect on DRUG2 absorption mainly comes from studies that did not isolate the effect of DRUG1 from that of other dietary components, because it was detected in single-meal studies. ",mechanism,calcium,iron
"However, the evidence for a DRUG1 effect on DRUGOTHER absorption mainly comes from studies that did not isolate the effect of DRUG1 from that of other dietary components, because it was detected in single-meal studies. ",negative,calcium,calcium
"However, the evidence for a DRUG2 effect on DRUG1 absorption mainly comes from studies that did not isolate the effect of DRUG2 from that of other dietary components, because it was detected in single-meal studies. ",negative,iron,calcium
Our objective was to establish potential effects of DRUG1 on absorption of nonheme and DRUGOTHER and the dose response for this effect in the absence of a meal. ,negative,calcium,nonheme iron
Our objective was to establish potential effects of DRUG1 on absorption of nonheme and heme DRUGOTHER and the dose response for this effect in the absence of a meal. ,negative,calcium,heme iron
Our objective was to establish potential effects of DRUGOTHER on absorption of nonheme and heme DRUGOTHER and the dose response for this effect in the absence of a meal. ,negative,nonheme iron,heme iron
We evaluated the effects of DRUG1 doses between 200 and 1500 mg on absorption of 5 mg nonheme DRUGOTHER (as DRUGOTHER). ,negative,calcium,nonheme iron
We evaluated the effects of DRUG1 doses between 200 and 1500 mg on absorption of 5 mg nonheme DRUGOTHER (as DRUG2). ,negative,calcium,ferrous sulfate
We evaluated the effects of DRUGOTHER doses between 200 and 1500 mg on absorption of 5 mg nonheme DRUGOTHER (as DRUG2). ,negative,nonheme iron,ferrous sulfate
We also evaluated the effects of DRUG1 doses between 200 and 800 mg on absorption of 5 mg heme DRUGOTHER [as concentrated RBC (CRBC)]. ,negative,calcium,heme iron
DRUG1 was administered as DRUG1 chloride in all studies and DRUGOTHER were ingested on an empty stomach. ,negative,Calcium,calcium chloride
DRUG1 was administered as DRUGOTHER in all studies and DRUG2 were ingested on an empty stomach. ,negative,Calcium,minerals
DRUGOTHER was administered as DRUGOTHER chloride in all studies and DRUG2 were ingested on an empty stomach. ,negative,calcium chloride,minerals
DRUG1 doses   1000 mg diminished nonheme DRUGOTHER absorption by an average of 49.6%.,mechanism,Calcium,nonheme iron
A DRUG1 dose of 800 mg diminished absorption of 5 mg heme DRUGOTHER by 37.7%. ,mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of DRUG1 (as chloride) on absorption of 5 mg of DRUGOTHER provided as nonheme (as sulfate) and heme (as CRBC) DRUGOTHER. ",mechanism,calcium,nonheme iron
"In conclusion, we demonstrated an isolated effect of DRUG1 (as chloride) on absorption of 5 mg of DRUGOTHER provided as nonheme (as sulfate) and heme (as CRBC) DRUGOTHER. ",mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of DRUGOTHER (as chloride) on absorption of 5 mg of DRUGOTHER provided as nonheme (as sulfate) and heme (as CRBC) DRUGOTHER. ",negative,nonheme iron,heme iron
"DRUG1 locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with DRUG2.
",negative,Amphetamine,quinpirole
The objective was to analyze the effects of neonatal DRUG1 treatment on effects of DRUG2 in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,negative,quinpirole,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",effect,quinpirole,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced DRUGOTHER locomotor sensitization compared with DRUG1-free controls sensitized to DRUGOTHER. ",negative,quinpirole,quinpirole
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",negative,quinpirole,amphetamine
"In female rats, neonatal DRUG2 treatment enhanced DRUG1 locomotor sensitization compared with DRUG2-free controls sensitized to DRUG1. ",negative,amphetamine,quinpirole
"In female rats, neonatal DRUGOTHER treatment enhanced DRUG1 locomotor sensitization compared with DRUGOTHER-free controls sensitized to DRUG1. ",negative,amphetamine,amphetamine
"In female rats, neonatal DRUG1 treatment enhanced DRUG2 locomotor sensitization compared with DRUG1-free controls sensitized to DRUG2. ",negative,quinpirole,amphetamine
"Male rats demonstrated sensitization to DRUG1, although this was muted compared with female rats, and were unaffected by neonatal DRUG2. ",negative,amphetamine,quinpirole
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUGOTHER-paired context compared with DRUG1-free controls conditioned with DRUGOTHER, but only female controls conditioned with DRUGOTHER spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,quinpirole
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG2 enhanced time spent in the DRUG1-paired context compared with DRUG2-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,amphetamine,quinpirole
"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUG1 enhanced time spent in the DRUG2-paired context compared with DRUG1-free controls conditioned with DRUG2, but only female controls conditioned with DRUG2 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,quinpirole,amphetamine
"Rats treated with neonatal DRUGOTHER enhanced time spent in the DRUG1-paired context compared with DRUGOTHER-free controls conditioned with DRUG1, but only female controls conditioned with DRUG1 spent more time in the DRUGOTHER-paired context compared with saline-treated controls. ",negative,amphetamine,amphetamine
"In vitro activity of DRUG1 combined with DRUG2 against clinical isolates of DRUGOTHER-resistant Staphylococcus aureus.
",negative,minocycline,fosfomycin
"In vitro activity of DRUG1 combined with DRUGOTHER against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",negative,minocycline,methicillin
"In vitro activity of DRUGOTHER combined with DRUG1 against clinical isolates of DRUG2-resistant Staphylococcus aureus.
",negative,fosfomycin,methicillin
This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUG2 against isolates of DRUGOTHER-resistant Staphylococcus aureus (MRSA). ,negative,minocycline,fosfomycin
This study aimed to evaluate the in vitro activity of DRUG1 combined with DRUGOTHER against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,negative,minocycline,methicillin
This study aimed to evaluate the in vitro activity of DRUGOTHER combined with DRUG1 against isolates of DRUG2-resistant Staphylococcus aureus (MRSA). ,negative,fosfomycin,methicillin
The susceptibility results for DRUG1 and DRUG2 were interpreted according to the most relevant criteria. ,negative,minocycline,fosfomycin
The combination of DRUG1 and DRUG2 can be synergistic against MRSA. ,effect,minocycline,fosfomycin
"DRUG1 enhances DRUG2-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
",effect,Lapatinib,herceptin
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",effect,lapatinib,Herceptin
"Although it was previously reported that DRUG1 combined with DRUGOTHER improved the progression-free survival rate compared with DRUG1 alone for patients with DRUGOTHER-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,lapatinib
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"Although it was previously reported that DRUG2 combined with DRUG1 improved the progression-free survival rate compared with DRUG2 alone for patients with DRUG1-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,lapatinib
"Although it was previously reported that DRUGOTHER combined with DRUG1 improved the progression-free survival rate compared with DRUGOTHER alone for patients with DRUG1-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,Herceptin
"Although it was previously reported that DRUG1 combined with DRUG2 improved the progression-free survival rate compared with DRUG1 alone for patients with DRUG2-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"We evaluated how DRUG1 interacts with DRUG2 in HER2-positive breast cancer, with a particular focus on DRUG2-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,lapatinib,Herceptin
"We evaluated how DRUG1 interacts with DRUG2 in HER2-positive breast cancer, with a particular focus on DRUG2-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,lapatinib,Herceptin
"We evaluated how DRUGOTHER interacts with DRUG1 in HER2-positive breast cancer, with a particular focus on DRUG1-mediated antibody-dependent cellular cytotoxicity (ADCC). ",negative,Herceptin,Herceptin
"In an in vitro assay, DRUG1 induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of DRUG2-mediated ADCC. ",effect,lapatinib,Herceptin
"Furthermore, we present a case report in which a second DRUG1 treatment following DRUG2 resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ",effect,Herceptin,lapatinib
DRUG1 may have the potential to convert DRUG2-refractory to DRUG2-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
DRUG1 may have the potential to convert DRUG2-refractory to DRUG2-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
DRUGOTHER may have the potential to convert DRUG1-refractory to DRUG1-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Herceptin,Herceptin
"Influence of DRUG1 on DRUG2 induced antinociception and its pharmacokinetics.
",negative,piperine,ibuprofen
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG2. ",effect,piperine,ibuprofen
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUGOTHER evaluated by both DRUG2 writhing and formalin test, when it was administered with DRUGOTHER. ",negative,piperine,acetic acid
"In the present study DRUG1 (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG2. ",negative,piperine,ibuprofen
"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both DRUG2 writhing and formalin test, when it was administered with DRUG1. ",negative,ibuprofen,acetic acid
"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG1 evaluated by both DRUGOTHER writhing and formalin test, when it was administered with DRUG1. ",negative,ibuprofen,ibuprofen
"In the present study DRUGOTHER (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of DRUG2 evaluated by both DRUG1 writhing and formalin test, when it was administered with DRUG2. ",negative,acetic acid,ibuprofen
DRUG1 plasma concentration was also increased when it was administered with DRUG2. ,mechanism,Ibuprofen,piperine
The synergistic antinociception activity of DRUG1 when administered with DRUG2 can be attributed to increased plasma concentration of DRUG1. ,mechanism,ibuprofen,piperine
The synergistic antinociception activity of DRUG1 when administered with DRUGOTHER can be attributed to increased plasma concentration of DRUG1. ,negative,ibuprofen,ibuprofen
The synergistic antinociception activity of DRUG2 when administered with DRUG1 can be attributed to increased plasma concentration of DRUG2. ,negative,piperine,ibuprofen
From this study it can be concluded that DRUG1 can be used as a bioenhancer along with DRUG2.,effect,piperine,ibuprofen
To determine whether the DRUGOTHER-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of DRUG1 (DRUG2).,negative,adeno-associated virus-2,AAV2
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG2, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",negative,AAV2,collagenase
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,AAV2,hyaluronan lyase
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,AAV2,heparinase III
"DRUG1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,AAV2,chondroitin ABC lyase
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, DRUG2, DRUGOTHER, or DRUGOTHER. ",negative,collagenase,hyaluronan lyase
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, DRUGOTHER, DRUG2, or DRUGOTHER. ",negative,collagenase,heparinase III
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUG1, DRUGOTHER, DRUGOTHER, or DRUG2. ",negative,collagenase,chondroitin ABC lyase
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUG1, DRUG2, or DRUGOTHER. ",negative,hyaluronan lyase,heparinase III
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUG1, DRUGOTHER, or DRUG2. ",negative,hyaluronan lyase,chondroitin ABC lyase
"DRUGOTHER containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including DRUGOTHER, DRUGOTHER, DRUG1, or DRUG2. ",negative,heparinase III,chondroitin ABC lyase
The addition of DRUG1 or DRUG2 greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ,negative,heparinase III,chondroitin ABC lyase
DRUG1 had a limited effect and DRUG2 was ineffective. ,negative,Hyaluronan lyase,collagenase
Electroretinograms survived with higher concentrations of DRUG1 and DRUG2 than were required for optimal retinal transduction. ,negative,heparinase III,chondroitin ABC lyase
DRUG1-mediated retinal transduction is improved by DRUGOTHER-injection of DRUG2 or DRUGOTHER. ,effect,AAV2,heparinase III
DRUG1-mediated retinal transduction is improved by DRUGOTHER-injection of DRUGOTHER or DRUG2. ,effect,AAV2,chondroitin ABC lyase
DRUGOTHER-mediated retinal transduction is improved by DRUGOTHER-injection of DRUG1 or DRUG2. ,negative,heparinase III,chondroitin ABC lyase
"The aim of the present study was to investigate whether HB-DRUGOTHER is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-DRUGOTHER, DRUG1 (DRUG2). ",negative,cross-reacting material 197,CRM197
"We elucidated the expression of HB-DRUGOTHER in T-ALL cell lines, and evaluated the effect of DRUG1 on these cells alone or in combination with DRUG2. ",negative,CRM197,anticancer agent
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus DRUGOTHER enhanced cytotoxicity in a T-ALL cell line. ",negative,CRM197,CRM197
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus DRUG2 enhanced cytotoxicity in a T-ALL cell line. ",negative,CRM197,doxorubicin
"DRUG1 induced apoptosis, and furthermore, the combination of DRUG1 plus DRUG2 enhanced cytotoxicity in a T-ALL cell line. ",effect,CRM197,doxorubicin
"Prevention of emergence agitation in seven children receiving low-dose DRUG1 and DRUG2 total intravenous DRUGOTHER.
",negative,ketamine,propofol
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose DRUG1 in conjunction with DRUG2 for total intravenous DRUGOTHER (TIVA) repeatedly for radiation therapy. ,negative,ketamine,propofol
EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent DRUGOTHER sessions during which low-dose DRUG2 was added to DRUG1. ,negative,propofol,ketamine
EA signs were observed in all 7 patients in association with DRUG1 TIVA but did not recur in any of 123 subsequent DRUGOTHER sessions during which low-dose DRUGOTHER was added to DRUG1. ,negative,propofol,propofol
EA signs were observed in all 7 patients in association with DRUG2 TIVA but did not recur in any of 123 subsequent DRUGOTHER sessions during which low-dose DRUG1 was added to DRUG2. ,negative,ketamine,propofol
"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",effect,ketamine,propofol
"Based on this experience, we suggest that low-dose DRUG1 added to DRUG2 may be associated with prevention of EA in children with a history of EA with DRUG2 TIVA.",negative,ketamine,propofol
"Based on this experience, we suggest that low-dose DRUGOTHER added to DRUG1 may be associated with prevention of EA in children with a history of EA with DRUG1 TIVA.",negative,propofol,propofol
"Distinct synergistic action of DRUG1 and DRUG2 against Pseudomonas aeruginosa.
",negative,piperacillin,methylglyoxal
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUG1, DRUG2, DRUGOTHER and DRUGOTHER showed resistances at comparatively lower levels. ",negative,piperacillin,carbenicillin
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER showed resistances at comparatively lower levels. ",negative,piperacillin,amikacin
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUG1, DRUGOTHER, DRUGOTHER and DRUG2 showed resistances at comparatively lower levels. ",negative,piperacillin,ciprofloxacin
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER showed resistances at comparatively lower levels. ",negative,carbenicillin,amikacin
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUGOTHER, DRUG1, DRUGOTHER and DRUG2 showed resistances at comparatively lower levels. ",negative,carbenicillin,ciprofloxacin
"Results revealed that the strains were resistant to many DRUGOTHER at high levels, only DRUGOTHER, DRUGOTHER, DRUG1 and DRUG2 showed resistances at comparatively lower levels. ",negative,amikacin,ciprofloxacin
Distinct and statistically significant synergism was observed between DRUG1 and DRUG2 by disc diffusion tests when compared with their individual effects. ,effect,methylglyoxal,piperacillin
Synergism was also noted when DRUG1 was combined with DRUG2 and DRUGOTHER.,effect,methylglyoxal,carbenicillin
Synergism was also noted when DRUG1 was combined with DRUGOTHER and DRUG2.,effect,methylglyoxal,amikacin
Synergism was also noted when DRUGOTHER was combined with DRUG1 and DRUG2.,negative,carbenicillin,amikacin
"Interaction study of DRUG1 and DRUG2 with DRUGOTHER-administered DRUGOTHER.
",negative,moxifloxacin,lomefloxacin
DRUG1 and DRUG2 are fluoroquinolone DRUGOTHER used in treating urinary and respiratory tract infections. ,negative,Moxifloxacin,lomefloxacin
DRUG1 and DRUGOTHER are fluoroquinolone DRUGOTHER used in treating urinary and respiratory tract infections. ,negative,Moxifloxacin,fluoroquinolone antibiotics
DRUGOTHER and DRUG1 are fluoroquinolone DRUGOTHER used in treating urinary and respiratory tract infections. ,negative,lomefloxacin,fluoroquinolone antibiotics
"Being DRUG1 and DRUGOTHER DRUG2 the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,moxifloxacin,fluoroquinolones
"Being DRUG1 and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,moxifloxacin,sucralfate
"Being DRUG1 and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,moxifloxacin,gelusil
"Being DRUG1 and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,moxifloxacin,erythromycin
"Being DRUG1 and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUGOTHER and multi DRUGOTHER. ",negative,moxifloxacin,multi minerals
"Being DRUGOTHER and DRUGOTHER DRUG1 the interaction study of was carried out with DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",negative,fluoroquinolones,sucralfate
"Being DRUGOTHER and DRUGOTHER DRUG1 the interaction study of was carried out with DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,fluoroquinolones,gelusil
"Being DRUGOTHER and DRUGOTHER DRUG1 the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,fluoroquinolones,erythromycin
"Being DRUGOTHER and DRUGOTHER DRUG1 the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUGOTHER and multi DRUGOTHER. ",negative,fluoroquinolones,multi minerals
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUG1, DRUG2, DRUGOTHER and DRUGOTHER. ",negative,sucralfate,gelusil
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUG1, DRUGOTHER, DRUG2 and DRUGOTHER. ",negative,sucralfate,erythromycin
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUG1, DRUGOTHER, DRUGOTHER and multi DRUGOTHER. ",negative,sucralfate,multi minerals
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUG1, DRUG2 and DRUGOTHER. ",negative,gelusil,erythromycin
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUG1, DRUGOTHER and multi DRUGOTHER. ",negative,gelusil,multi minerals
"Being DRUGOTHER and DRUGOTHER DRUGOTHER the interaction study of was carried out with DRUGOTHER, DRUGOTHER, DRUG1 and multi DRUGOTHER. ",negative,erythromycin,multi minerals
The response of DRUG1 and DRUG2 after interaction with DRUGOTHER-administered DRUGOTHER at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,negative,moxifloxacin,lomefloxacin
DRUG1 and DRUG2 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,negative,Moxifloxacin,Lomefloxacin
DRUG1 and DRUGOTHER reacts faster with DRUG2 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,mechanism,Moxifloxacin,sucralfate
DRUG1 and DRUGOTHER reacts faster with DRUGOTHER and DRUG2 in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,mechanism,Moxifloxacin,gelusil
DRUG1 and DRUGOTHER reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,mechanism,Moxifloxacin,erythromycin
DRUG1 and DRUGOTHER reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and multi-DRUGOTHER in neutral media. ,mechanism,Moxifloxacin,multi-minerals
DRUGOTHER and DRUG1 reacts faster with DRUG2 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,mechanism,Lomefloxacin,sucralfate
DRUGOTHER and DRUG1 reacts faster with DRUGOTHER and DRUG2 in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,mechanism,Lomefloxacin,gelusil
DRUGOTHER and DRUG1 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,mechanism,Lomefloxacin,erythromycin
DRUGOTHER and DRUG1 reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and multi-DRUGOTHER in neutral media. ,mechanism,Lomefloxacin,multi-minerals
DRUGOTHER and DRUGOTHER reacts faster with DRUG1 and DRUG2 in acidic media whereas with DRUGOTHER in basic media and DRUGOTHER in neutral media. ,negative,sucralfate,gelusil
DRUGOTHER and DRUGOTHER reacts faster with DRUG1 and DRUGOTHER in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,negative,sucralfate,erythromycin
DRUGOTHER and DRUGOTHER reacts faster with DRUG1 and DRUGOTHER in acidic media whereas with DRUGOTHER in basic media and multi-DRUGOTHER in neutral media. ,negative,sucralfate,multi-minerals
DRUGOTHER and DRUGOTHER reacts faster with DRUGOTHER and DRUG1 in acidic media whereas with DRUG2 in basic media and DRUGOTHER in neutral media. ,negative,gelusil,erythromycin
DRUGOTHER and DRUGOTHER reacts faster with DRUGOTHER and DRUG1 in acidic media whereas with DRUGOTHER in basic media and multi-DRUGOTHER in neutral media. ,negative,gelusil,multi-minerals
DRUGOTHER and DRUGOTHER reacts faster with DRUGOTHER and DRUGOTHER in acidic media whereas with DRUG1 in basic media and multi-DRUGOTHER in neutral media. ,negative,erythromycin,multi-minerals
"DRUG1, an DRUGOTHER antagonist, is the standard hormone treatment for breast cancer. ",negative,Tamoxifen,estrogen antagonist
DRUG1 and DRUG2 reduce the plasma concentration of DRUGOTHER by about 50%. ,negative,Paroxetine,fluoxetine
DRUG1 and DRUGOTHER reduce the plasma concentration of DRUG2 by about 50%. ,mechanism,Paroxetine,endoxifen
DRUGOTHER and DRUG1 reduce the plasma concentration of DRUG2 by about 50%. ,mechanism,fluoxetine,endoxifen
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUGOTHER and DRUGOTHER. ",advise,tamoxifen,SSRI antidepressants
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUG2 and DRUGOTHER. ",advise,tamoxifen,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUG1 for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUGOTHER and DRUG2. ",advise,tamoxifen,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGOTHER for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUG2 and DRUGOTHER. ",negative,SSRI antidepressants,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGOTHER for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUGOTHER and DRUG2. ",negative,SSRI antidepressants,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with DRUGOTHER for breast cancer, especially DRUGOTHER DRUGOTHER such as DRUG1 and DRUG2. ",negative,paroxetine,fluoxetine
"Depression does not always require DRUGOTHER DRUGOTHER therapy, and DRUG2 have no proven preventive impact on hot flushes linked to the menopause. ",negative,antidepressant drug,antidepressants
"If in certain cases, an DRUG1 is considered necessary, it may be advisable to replace DRUG2 with DRUGOTHER.",advise,antidepressant,tamoxifen
"If in certain cases, an DRUG1 is considered necessary, it may be advisable to replace DRUGOTHER with DRUG2.",negative,antidepressant,anastrozole
"If in certain cases, an DRUGOTHER is considered necessary, it may be advisable to replace DRUG1 with DRUG2.",negative,tamoxifen,anastrozole
[Efficacy of fixed combination DRUG1/DRUG2 in hospitalized patients with hypertensive disease],negative,amlodipine,valsartan
Efficacy and tolerability of fixed DRUG1/DRUG2 combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ,negative,amlodipine,valsartan
All patients had indications for DRUGOTHER therapy and were randomized either to fixed combination DRUG1/DRUG2 (n=43) or to therapy which corresponded to the hospital formulary (n=43). ,negative,amlodipine,valsartan
Rate of achievement of target BP with fixed combination DRUG1/DRUG2 (93%) was comparable with that on traditional therapy (90%). ,negative,amlodipine,valsartan
"But the use of fixed combination DRUG1/DRUG2 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUGOTHER DRUGOTHER (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",effect,amlodipine,valsartan
"But the use of fixed combination DRUG1/DRUGOTHER compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUGOTHER DRUGOTHER (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",negative,amlodipine,antihypertensive drugs
"But the use of fixed combination DRUGOTHER/DRUG1 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of DRUGOTHER DRUGOTHER (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",negative,valsartan,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/DRUG2 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUGOTHER DRUGOTHER, and diminishing concealed inefficacy of treatment.",effect,amlodipine,valsartan
"We have demonstrated appropriateness of inhospital administration of fixed DRUG1/DRUGOTHER combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUGOTHER DRUGOTHER, and diminishing concealed inefficacy of treatment.",negative,amlodipine,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed DRUGOTHER/DRUG1 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer DRUGOTHER DRUGOTHER, and diminishing concealed inefficacy of treatment.",negative,valsartan,antihypertensive drugs
"Interaction of DRUG1 and DRUG2, in vitro and in vivo, in human A375 melanoma cells.
",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DRUG2) and the pro-oxidant, DRUGOTHER, in the human A375 melanoma cell line.",negative,dacarbazine,DTIC
"We evaluated mechanisms of interaction between the alkyating agent DRUG1 (DRUGOTHER) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent DRUGOTHER (DRUG1) and the pro-oxidant, DRUG2, in the human A375 melanoma cell line.",negative,DTIC,imexon
"The effect of DRUG1 and DRUG2, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled DRUGOTHER uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ",negative,DTIC,imexon
There was a >75% reduction in cellular glutathione and DRUGOTHER with DRUG1 but not DRUG2. ,negative,imexon,DTIC
DRUG1 and DRUG2 show additive effects in vitro but not in vivo in human A375 melanoma cells.,effect,Imexon,dacarbazine
"[Influence of DRUG1 and DRUG2 on DRUGOTHER-evoked behavior violations in C57BL/6 mice].
",negative,hemantane,doxycycline
"The effects of anti-parkinsonian DRUGOTHER DRUG2 [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,anti-parkinsonian drug,hemantane
"The effects of anti-parkinsonian DRUGOTHER DRUGOTHER [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,anti-parkinsonian drug,(2-adamantyl)hexamethylenimine
"The effects of DRUGOTHER DRUG1 [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",negative,hemantane,(2-adamantyl)hexamethylenimine
"and/or DRUGOTHER DRUGOTHER DRUG2 (100 mg/kg, p. o.), as well as that of neurotoxin DRUGOTHER (DRUGOTHER) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,doxycycline
"and/or DRUGOTHER DRUGOTHER DRUGOTHER (100 mg/kg, p. o.), as well as that of neurotoxin DRUG2 (DRUGOTHER) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or DRUGOTHER DRUGOTHER DRUGOTHER (100 mg/kg, p. o.), as well as that of neurotoxin DRUGOTHER (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,antibiotic drug,MPTP
"and/or DRUGOTHER DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUG2 (DRUGOTHER) (4 x 20 mg/kg, i. p.) ",negative,doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or DRUGOTHER DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUGOTHER (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,doxycycline,MPTP
"and/or DRUGOTHER DRUGOTHER (100 mg/kg, p. o.), as well as that of neurotoxin DRUG1 (DRUG2) (4 x 20 mg/kg, i. p.) ",negative,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP
"Acute administration of DRUG1 or DRUG2 failed to influence locomotion in mice, while their combination normalized motor activity. ",effect,hemantane,doxycycline
"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, DRUG1 (DRUG2) and isoform-specific inhibitors. ",negative,1-aminobenzotriazole,ABT
"DRUG1 decreased the toxicity of DRUG2, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",effect,ABT,precocene I
"Of the isoform-specific CYP inhibitors tested for an effect on the DRUG1 metabolite profile, only DRUG2 was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",negative,precocene I,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>DRUG2~DRUGOTHER>DRUGOTHER. ",negative,ABT,diethyldithiocarbamate
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>DRUGOTHER~DRUG2>DRUGOTHER. ",negative,ABT,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUG1>DRUGOTHER~DRUGOTHER>DRUG2. ",negative,ABT,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUG1~DRUG2>DRUGOTHER. ",negative,diethyldithiocarbamate,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUG1~DRUGOTHER>DRUG2. ",negative,diethyldithiocarbamate,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was DRUGOTHER>DRUGOTHER~DRUG1>DRUG2. ",negative,tranylcypromine,ketoconazole
"DRUG1 and DRUG2 had no effect, while DRUGOTHER appeared to augment DRUGOTHER toxicity. ",negative,Furafylline,sulfaphenazole
"DRUG1 and DRUGOTHER had no effect, while DRUG2 appeared to augment DRUGOTHER toxicity. ",negative,Furafylline,quinidine
"DRUG1 and DRUGOTHER had no effect, while DRUGOTHER appeared to augment DRUG2 toxicity. ",negative,Furafylline,precocene I
"DRUGOTHER and DRUG1 had no effect, while DRUG2 appeared to augment DRUGOTHER toxicity. ",negative,sulfaphenazole,quinidine
"DRUGOTHER and DRUG1 had no effect, while DRUGOTHER appeared to augment DRUG2 toxicity. ",negative,sulfaphenazole,precocene I
"DRUGOTHER and DRUGOTHER had no effect, while DRUG1 appeared to augment DRUG2 toxicity. ",effect,quinidine,precocene I
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of DRUG1 and therefore may not be an appropriate model for DRUG1 metabolism. ,negative,precocene I,precocene I
